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1 Abstract 
1.1 Abstract 
Tuberculosis (TB) remains a threat to public health. Diagnostic of TB is often expensive 
or time-consuming. The use of recombinant antibodies for direct detection of 
M. tuberculosis (Mtb) antigens in human specimens could facilitate a simple point of care 
TB test. A diverse series of antigens was evaluated for this task, including 16 kDa, 
ESAT-6, CFP-10, LAM, AlaDH, 85 A, 85 B and 85 D. Twenty-two recombinant 
antibodies against 16 kDa, CFP-10, 85 A, 85 B and 85 D were generated by panning of 
human naïve phage display libraries. A recombinant α-LAM antibody was generated by 
isolation of the variable gene segments of the IgM encoding sequences from a 
hybridoma clone. These antibodies were purified as scFv from E. coli or scFv-Fc 
(scFab-Fc) from HEK293-6E cells, and characterized in detail. It was found, that the 
α-LAM antibody was only producible in a multivalent scFab-Fc format. Seven antibodies 
showed a supposed preferential germline gene combination against the 16 kDa antigen. 
Sandwich detection of 16 kDa and CFP-10 was not possible. Specific antibodies against 
85 A, 85 B and 85 D were isolated, allowing for the first time discrimination of individual 
components of the 85 complex. Furthermore, sandwich detection of recombinant antigen 
85 A or 85 B was possible. However multimeric conformation of the antigen was 
enhancing the recognition. Lack of multimers reduced binding to a minimum. Although 
no sandwich detection of Mtb samples was possible, a functional α-85 B immuno blot 
assay was developed. In summary, a variety of antibodies was generated with potential 
for further development of a TB diagnostic assay or for use in infection research, drug 
development or passive immunization. 
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1.2 Zusammenfassung 
Tuberkulose (TB) ist immer noch eine Bedrohung für die öffentliche Gesundheit. Die 
Diagnose von TB ist häufig teuer oder zeitaufwendig. Der Gebrauch von rekombinanten 
Antikörpern (AK) zur direkten Detektion von M. tuberculosis (Mtb) Antigenen in humanen 
Proben könnte einen simplen TB Schnelltest ermöglichen. Eine mannigfaltige Serie von 
Antigenen wurde für diesen Zweck untersucht, einschließlich 16 kDa, ESAT-6, CFP-10, 
LAM, AlaDH, 85 A, 85 B und 85 D. Zweiundzwanzig rekombinante AK gegen 16 kDa, 
CFP-10, 85 A, 85 B und 85 D wurden mittels Panning von humanen naïven 
Phagendisplaybibliotheken generiert. Ein rekombinanter α-LAM AK wurde generiert 
durch Isolierung der variablen Gensegmente der IgM kodierenden Sequenzen eines 
Hybridoms. Diese AK wurden als scFv aus E. coli oder als scFv-Fc (scFab-Fc) aus 
HEK293-6E Zellen aufgereinigt und detailliert charakterisiert. Der α-LAM AK war nur als 
multivalenter scFab-Fc produzierbar. Sieben AK zeigten eine bevorzugte 
Genkombination gegen das 16 kDa Antigen. Ein Sandwichnachweis von 16 kDa und 
CFP-10 war nicht möglich. Spezifische AK gegen 85 A, 85 B und 85 D konnten isoliert 
werden, die erstmals eine Unterscheidung individueller Komponenten des 85 Komplexes 
ermöglichen. Weiterhin war der Sandwichnachweis von rekombinantem 85 A oder 85 B 
möglich, wobei eine multimere Antigenkonformation die Erkennung verbesserte. Das 
Fehlen von Multimeren reduzierte die Bindung auf ein Minimum. Ein Sandwichnachweis 
von Mtb Proben war nicht möglich, jedoch konnte ein funktionaler α-85 B Immunoblottest 
entwickelt werden. Insgesamt wurden eine Vielzahl von AK generiert mit Potential für die 
weitere Entwicklung eines TB Schnelltests, für die Verwendung in der 
Infektionsforschung, für die Medikamentenentwicklung oder zur passiven Immunisierung. 
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2 Introduction 
2.1 Tuberculosis 
Tuberculosis (TB) is an infectious disease, spread through the air, which is caused by 
various strains of mycobacteria. Besides Mycobacterium tuberculosis (M. tuberculosis, 
Mtb), the main cause of TB in humans, the M. tuberculosis complex includes minimum 
four other human-pathogenic mycobacteria: M. bovis, M. africanum, M. canettii, and 
M. microti (van Soolingen et al., 1997; Brosch et al., 2002). M. bovis causes TB in cattle 
and was once a common cause of TB in humans due to consummation of unpasteurized 
milk (Kumar et al., 2007; Thoen et al., 2006). M. africanum is not widespread, but it is a 
significant cause of TB in parts of Africa (Niemann et al., 2002). M. canettii is rare and 
seems to be limited to the Horn of Africa (Acton, 2011; Pfyffer et al., 1998; van Soolingen 
et al., 1997). M. microti’s natural hosts are small rodents such as voles, shrews and 
wood mice, nonetheless it can cause TB in immune deficient humans (Panteix et al., 
2010).  
Predominantly a disease of the lung, so called pulmonary TB (70 % of the cases), the 
pathogen can infect any organ system (extrapulmonary TB) like the heart, bones, joints, 
gastrointestinal system, genitourinary system, central nervous system, mastoid 
processes and eyes (Harisinghani et al., 2000). The combination of symptoms in 
pulmonary TB may range from systemic responses such as weight loss (“consumption”), 
fever and night sweats, to local consequences of the infection such as cough and 
haemoptysis (Brändli, 1998) to radiological abnormalities (Figure 1) such as thoracic 
lymphadenopathy and lung cavities or densities (O'Garra et al., 2013).  
                
Figure 1: Coloured chest X-ray of a woman with pulmonary tuberculosis. 
In retrospect lung densities (consisting of TB granulomas) were highlighted in purple. Figure 
adapted from science photo library, M270/0179, Simon Fraser. 
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According to the World Health Organisation (WHO, 2012) approximately 8.7 million 
people fell ill with TB in 2011 and 1.4 million deaths were reported worldwide. Therefore 
TB ranks as the second cause of death from an infectious disease worldwide, after the 
human immunodeficiency virus (HIV). In addition to that one third of the world population 
is estimated to be infected with Mtb, yet they remain asymptomatic, defined as latent TB 
infection (LTBI) (Dye et al., 1999). LTBI is specified by the presence of an immune 
response directed against Mtb antigens and not by the confirmed presence of the 
pathogenic bacilli. Some LTBI individuals may progress to postprimary active TB after 
years of subclinical infection, others may maintain a persistent lifelong asymptomatic 
infection and some are able to effectively clear the pathogen (O'Garra et al., 2013). 
2.1.1 M. tuberculosis 
M. tuberculosis was first discovered in 1882 as the etiology of TB by Robert Koch (Koch, 
1882). This facultative intracellular parasite is a rod shaped, aerob, non-motile, gram 
positive and acid-fast bacterium of max. 0.5 x 4 μm size which divides only every 15 – 20 
hours (Mandell et al., 2009). Mycobacteria possess a complex cell envelope (Figure 2), 
that consists of a thick asymmetric lipid bilayer located beyond the plasma membrane, 
peptidoglycan, and an arabinogalactan layer esterified with mycolic acids (mAG) 
(Umesiri et al., 2010). Proteins and polysaccharides are found in the outermost stratum 
known as the capsule, and somewhere interspaced lipopolysaccharides such as 
lipoarabinomannan (LAM) are located (Brennan, 2003). The extremely hydrophobic cell 
envelope forms a permeability barrier that prevents entry of many hydrophilic solutes, 
thereby making these bacteria acid-fast and able to survive extremely hostile 
surroundings (Favrot and Ronning, 2012). 
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Figure 2: Schematic representation of the general structure of the mycobacterial cell 
envelope. 
LAM: lipoarabinomannan, ManLAM: mannose-capped LAM, TDM: trehalose dimycolate, TMM: 
trehalose monomycolate, mAG: branched arabinogalactan polymer esterified with mycolic acids. 
Figure adapted from Umesiri et al., 2010.  
2.1.2 Pathogenesis 
When a TB infected individual coughs, sneezes or spits, contagious aerosols can be 
inhaled into the airways and alveoli of a new host (Fennelly et al., 2012). The 
mycobacteria are then phagocytosed by alveolar macrophages, dendritic cells 
(Schlesinger, 1996) and neutrophils (Wolf et al., 2007). The following immune response 
to Mtb is complex and incompletely characterized. Mtb can be eliminated by 
macrophages via different mechanisms (Pieters, 2008) but it is also known that Mtb can 
suppress autophagic pathways in macrophages and survive and replicate within the 
phagosome (Deretic et al., 2009). In dendritic cells the pathogen is carried to the lung-
draining lymphnodes, where Mtb–derived antigens are presented to T-lymphocytes and 
Mtb antigen-specific T cells are generated (Wolf et al., 2008). These cells recirculate and 
induce formation of granulomas in the lung (Cayabyab et al., 2012). Human TB 
granulomas (“tubercle”, Figure 3) consist of a central mass of infected macrophages 
surrounded by a variety of lymphocytes, largely T cells, B cells, fibroblasts and dendritic 
cells (Ehlers and Schaible, 2013). Granulomas can restrain bacterial cells from 
spreading and slow down their physiological dynamics, but often the bacilli are not 
eliminated and latency is promoted (O'Garra et al., 2013). 
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Figure 3: Schematic composition of a protective granuloma. 
Human TB granulomas are formed in the lung as a tissue reaction to limit bacillary growth and 
sequester infection. Granulomas consist of a central mass of infected macrophages surrounded 
by a variety of lymphocytes, largely T cells, B cells, fibroblasts and dendritic cells. Figure modified 
after Ehlers and Schaible, 2013. 
2.1.3 Vaccination 
The only available vaccine against TB remains M. bovis bacilli Calmette-Guérin (M. bovis 
BCG), which was generated in 1920 after continual passaging of the parental strain M. 
bovis for 13 years resulting in an attenuated strain with reduced virulence (Calmette 
1931). BCG is a living vaccine, applied as a single intradermal inoculation dose, routinely 
administered to infants in many countries worldwide (Ottenhoff et al. 2012). It provides 
protection against miliary TB and meningitis TB in infants (Trunz et al. 2006), but fails to 
protect against pulmonary and latent TB in adults and children (Narayanan 2006; ICMR 
1999). Due to the lack of efficacy (0 – 80 % for pulmonary TB (Colditz et al. 1994)) and 
an associated risk of infection with the viable vaccine in TB-HIV population (Reyn et al. 
2010) innovative approaches are being pursued to further improve the existing vaccine, 
as well as to discover new ones (Ottenhoff et al. 2012; Cayabyab et al. 2012; Evans et 
al. 2013). 
2.1.4 TB treatment 
Tuberculosis is the leading cause of death among HIV-infected people in developing 
countries, and treatment is complex due to interactions between anti-retrovirals and 
anti-TB drugs and increased risk of adverse effects (Lienhardt et al., 2012). In HIV-
negative patients the globally accepted standard treatment consists of a four drug 
chemotherapy over a duration of six months (rifampicin, isoniazid, ethambutol, and 
pyrazinamide for 2 months, followed by rifampicin and isoniazid for 4 months) with a cure 
rate of ~ 90 % (WHO, 2010b). The currently used anti-TB drugs have been discovered 
before 1970 and resistance to all of these pharmaceuticals by bacterial chromosomal 
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mutations has appeared (Mitchison and Davies, 2012). In 2008, 3.6 % of all TB incidents 
globally were estimated to involve multi drug resistant TB (MDR-TB, defined as 
resistance to at least rifampicin and isoniazid). From those MDR-TB cases approximately 
5.4 % were found to have extensively drug resistant TB (XDR-TB, defined as MDR-TB 
plus resistance to a fluoroquinolone and at least one second-line injectable agent, i.e. 
amikacin, kanamycin, and/or capreomycin) (WHO, 2010a). Even though XDR-mortality 
has been reduced from 100 to 45 %, it remains a challenge to treat due to the long 
medication duration (up to 22 months) and the unfavourable side effects of the used 
substances (Janssen et al., 2012). 
2.1.5 TB diagnosis  
Only 66 % of the estimated TB-cases worldwide are correctly diagnosed, even less in 
high-TB-burden, low-resource settings (WHO, 2012). The first step of TB diagnosis is a 
proper anamnesis, usually followed by imaging techniques such as chest X-ray or 
computer tomography and microbiological methods (Norbis et al., 2013). The gold 
standard in TB diagnosis remains the preparation of liquid cultures in selective media 
from sputum or tissue/body fluid specimens (Kumar and Robbins, 2007), followed by 
further Mtb specific tests (i.e. MPT64 antigen detection (Kumar et al., 2011)) or 
sequencing of Mtb genomic DNA. But the cultivation of Mtb is time consuming and not 
always successful. A variety of nucleic acid amplification tests (NAAT) are commercially 
available for laboratory-based diagnosis of active TB (i.e. Xpert MTB/RIF (Helb et al., 
2010)). These tests allow sensitive and specific detection of Mtb and rifampicin or 
isoniazid drug resistance. Yet they need special trained stuff, expensive equipment and 
are prone to intralaboratory DNA contamination (Dheda et al., 2013). Analysis of cell wall 
lipids by high performance liquid chromatography (HPLC), mass spectroscopy (MS) or 
gas chromatography (GC) are promising but in need of expensive equipment and highly 
trained staff (Lefmann et al., 2004). 
A great number of TB tests targeting the human immune response to Mtb are 
commercially available. Interferon gamma release assays (IGRA) use the Mtb-derived 
antigens ESAT-6 and CFP-10 to stimulate pre-primed T cells in full blood to release 
interferon gamma (Tsiouris et al., 2006). These tests lack sensitivity and cannot 
differentiate between TB and LTBI (Brock et al., 2006). For the tuberculin skin test (TST) 
a patient is intradermally challenged with an extract containing Mtb antigens (purified 
protein derivative (PPD)), the resulting induration in the skin, which is due to the 
development of a delayed-type hypersensitivity reaction, is measured in millimetres 
(Dacso, 1990). This tests are still widely practised in endemic countries, although they 
give false positive results for BCG vaccinated (Pai et al., 2006) and false negative results 
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in immune deficient people (Fisk et al., 2003). Serological TB-assays are strongly 
represented, measuring antibodies against Mtb-related antigens in blood via ELISA or 
Lateral Flow Immuno Assays (LFIA). These tests displayed poor sensitivity and 
specificity in randomized controlled trials (Steingart et al., 2011) and their use has been 
advised against by WHO (WHO, 2011). 
Diagnosis of TB in most low- and middle-income countries continues to rely on sputum 
smear microscopy for acid-fast bacilli (Ziel-Neelsen stain) (WHO, 2012). This technique 
detects only 40 – 60 % of pulmonary TB cases, is not able to differentiate between Mtb 
and other ubiquitous mycobacteria (Rai et al., 2006; van Deun and Portaels, 1998), and 
is less sensitive in children, in HIV co-infected patients and in patients with 
extrapulmonary TB (Steingart et al., 2006; Perkins and Cunningham, 2007). 
Improvement of sputum smear microscopy by fluorescent staining and LED visualization 
led to ~10 % higher sensitivity (Dheda et al., 2013). An overview of current diagnostic 
tools for TB and LTBI is given in Table 1. 
Table 1: Current diagnostic tools for TB and LTBI. 
detection of TB LTBI 
pathogen culture - 
 sputum smear microscopy - 
 NAAT - 
 histopathology - 
 LFIA (antigen detection) - 
 DNA sequencing - 
 HPLC, GC, MS  
host response anamnesis history of TB contacts 
 chest X-ray chest X-ray (exclusion of PTB) 
 TST TST 
 IGRA IGRA 
 serology (LFIA, ELISA) serology (LFIA, ELISA) 
Abbreviations: Nucleic acid amplification techniques (NAAT), lateral flow immuno assay (LFIA), 
high-performance liquid chromatography (HPLC), gas chromatography (GC), mass spectroscopy 
(MS), radiography (X-ray), Tuberculin skin test (TST), interferon gamma release assay (IGRA), 
pulmonary TB (PTB), enzyme linked immuno sorbent assay (ELISA).  
 
Only 15 of the 22 high TB burden countries met the WHO recommendation of having 
one microscopy centre per 100,000 population in 2011, furthermore among the 36 
countries with a high burden of MDR-TB, 19 did not have the recommended capacity of 
one laboratory to perform culture and drug susceptibility testing per five million 
population in 2011 (WHO, 2012). Even if a laboratory is within reach, that does not mean 
that the necessary equipment and infrastructure are continuously available (i.e. lack of 
reagent supply or constant electricity). Furthermore the know-how for maintenance and 
resistance to environmental conditions of modern high-tech devices is often critical 
(Norbis et al., 2013). TB is partly a disease of poverty (Kearney et al., 1993). Although 
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TB treatment is usually free, sometimes patients are required to pay for diagnostic 
assays (Aspler et al., 2008). Accuracy, simplicity, affordability and technical robustness 
are important factors for a point of care (POC) TB-test, but the main advantage is its 
celerity. Rapid diagnosis allows initiation of treatment while the patient is still accessible 
(Dheda et al., 2013). This is important because a great portion of patients in high TB 
burden countries do not return to the health-care facility for the uptake of diagnostic 
results (Millen et al., 2008). 
Direct detection of Mtb antigens in human specimens would allow specific diagnostic of 
active TB independent from the hosts immune response. Furthermore, the use of 
antibodies binding Mtb antigens in a lateral flow strip assay would facilitate a rapid POC 
test in a cost effective, easy-to-use format. By now the only commercially available POC 
Mtb antigen detection test is the Determine TB-LAM (Alere, Waltham, MA, USA). This 
LFIA detects a component of the mycobacterial cell wall, lipoarabinomannan (LAM), in 
urine but has poor sensitivity and specificity (Lawn, 2012).  
2.1.6 Immunodominant Mtb antigens 
Potential target antigens for POC TB-detection in human samples should be selected by 
the following criteria: substantial expression by bacteria in vivo, presence in the 
extracellular environment or association with the cell membrane, and resistance to 
degradation by host enzymes (Flores et al., 2011). 
ESAT-6 and CFP-10 
Early secretory antigenic target 6 kDa (ESAT-6) and culture filtrate protein 10 kDa (CFP-
10) are some of the most abundant culture filtrate proteins of Mtb. The genes encoding 
these antigens (Rv3874 and Rv3875) are located in a gene cluster, the so called region 
of difference 1 (RD1), are absent in the vaccine strain M. bovis BCG and are co-
transcribed (Berthet et al., 1998). M. bovis BCG displayed increased virulence when 
complemented with RD1 in comparison to the parental BCG (Majlessi et al., 2005). 
Inactivation of Rv3874 and Rv3875 in M. bovis resulted in dramatically reduced virulence 
(Renshaw et al., 2005). ESAT-6 and CFP-10 are secreted by an active process, 
involving the specialized transport system ESX-1 (Brodin et al., 2004), and form a tight 
1:1 complex , which is involved in binding to the cell surface of macrophages and 
monocyte cells (Renshaw et al., 2002; Renshaw et al., 2005). CFP-10 and ESAT-6 are 
potent T cell antigens (Arend et al., 2000) and are used in the interferon gamma release 
assays for TB diagnostic (Tsiouris et al., 2006). The antigen ESAT-6 was demonstrated 
in human plasma (Mukundan et al., 2012) and cerebrospinal fluid (Song et al., 2013) of 
TB infected individuals. 
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AlaDH 
AlaDH is a functional L-alanine dehydrogenase encoded by the gene ald in 
M. tuberculosis (Andersen et al., 1992), probably involved in alanine biosynthesis 
(Sassetti et al., 2003). In addition, AlaDH might play a role in cell wall synthesis, because 
alanine is an important constituent of the mycobacterial peptidoglycan layer (Brennan, 
2003; Hutter and Singh, 1999). Therefore, AlaDH detection in human samples may be a 
potent tool for confirmation of living and replicating mycobacteria and thereby diagnostic 
of active TB. An ald knock-out strain of M. tuberculosis was able to grow without alanine 
or glycine as nitrogen source (Giffin et al., 2012), suggesting a non-essential role of the 
enzyme. M. bovis BCG expressing the M. tuberculosis ald showed similar survival in 
both macrophages and mice, indicating a role in pathogenicity (Scandurra et al., 2006). 
AlaDH is present early in Mtb cultures but lacks a consensus signal peptide (Andersen et 
al., 1992). Presence and enzymatic activity were demonstrated only in the cell and on 
the cell membrane, not in the extracellular medium (Giffin et al., 2012).  
LAM 
Lipoarabinomannan (LAM) is a component of the mycobacterial cell wall (Besra and 
Brennan, 1997; Chatterjee et al., 1992). It is a lipoglycan that is characterized by three 
main components: a mannosylphosphatidylmyoinositol linker, a polysaccharide 
backbone that consists of a mannan and branched arabinan chains, and a capping motif 
(Petzold et al., 2005). LAM can influence the phagosome maturation, apoptosis and 
interferon gamma signal transduction in macrophages (Schlesinger et al., 1994). In 
addition, LAM disturbs the IL12 cytokine secretion in dendritic cells (Maeda et al., 2003). 
Numerous studies about the potential role of LAM as an effector in M. tuberculosis 
pathogenicity were published (Hetland et al., 1998; Hamasur et al., 1999; Glickman and 
Jacobs, Jr., 2001; Brennan, 2003; Flynn and Chan, 2003; Briken et al., 2004; Appelmelk 
et al., 2008; Mishra et al., 2011). LAM and lipomannan (LM) have a significant impact on 
the cell wall integrity of mycobacteria, furthermore mutation of LAM or LM can increase 
β-lactam susceptibility and cause attenuated virulence of M. tuberculosis (Fukuda et al., 
2013). LAM was detected in human serum (Sada et al., 1992; Sarkar et al., 2012), urine 
(Achkar et al., 2011; Lawn et al., 2012; Mukundan et al., 2012), sputum (Pereira Arias-
Bouda et al., 2000) and cerebrospinal fluid (Mathai et al., 2003). 
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16 kDa 
The 16 kDa antigen (α-crystallin (Acr)/heat shock protein X (HspX)) is the most abundant 
protein in M. tuberculosis during its dormant, non-replicative phase but is not present 
under conditions of logarithmic growth (Yuan et al., 1996; Hu and Coates, 1999), 
indicating applicability as a marker for LTBI. HspX was suggested to be associated with 
the Mtb cell membrane (Lee et al., 1992) and to function as a heat induced chaperone in 
vitro (Chang et al., 1996). Yuan and colleagues (Yuan et al., 1998) generated an Mtb 
mutant, replacing the 16 kDa encoding gene acr with a hygromycin resistance cassette, 
which showed impaired growth in macrophages. On the contrary, Hu and co-workers (Hu 
et al., 2006) found an acr deletion mutant to exhibit increased growth in macrophages. 
These results may be conflictive, but indicate none the less an important role in growth 
regulation in the host. Humoral immune responses against 16 kDa were measured in 
various studies (Lee et al., 1992; Imaz et al., 2001; Silva et al., 2003; Demissie et al., 
2006; Kaushik et al., 2012), suggesting antigen expression during infection.  
85 complex 
The 85 complex is a major secretion product of Mtb (Wiker and Harboe, 1992; 
Sonnenberg and Belisle, 1997) which comprises three variant 85 proteins (A, B and C, 
68 – 80 % homology) that are encoded by three different genes (fbpA, fbpB and fbpC) 
(Wiker et al., 1990). Antigen 85 A, B and C possess mycolyltransferase activity, 
furthermore they are associated with the formation of the mycobacterial cell wall (Belisle 
et al., 1997; Kremer et al., 2002; Ronning et al., 2004). Disruption of fbpA resulted in the 
disability of Mtb to replicate within macrophage like cell lines, indicating a key role in 
virulence (Armitige et al., 2000). It was shown that 85 complex proteins interact with 
gelatine-binding sites of human fibronectin, enhancing complement-mediated 
phagocytosis by macrophages (Abou-Zeid et al., 1988; Abou-Zeid et al., 1991; Bentley-
Hibbert et al., 1999). The presence of the 85 complex was demonstrated in human 
serum (Kashyap et al., 2007; Landowski et al., 2001), urine (Bentley-Hibbert et al., 
1999), cerebrospinal fluid (Kashyap et al., 2005) and sputum (Wallis et al., 1998). 
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2.2 Antibodies 
Immune responses, innate or adaptive, are reactions directed against an infection with 
pathogens (viruses, bacteria, fungi or higher eukaryotic parasites). The innate immunity 
is amongst others characterized by action as a physical and chemical barrier, 
recruitment of immune cells to the sites of infection, activation of the complement system 
and activation of the adaptive immune response. This is a hereditary, non-specific first 
line of defence, conferring no long lasting immunity. On the contrary, the adaptive 
immune system is a second line of specific defence (found only in higher vertebrates) 
generating an immunological memory (Murphy et al., 2008). Immunoglobulins (Ig), 
likewise called antibodies, are the main part of the humoral component of acquired 
immunity. Antibodies are secreted by plasma cells, a mature differentiated form of B 
lymphocytes, generated after antigen contact. Antibodies are combining antigen 
(antibody generator) recognition through a highly variant aminoterminal (N-terminal) 
region, with activation of effector mechanisms by the conserved carboxyterminal (C-
terminal) region (Dübel and Breitling, 1999). Thereby antibodies structurally connect 
acceptor and effector functions (like opsonisation, activation of the complement 
dependent cytotoxicity (CDC) and the antibody dependent cellular cytotoxicity (ADCC)) 
in one molecule (Descamps et al., 1979). 
 
Figure 4: Schematic constitution of an IgG antibody 
Adapted from M. Hust with permission. For abbrevations see text.  
The antibody matrix is conserved, consisting of four polypeptide chains, stabilized by 
disulphide and non-covalent bonds between amino acids (Porter, 1973). Two different 
classes of light chains are known, kappa (κ) and lambda (λ), displaying no difference in 
function. The effector capacities of an antibody are defined by the constant regions of the 
heavy chain (α, δ, ε, γ or μ), dividing immunoglobulins into five isotypes (IgA, IgD, IgE, 
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IgG and IgM) (Abbas and Lichtman, 2011). Affinity matured IgG is the most abundant, 
providing 80 % of the overall serum immunoglobulin (Murphy et al., 2008). IgG 
antibodies are combining two identical heavy chains with two identical light chains to a Y-
shaped heterotetramer (Harris et al., 1992) (Figure 4). Light chains consist of a variable 
domain (VL) at the N-terminus and a constant domain (CL) at the C-terminus. An IgG 
heavy chain for example comprises a variable domain at the N-terminus (VH), followed 
by a constant domain (CH1). CH1 in turn is connected through the Hinge-region with the 
constant domains CH2 and CH3. The Hinge-region is highly flexible, connecting two 
heavy chains by disulphide bonds and strong hydrophobic interactions (Davies and 
Metzger, 1983). Light and heavy chains are connected through disulphide bonds 
between CL and CH1 (Murphy et al., 2008). The better part of the constant antibody 
domains form the Fc-part (fragment crystallisable), which induces effector functions. The 
variable areas (Fv, fragment variable) mediate antigen specificity by six hypervariable 
domains (three per polypeptide chain, consisting of 3 – 20 amino acids). These 
complementarity determining regions (CDR) are flanked by more or less constant 
framework regions (Wu and Kabat, 1970; Griffiths et al., 1993). The six CDRs are in 
close proximity in a native folded antibody, forming the antigen binding site (paratope), 
which offers a complementary surface to the antigenic pendant (epitope). The antibody-
antigen-binding is conferred through non-covalent interactions like electrostatic 
attraction, hydrogen bonds, Van-der-Waals forces and hydrophobic interactions (Murphy 
et al., 2008). 
2.2.1 Antibody formats 
Different antibody fragments can be obtained by enzymatic cleavage or recombinant 
methods, which are nowadays preferred due to better handling. In therapeutic 
applications, small antibody fragments have advantages like better tissue penetration or 
lack of complement activation (by absence of the Fc-part), but also potential 
disadvantages like faster renal clearance and reduced stability (Wörn and Plückthun, 
2001; Beckman et al., 2007; Schirrmann et al., 2011). The smallest antibody fragment is 
the single chain fragment variable (scFv), which is obtained by genetic fusion of VH and 
VL over a peptide linker (Dübel and Breitling, 1999). The single chain fragment antigen 
binding (scFab) consists of the complete light chain (VL and CL) fused to the VH and CH1 
domains of the heavy chain by a peptide linker (Hust et al., 2007). To overcome 
problems like fast renal clearance and reduced stability, scFv and scFab can be fused to 
Fc-parts by a Hinge-region, resulting in the so called scFv-Fc or scFab-Fc (scIgG) 
antibodies (Jäger et al., 2013). Dimerization of two Fc-parts through disulphide bonds 
leads to bivalent constructs (Powers et al., 2001). These scFv-Fc or scFab-Fc 
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homodimers possess increased affinity due to an avidity effect. Effector functions like 
CDC and ADCC are gained, furthermore fusion to effector molecules like toxins or 
RNases for site directed drug targeting is possible (Kreitman, 2006; Wezler et al., 2012). 
An overview of the recombinant antibody formats used in this study is given in Figure 5.  
      a) scFv           b) scFab             c) scFv-Fc                    d) scFab-Fc (scIgG) 
 
Figure 5: Recombinant antibody formats. 
Antibody symbols adapted from M. Hust, with permission. 
2.2.2 Generation of recombinant antibodies 
Polyclonal antibodies are generated by immunization of animals, a method established 
for more than a century. The hybridoma technology allows the production of monoclonal 
antibodies by the fusion of an immortal myeloma cell with an antibody producing spleen 
cell (Köhler and Milstein, 1975). Both techniques require immunization and are not 
facilitating the generation of antibodies against conserved mammalian proteins or toxic 
substances (Winter and Milstein, 1991). Mostly goat, rat, rabbit or mouse antibodies are 
produced by one of the two methods, which have immunogenic potential, crucial for 
therapeutic use (Tjandra et al., 1990). The availability of human B-lymphocytes for the 
generation of human hybridomas is not only limited, but problematical due to ethnical 
reasons. An alternative is the usage of transgenic animals, but this method is as well 
limited by the immunization step (Weiner, 2006).  
Selection of human antibodies, completely independent from any immune system, is 
possible by in vitro display technologies (Bradbury et al., 2011). Antibody phage display 
is the most commonly used method, where antibodies are genetically and physically 
linked to one of the surface proteins (i.e. pIII) of the filamentous bacteriophage M13 
(Smith, 1985; Barbas, 3rd et al., 1991). Higher genetic stability and simplification of the 
antibody gene library amplification was achieved by uncoupling phage propagation from 
antibody expression (Frenzel et al., 2012). Therefore the antibody: pIII fusion proteins 
were encoded on a separate plasmid (so called phagemide), containing a phage 
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morphogenetic signal for packaging the vector into the assembled phage particles 
(Figure 6). Using the phagemid system, a helper-phage (i.e. Hyperphage (Broders et al., 
2003)) is needed for the production of antibody phage particles (Schirrmann et al., 2011). 
              A)                                              B) 
 
Figure 6: A) Antibody-phage and B) phage display vector pHAL14. 
A) Phage presenting a scFv-antibody fused to pIII-protein, pIII-pIX: phage coat proteins, 
phagemid encoding scFv. B) Phagemid pHAL14, displaying Lac Pr.: lac promotor, RBS: ribosome 
binding site, VH: antibody heavy chain gene, VL: antibody light chain gene, pelB: secretion signal 
sequence, bla: beta lactamase gene, gIII: pIII encoding gene, cloning sites, termination 
sequences and two origins of replication (colE1 and M13 ori). Figure adapted from (Schirrmann 
and Hust, 2010). 
 
Different types of antibody gene libraries can be constructed in the phage display format. 
Immune libraries are generated from affinity matured B cells (IgG) of immunized donors, 
usually to obtain antibodies against a particular pathogenic target (Pelat et al., 2007). 
Naïve, semi-synthetic and synthetic libraries are constructed to generate antibodies 
against every possible antigen (Hust and Dübel, 2004; Chan et al., 2011; Tiller et al., 
2013). In this study the human naïve libraries HAL4/7/8 are used, constructed from 
rearranged V genes of B cells (IgM) of non-immunized donors cloned into the phagemid 
pHAL14 (Figure 6:B) and packaged using Hyperphage (Hust et al., 2011). 
2.2.3 Selection of recombinant antibodies by “panning” 
The in vitro isolation of antibody fragments from antibody gene libraries by their binding 
activity is called panning. Surface-immobilized antigen is incubated with the respective 
phage library followed by washing steps to remove unbound phages. After an elution 
step (i.e. with trypsin), phage are reamplified by infecting E. coli. Then the bacteria are 
infected with a helper-phage to produce new antibody phage. These can be used for 
further panning rounds until a significant enrichment of antigen specific phage is 
achieved (Frenzel et al., 2012). Within successive rounds of panning, conditions  
(i.e. antigen amount, pH, temperature, competition) can be adapted according to the 
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desired properties (Hoogenboom, 2005). In addition, secondary libraries of selected 
antibodies can be constructed to further increase the specificity, affinity or stability 
(Steidl et al., 2008; Thie et al., 2009). 
 
Figure 7: Schematic overview of the selection of antibodies (“panning“) by phage display. 
Figure adopted from (Schirrmann et al., 2011). 
2.3 Aim of this work 
Tuberculosis is still the leading cause of death due to bacterial infections worldwide 
(WHO 2012). State of the art TB diagnostic is mostly expensive or time consuming, 
especially in developing countries a simple point of care TB test is needed (Dheda et al. 
2013). Direct detection of Mtb antigens in human specimens would allow specific 
diagnostic of active TB, independent from the host’s immune response. Furthermore, the 
use of antibodies binding Mtb antigens in a LFIA would facilitate a rapid test in a cost 
effective, easy-to-use format. For the development of diagnostic assays, recombinant 
antibodies generated by phage display are an alternative to polyclonal and monoclonal 
antibodies (Kirsch et al., 2008; Schütte et al., 2009; Meyer et al., 2011; Chan et al., 2013; 
Lillo et al., 2011). The aim of this work was, first to isolate recombinant antibodies 
against the Mtb antigens 16 kDa, ESAT-6, CFP-10, LAM, AlaDH, 85 A, 85 B and 85 D 
from naïve human phage display libraries. Second, a recombinant antibody should be 
constructed from an IgM expressing hybridome. Third, the generated antibodies ought to 
be purified, biochemically characterised and examined regarding their suitability in 
different Mtb antigen detection assays. 
  3 Materials and Methods 
17 
 
3 Materials and Methods 
3.1 Materials 
3.1.1 Consumables 
All consumables used in this study are listed in Table 2.  
Table 2: Consumables 
product supplier catalog number 
pipette tips (10 µL) Biohit, Germany 783211 
pipette tips (200 µL) Biohit, Germany 790201 
pipette tips (350 µL) Biohit, Germany 790350 
pipette tips (1000 µL) Biohit, Germany 791001 
pipette tips (1200 µL) extended Biohit, Germany 791211 
polypropylene tubes (15, 50 mL) Greiner, Germany 188271, 227261 
syringes (5, 10, 25 mL) Braun, Germany 0057.1, 0058.1, 0059.1 
syringe filter (0.22 μm) Millipore, Germany P668.1 
micro centrifuge tubes (1.5 mL) Greiner, Germany 616201 
micro centrifuge tubes (2 mL) Eppendorf, Germany 10073321 
PCR tubes Abgene, UK AB-0620 
petri dishes Sarstedt, Germany 82.1473 
screw cap tubes (1.5, 2 mL) Biozym, Germany 710056 
PVDF membrane Millipore, Germany T831.1 
blotting paper Carl Roth, Germany 4926.1 
sensor chip CM5 GE Healthcare, Germany BR-1000-12 
Unisart CN 95 Nitrocellulose 
membrane Sartorius, Germany 1UN95ER050025WS 
backing cards DIMA, Germany custom 
cellulose fibre pads Millipore, Germany CFSP001750 
glass fibre conjugate pads Millipore, Germany GFCP000850 
LFST cassettes Shanghai Jieyi Biotechnology, China custom 
Dessicant Wisepac, UK MT-1/6 
LDPE bags (70 x 100 mm) Viking, Germany Q87-B221 
screen tape Agilent, Germany 5067-5371 
Microlon 96 Well Plates Greiner, Germany 655061 
Maxisorp Polystyrol 96 Well Plates Nunc, USA 44-2404-21 
PP- Mikrotiterplatten Greiner, Germany 650201 
cover for MTP 
 
Greiner, Germany 656190 
seal breathable for MTP Greiner, Germany 676001 
75 cm2 cell culture flasks Corning, Netherlands CLS3290 
Vivaspin20 concentrator 
(MWCO 10 kDa) Sartorius, Germany VS2001 
Vivacell100 concentrator 
(MWCO 10 kDa) Sartorius, Germany VC1002 
polycarbonate Erlenmeyer flasks Corning, Netherlands CLS430421 
ventilation membrane caps Corning, Netherlands CLS431449-4EA 
Bio-Scale Mini UNOsphere SUPrA 
Cartridges Bio-Rad, Germany 732-4400 
Ni-NTA Superflow QIAGEN, Germany 30450 
Sephadex G-25 GE Healthcare, Germany G25150-500G 
glassware Schott, Germany  
 
3 Materials and Methods   
18 
 
3.1.2 Technical Equipment 
The technical equipment used in this study is listed in Table 3 
Table 3: Technical equipment 
product class specific type supplier 
0.5 – 10 µL pipette Reference Eppendorf 
2 – 20 µL pipette Pipetman Gilson 
10 – 100 µL pipette Proline Plus Biohit 
20 – 200 µL pipette Pipetman Gilson 
50 – 1000 µL pipette Pipetman Gilson 
50 – 300 µL multichannel pipette Proline Plus Biohit 
50 – 1200 µL eletronic multichannel 
pipette eLine Biohit 
pipette controler pipetus  Hirschmann 
analytical balance EW600-2M Kern 
semi dry electro blotter Perfect Blue Sedec M Agilent (Peqlab) 
centrifuge (Eppenedorf Cap) Eppendorf 5414 D Eppendorf 
centrifuge (Falcon tube) Eppendorf 5810 R Eppendorf 
centrifuge (bottle, SS34) Sorvall RC5C Sorvall 
Oak Ridge Centrifuge Tube, PC, 50 mL 525-2234 Nalgene 
centrifuge bottle with sealing cap, PPCO, 
500 mL 3141-0500 Nalgene 
clean bench Hera safe Heaeus 
incubator Heraeus B12 Heraeus 
thermo shaker PST-60HL-4 lab4you 
mini rocker MR-1 biolab 
agarose gel electrophoresis chamber HW10 Biometra 
polyacrylamid gel electrophoresis 
chamber Mini Hoeffer SE250 Hoeffer 
columns for Ni-NTA, Sephadex XK-16, XK-26 GE Healthcare 
automatic protein purification automate Profinia 2.0 Biorad 
protein purification system Smartline preparative pump 1800 Knauer 
 Smartline UV detector 2520 Knauer 
 
Smartline 2900 conductivity/pH 
monitor Knauer 
 Dynamic mixing chamber Knauer 
 Foxy R1 fraction collector Teledyne Isco 
HPLC system PLATINblue HPLC Plus system Knauer 
ELISA washer Ultrawash 96 channel Dynatec 
ELISA reader MRX Dynatec 
thermocycler Tpersonal Biometra 
surface plasmon resonance analysis unit Biacore 2000 Biacore 
Tape Station System 2200 Agilent (Peqlab) 
Milli-Q ultrapure water facility 07.4415 TKA 
dispenser  xyz-dispenser Biodot 
guillotine-cutter CM4000 Biodot 
gel documentation station Herolab Easy LTF 
Transilluminator Dark Reader DR89X Clare Chemical 
autoclave Fedegari Autoclavi Spa Integra 
spectrophotometer Nanophotometer Implen 
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3.1.3 Chemicals, buffers and solutions 
All chemicals used were p.a. purity grade and purchased from Sigma, Merck or Carl 
Roth (all located in Germany) or as indicated otherwise. All buffers and solutions used in 
this study are listed in Table 4. They were either prepared with Milli-Q ultra pure water 
[0.055 mS cm-1 ] or as indicated otherwise. 
Table 4: Buffers and solutions 
purpose solution recipe 
ELISA PBS (Sambrook and Russell, 2001) 
137 mM NaCl, 2.5 mM KCl,  
8 mM Na2HPO4, 1.5 mM 
KH2PO4, pH 7.4 
 PBS-B PBS + 1 % (w/v) BSA 
 PBST0.1 PBS + 0.1 % (w/v) Tween-20 
 PBST0.05 PBS + 0.05 % (w/v) Tween-20 
 PBST-B PBST0.1 + 1 % (w/v) BSA 
 MPBST PBST0.1 + 2 % (w/v) skim  milk 
 
TMB (3,3',5,5'-
tetramethylbenzidine) 
ready to use (Seramun, S-004-5-
TMB) 
 stop solution 0.2 M H2SO4 
panning panning block PBS + 1 % BSA + 1 % skimmed 
milk 
 trypsin 10 µg/mL in PBS 
preparation of the 
periplasmatic fraction PE buffer 
20 % (w/v) sucrose; 50 mM 
Tris/HCl; 1 mM EDTA; pH 8.0 
preparation of the 
osmotic shock 
fraction 
OS buffer 5 mM MgSO4  
epitope mapping 10x PBS 1.5 M NaCl, 92 mM Na2HPO4, 16 
mM NaH2PO4, pH 7.2 
 TBS 6.06 g tris base, 0.2 g KCl, 8 g NaCl, pH 8.0, ad 1 L 
 TBS-T TBS + 0.1 % (w/v) Tween-20 
 regeneration buffer  62.5 mM tris, 2 % (w/v) SDS, 100 
mM ß-mercaptoethanol, pH 6.7 
SDS-PAGE anode buffer 200 mM tris base, pH 8.9 
 cathode buffer 100 mM tris base, 100 mM tricine, 0.1 % (w/v) SDS, pH 8.25 
 
Rotiphorese Gel 40  
(ready to use, Roth, A515.1) 
30 % (w/v) acrylamide, 0.8 % 
(w/v) bis-acrylamide 
 ammonium persulfate (APS) 40 % (w/v) 
 gel buffer 3 M tris base, 0.3 % (w/v) SDS, pH 8.45 
 bromophenol blue 0.1 % (w/v)  
 2x sample buffer 
100 mM tris/HCl, 200 mM DTT, 4 
% (w/v) SDS, 0.2 % (w/v) 
bromophenol blue, 20 % (w/v) 
glycerol, pH 6.8 
 
Page Ruler Unstained Protein 
Ladder 
ready to use (Fermentas, 
SM0661) 
 
Page Ruler Prestained Protein 
Ladder 
ready to use (Fermentas, 
SM0671) 
western blot transfer buffer 60 mM tris, 48.8 mM Glycin, 0.46 % (w/v) SDS, pH 8.3 
immunostain TMB membrane substrate ready to use (Seramun, S-002-4-TMB) 
coomassie staining staining 40 % (v/v) ethanol, 10 % (v/v) 
acetic acid, 1.45 mM coomassie 
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brilliant blue 
 destaining 25 % (v/v) ethanol, 8 % (v/v) 
acetic acid 
silver staining fixation 
20 % (v/v) ethanol 
12 % (v/v) acetic acid 
0.5 mL/L formaldehyde (37 %) 
 dehydration 1  50 % (v/v) ethanol 
 dehydration 2  30 % (v/v) ethanol 
 pre-treatment 0.2 g/L Na2S2O3 
 staining 2 g/L AgNO3  
0.75 ml/L formaldehyde (37 %) 
 development 
60 g/L Na2CO3 
4 mg/L Na2S2O3 
0.5 mL/L formaldehyde (37 %) 
 stop 10 % (v/v) ethanol 
12 % (v/v) acetic acid 
Biacore EDC 75 g/L 
 NHS 11.5 g/L 
 ethanolamine 1 M  
 acetate buffer 10 mM sodium acetate pH 4.0  
 MgCl2  3 M 
Ni-NTA affinity 
chromatography running buffer 
20 mM tris/HCl, 500 mM NaCl, 
pH 8.0 
 elution buffer 20 mM tris/HCl, 500 mM NaCl, 
500 mM imidazole pH 8.0 
Profinia protein 
purification running buffer 
20 mM Na2HPO4, 20 mM 
NaH2PO4, pH 7.2 
 elution buffer 100 mM trisodiumcitrate, pH 3.0 
 neutralization buffer 1 M tris/HCl, pH 9.0 
analytical SEC running buffer 10 mM NH4HCO3 pH 8.0 or PBS 
pH 7.4 
PCR dNTP 
dATP, dCTP,d GTP, dTTP (10 mM 
each) ready to use (Fermentas, 
R0191) 
agarose gel 
electrophoresis TBE 
89 mM tris base, 89 mM boric 
acid, 2 mM EDTA pH 8.0 
 6x sample buffer 
0.5x TBE, 43.5 % (w/v) glycerol, 
0.1 % (w/v) bromphenol blue, 
0.1 % (w/v) xylenecyanol blue 
 100 bp DNA Ladder ready to use (Fermentas, SM0243) 
 1 kb DNA Ladder ready to use (Fermentas, SM0313) 
DNA staining Gel Star Nucleic Acid Stain 1:40,000 in TBE (Lonza, 50535) 
DNA storage EB (elution buffer) 10 mM Tris/HCl, pH 8.5 
 
3.1.4 Enzymes 
All enzymes used in this study are listed in Table 5. 
Table 5: Enzymes and appropriate buffers 
enzyme supplier catalog 
number 
restriction endonuclease NcoI (10 U/µL) Fermentas, Germany ER0571 
restriction endonuclease NotI (10 U/µL) Fermentas, Germany ER0591 
restriction endonuclease HindIII, HC (50 U/µL) Fermentas, Germany ER0503 
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restriction endonuclease NdeI (10 U/µL) Fermentas, Germany FD0584 
restriction endonuclease NheI (10 U/µL) Fermentas, Germany ER0971 
restriction endonuclease MfeI (10 U/µL) Fermentas, Germany ER0751 
restriction endonuclease XhoI (10 U/µL) Fermentas, Germany FD0694 
restriction endonuclease MluI (10 U/µL) Fermentas, Germany ER0561 
restriction endonuclease buffer O Fermentas, Germany included with 
enzyme 
restriction endonuclease buffer Tango Fermentas, Germany included with 
enzyme 
restriction endonuclease buffer R Fermentas, Germany included with 
enzyme 
restriction endonuclease buffer EcoRI Fermentas, Germany included with 
enzyme 
T4 DNA Ligase (3 U/µL) Promega, Germany M180A 
T4 DNA Ligase buffer Promega, Germany included with 
enzyme 
Superscript Reverse Transcriptase II Invitrogen, Germany 18064-022 
5 x RT-Puffer Invitrogen, Germany included with 
enzyme 
Phusion® High-Fidelity DNA Polymerase 
(2u/µl) Finnzymes, Keilaranta F530L 
Phusion-Puffer HF 5x Finnzymes, Keilaranta included with enzyme 
DreamTaq™ Green PCR Master Mix (2X) Fermentas, Germany K1081 
RNaseOut Invitrogen, Germany VX10777019 
 
3.1.5 Antibodies and antigens 
All antibodies used in this study are listed in Table 6 
Table 6: Commercial and in-house produced antibodies 
antibody format conc. [mg/mL] 
antibody 
type 
supplier (catalog 
number) 
dilution 
WB / ELISA 
Mouse α-C-Myc-
tag (9E10) IgG  monoclonal 
in-house produced 
culture 
supernatant 
1:2,000 / 
1:1,000 
Mouse α-C-Myc-
tag-HRP (9E10) IgG 1.00 monoclonal Abcam (ab62928) 1:10,000 / - 
Goat α-mouse IgG  
(Fc specific)-HRP IgG 6.00 polyclonal Sigma (A0168) 
1:12,000 / 
1:30,000 
Goat α-mouse IgG 
(Fab specific)-HRP IgG 5.70 polyclonal Sigma (A2304) - / 1:20,000 
Goat α-human-IgG 
(Fc specific)-HRP IgG 7.40 polyclonal Sigma (A0170) 
1:10,000 / 
1:130,000 
Goat α-mouse-IgM 
(µ specific)-HRP IgG 3.00 polyclonal Sigma (A8786) 
1:10,000 / 
1:2,000 
Mouse α-LAM 
(Lx143) IgM 1.06 monoclonal Lionex (Lx143) - / 1:1,000 
Mouse α-penta-
His-tag IgG 0.10 monoclonal QIAgen (34660) 1:20,000 
 
 
 
3 Materials and Methods   
22 
 
All antigens used in this study are listed in Table 7. 
Table 7: Antigens 
antigen Uniprot ID origin used batches provider 
Mtb LAM - purified from M. tuberculosis H37Rv extract 09-2/1 Lionex 
BCG 
LAM - purified from M. bovis BCG extract 11-1/1 Lionex 
AlaDH P30234 recombinant M. tuberculosis gene Rv2780  
expressed in and purified from E. coli 
09-1/1, 
08-1/1 Lionex 
ESAT-6 P0A564 recombinant M. tuberculosis gene Rv3875 
expressed in and purified from E. coli 06-1/1 Lionex 
CFP-10 POA566 recombinant M. tuberculosis gene Rv3874 
expressed in and purified from E. coli 09-1/1 Lionex 
85 A 
(FbpA) P0A4V2 
recombinant M. tuberculosis gene Rv3804c 
expressed in and purified from E. coli 07-1/1 Lionex 
85 B 
(FbpB) P0C5B9 
recombinant M. tuberculosis gene Rv1886c 
expressed in and purified from E. coli 
10-1/1, 
10-1/2 Lionex 
85 D 
(FbpD) P0A4V6 
recombinant M. tuberculosis gene Rv3803c 
expressed in and purified from E. coli 07-1/3 Lionex 
16 kDa B2I424 recombinant M. tuberculosis gene Rv2031c 
expressed in and purified from E. coli 
04-3/1, 
04-3/2, 
12-2/1, 
C11-1/1 
Lionex 
3.1.6 Commercial kits 
All commercially available kits used in this study are listed in Table 8. 
Table 8: Commercial kits 
purpose specific type supplier catalog number 
plasmid DNA 
isolation QIAprep Spin Miniprep Kit 
QIAGEN, 
Germany 27106 
 QIAGEN Plasmid Midi Kit QIAGEN, Germany 12143   
DNA purification QIAquick Gel Extraction Kit QIAGEN, Germany 28706 
 QIAquick PCR Purification Kit QIAGEN, Germany 28104 
reducing gel analysis 
of proteins 
Screen Tape P200 Protein 
Standard Kit  
Agilent, 
Germany 5067-5371 
RNA isolation RNeasy Mini Kit QIAGEN, Germany 74104 
coupling HRP to 
proteins 
EZ-Link Plus Activated 
Peroxidase Kit 
Pierce, 
Germany 31489 
T/A-cloning TOPO T/A-cloning Kit Invitrogen, Germany 450641 
reverse transcription 
of RNA to cDNA Superscript II Kit 
Invitrogen, 
Germany 18064-022 
protein 
determination DC Protein Assay I 
Bio-Rad, 
Germany 500-0111 
surface plasmon 
resonance scFv-Fc Human Antibody Capture Kit 
GE Healthcare, 
Germany BR-1008-39 
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3.1.7 Materials for cultivation and storage of organisms 
All media were prepared with deionized water (dH2O) or as indicated otherwise. 
3.1.7.1 Prokaryotes 
All media and supplements used for cultivation of E. coli are listed in Table 9. 
Table 9: Media and supplements used for cultivation of E. coli  
purpose medium/supplement recipe 
standard culture 2xYT (Sambrook and Russell, 2001) 
1.0% (w/v) Bacto yeast 
extract, 1.6% (w/v) Bacto 
tryptone, 0.5% (w/v) NaCl, 
pH 7.0 
 2xYT-A 2xYT + 100 µg/mL ampicillin 
 2xYT-G/A 2xYT + 100 µg/mL ampicillin 
+ 100 mM glucose 
 ampicillin stock solution 100 mg/mL in Milli-Q 
 glucose stock solution 2 M in Milli-Q 
panning 2xYT-A/K 2xYT + 100 µg/mL ampicillin 
+ 10 µg/mL kanamycin 
 2xYT-T 2xYT + 5 µg/mL tetracyclin 
 2xYT-G/A agar 2xYT-G/A + 15 g/L agar-
agar 
 kanamycin stock solution 10 mg/mL in Milli-Q 
 tetracyclin stock solution 5 mg/mL in 96 % (v/v) 
ethanol 
chemically competent cells TFB1 
50 mM MnCl2·2 H2O, 100 
mM RbCl, 50 mM MgCl2, 30 
mM CH3COOK, 10 mM 
CaCl2, 15 % (w/v) glycerol, 
pH 5.8 
 TFB2 
10 mM MOPS, 10 mM RbCl, 
75 mM CaCl2, 15 % (w/v) 
glycerol, pH 8.0 
transformation SOC 
0.5% (w/v) Bacto yeast 
extract, 2.0% (w/v) Bacto 
tryptone, 0.05% (w/v) NaCl 
pH 7.0, after autoclaving 
addition of 
20 mM MgCl2, 20 mM 
glucose 
expression 2xYT-S/A-IPTG 
2xYT + 50 mM sucrose + 
100 µg/mL ampicillin + 50 
µM IPTG 
 sucrose stock solution 1 M in Milli-Q 
 IPTG stock solution 50 mM in Milli-Q 
 
TB (Sambrook and Russell, 
2001) 
12 % (w/v) Bacto tryptone, 
24 % (w/v) yeast extract, 4.3 
% (w/v) glycerol ad 900 mL 
 TB-salts 0.17 M KH2PO4, 0.72 M K2HPO4, 100 mL 
 TB-G/A TB + 100 µg/mL ampicillin + 100 mM glucose 
storage 2xYT-G/A + glycerol 2xYT-G/A + 30 % (w/v) glycerol 
 
 
3 Materials and Methods   
24 
 
All media and supplements used for cultivation of M. tuberculosis are listed in Table 10. 
Table 10: Media and solutions used for cultivation of M. tuberculosis 
purpose medium/supplement recipe 
standard culture 
Difco™ Middlebrook 7H9 Broth 
(dehydrated culture media, BD, 
271310) 
approximate formula per 900 
mL (supplier declaration): 
Ammonium Sulfate 0.5 g, L-
Glutamic Acid 0.5 g, Sodium 
Citrate 0.1 g, Pyridoxine 1.0 
mg, Biotin 0.5 mg, Disodium 
Phosphate 2.5 g, 
Monopotassium Phosphate 
1.0 g, Ferric Ammonium 
Citrate 0.04 g, Magnesium 
Sulfate 0.05 g, Calcium 
Chloride  0.5 mg, Zinc 
Sulfate, Copper Sulfate 1.0 
mg, ad 900 mL, pH 6.6 ± 0.2 
 
BBL™ Middlebrook ADC 
Enrichment (BD, 211887) 
Approximate formula per 
1000 mL (supplier 
declaration): 
Sodium Chloride 8.5 g, 
Bovine Albumin (Fraction V) 
50.0 g, Dextrose 20.0 g, 
Catalase 0.03 g, pH 6.9 ± 0.2 
 7H9 + ADC + Tween 
900 mL Difco™ Middlebrook 
7H9 Broth + 100 mL BBL™ 
Middlebrook ADC 
Enrichment + 0.05 % (w/v) 
Tween-80 
 Tween-80 stock solution 1 % (w/v)Tween-80 in Milli-Q 
 
7H9 + ADC + Tween + Gm + 
Cm + E* 
7H9 + ADC + Tween + 80 
µg/mL gentamycin + 34 
µg/mL chloramphenicol + 10 
µg/mL ethambutol 
 ethambutol stock solution 10 mg/mL ethambutol-dihydrochloride in methanol 
 gentamycin stock solution 80 mg/mL gentamycin 
sulfate in Milli-Q 
 chloramphenicol stock solution 34 mg/mL in 96 % (v/v) 
ethanol 
concentration of culture 
filtrate Sauton’s 
4 g/L L-asparagine x H2O, 
0.5 g/L MgSO4 x 7 H2O, 2 
g/L citric acid x H2O, 0.66 g/L 
K2H PO4 x 3 H2O, 0.05 g/L 
ammonium iron (III) citrate, 
4.83 g/L glucose x H2O, 4.83 
g/L pyruvic acid sodium salt, 
73.8 g/L 87% (w/v) glycerol, 
pH 6.8 
 Sauton’s + Gm +Cm + E* 
Sauton’s + 80 µg/mL 
gentamycin + 34 µg/mL 
chloramphenicol + 10 µg/mL 
ethambutol 
*Addition of antibiotics after sterile filtration of culture fluid. 
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3.1.7.2 Eukaryotes 
All media, solutions and supplements used for culture of mammalian cells are listed in 
Table 11. 
Table 11: Media, solutions and supplements used for cultivation of mammalian cells 
purpose medium/supplement working concentration 
suspension culture of 
HEK293-6E 
FreeStyle F17 medium 
(Invitrogen, 10388033)  
 
G418 sulfate (50 µg/mL, 
Invitrogen, 10131-027) 25 mg L
-1
  
 
pluronic F68 (Applichem, 
A1288,0100) 1 g L
-1
  
 L-glutamine (PAA, M11-004) 4 mM  
 
tryptone N1 (19553, 
Organotechnie S.A.S., France) 0.5 % (w/v) 
transfection of HEK293-6E 
cells 
polyethyleneimide 
(Polysciences, Germany) 2.5 µg mL
-1 
harvesting of culture 
supernatant from HEK293-
6E cells 
Fetal calf serum (FCS) 
(Invitrogen, 10084-168) 1 % (v/v)  
 PMSF (Carl Roth, 6367.1) 1 mM  
adherent culture of 
hybridoma Lx143 
DMEM high glucose with L-
glutamine and sodium pyruvate 
(GE Healthcare, E15-843) 
 
 FCS 10 % (w/v) 
 
Penicillin-Streptomycin 5000 U 
mL-1 (Pen/Strep, PAA, P11-
010) 
1 % (v/v) 
 
3.1.8 Organisms 
3.1.8.1 Bacterial strains and bacteriophages 
All bacterial strains and bacteriophages used in this study are listed in Table 12. 
Table 12: Bacterial strains and bacteriophages 
strain genotype origin 
E. coli XL1 Blue MRF’ 
supE44 hsdR17 recA1 endA1 
gyrA46 thi relA1lac-F' [proAB + lacq 
ZDM15 TN10(tetR)] 
Stratagene, Germany 
helper phage M13K07 - Agilent (Vieira and Messing, 1987)  
M. tuberculosis H37Rv - Lionex 
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3.1.8.2 Eukaryotic cell lines 
All eukaryotic cell lines used in this study are listed in Table 13. 
Table 13: Eukaryotic cell lines 
strain description origin 
HEK293-6E 
Immortalized human embryonic 
kidney cells, expression of Epstein-
Barr-Virus nuclear antigen 1, 
suspension culture 
NRC, BRI, Canada 
Lx143 mouse hybridome expressing α-LAM IgM, suspension culture Lionex 
 
3.1.9 Molecular vectors 
All molecular vectors used in this study are listed in Table 14. 
Table 14 Molecular vectors 
purpose vector description supplier / origin 
antibody sequence 
isolation pCR2.1-TOPO 
prokaryotic subcloning vector 
(heavy or light chain only) Invitrogen 
antibody library, 
phage display pHAL14 phagemid vector (scFv-pIII) 
TU-BS (Hust et 
al., 2011) 
antibody library, 
phage display pHAL20 phagemid vector (scFab-pIII) 
TU-BS (M. Hust 
unpublished) 
expression in E. coli pOPE101-XP prokaryotic expression vector (scFv, scFab) 
TU-BS (Hust et 
al., 2009) 
expression in  
HEK293-6E 
pCSE2.5-hIgG1-
Fc-XP 
eukaryotic transient 
expression vector (scFv-Fc, 
scFab-Fc) 
TU-BS (Jäger et 
al., 2013) 
 
3.1.10 Oligonucleotides 
All oligonucleotides used in this study were synthesized by Metabion Germany or as 
indicated otherwise and are listed in Table 15. 
Table 15: Oligonucleotides  
name sequence (5’ – 3’) application 
Oligo(dT)12-18 dPO4 [(T)12-18] (Invitrogen, 18418-012) cDNA synthesis 
Bi3* GAG GTG AAG CTG CAG GAG TCA GGA CCT AGC CTG GTG 
isolation mouse  
VH fo 
Bi3b* AGG TSM AAC TGC AGS AGT CWG G isolation mouse VH fo 
Bi3d* AGG TSC AGC TGC AGS AGT CWG G isolation mouse VH fo 
mouse VH rv* ATT TGG GAA GGA CTG ACT isolation mouse IgM VH CH1 rv 
Bi5* GGG AAG ATG GAT CCA GTT GGT GCA GCA TCA GC isolation mouse VLК rv 
Bi6* GGT GAT ATC GTG ATR ACM CAR GAT GAA CTC TC isolation mouse VLК fo 
Bi7* GGT GAT ATC WTG MTG ACC CAA WCT CCA CTC TC isolation mouse VLК fo 
Bi8* GGT GAT ATC GTK CTC ACY CAR TCT CCA GCA AT isolation mouse VLК fo 
NS21 GGT GAY ATY CAR ATG ACN CAR WSN CCN GCN WSN YTN WS isolation mouse VLК fo 
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M13 fwd GTT TTC CCA GTC ACG AC TOPO-cloning colony PCR 
M13 rev CAG GAA ACA GCT ATG AC TOPO-cloning colony PCR 
M13-FP TGT AAA ACG ACG GCC AGT Sequencing of TOPO-
constructs 
MFU_LAM_VL_MluI
I_fo 
ACC GCC TCC ACG CGT AGA TAT CGT 
GAT GAC CCA G 
integration of restriction 
sites to α-LAM VL 
Mouse IgM VL rv 
NotI 
ACC GCC TCC GCG GCC GCA GTT GGT 
GCA GCA TCA GC 
integration of restriction 
sites to α-LAM VL 
MFU_LAM_VH_Nco
I_fo 
ACC GCC TCC CCA TGG CCG AGG TGA 
AGC TGC AG 
integration of restriction 
sites to α-LAM VH 
Mouse IgM VH rv 
HindIII 
GTCCTCGCAAAGCTTATTTGGGAAGGA
CTGACT 
integration of restriction 
sites to α-LAM VH 
MHLacZPro_f CTA AAG TTT TGT CGT CTT TCC colony PCR pHAL14 
MHgIII_r1 GGC TCG TAT GTT GTG TGG colony PCR pHAL14 
MFU a-LAM scFab 
VLK Fo NcoI 
GAG TGA CCA TGG CCG ATA TCG TGA 
TGA CC 
subcloning of α-LAM 
scFv to scFab 
MFU a-LAM scFab 
VLK Rv XhoI 
ACG AGA CTC GAG CTT GGT GCC TCC 
ACC 
subcloning of α-LAM 
scFv to scFab 
MFU a-LAM scFab 
VH Fo MfeI 
GCG AGC CAA TTG CAG GAG TCA GGA 
CCT 
subcloning of α-LAM 
scFv to scFab 
MFU a-LAM scFab 
VH Rv NheI 
GCG AGC GCT AGC TGA GGA GAC GGT 
GAC 
subcloning of α-LAM 
scFv to scFab 
MHCH1_r3 GGT GCT CTT GGA GGA GGG colony PCR pHAL20 
MHpOPE_f2 CTT AGA TTC AAT TGT GAG CGG colony PCR pOPE101-XP 
MHpOPE_r2 CTG ATC ATT AGC ACA GGC C colony PCR pOPE101-XP 
α-LAM VLK Fo 
mut2 MluI 
ACC GCC TCC ACG CGT AGA TGT CGT 
GAT GAC CCA AAC TC mutation α-LAM VLК 
α -LAM VH Fo mut2 
NcoI 
ACC GCC TCC CCA TGG CCG AGG TGA 
AGC TGG AGG AGT CA mutation α-LAM VH 
α -LAM scFab2 VLK 
Fo NcoI 
AGC GCG TAA CCA TGG CCG ATG TCG 
TGA TGA CCC AA 
integration of restriction 
sites to α-LAM VLК 
α -LAM scFab2 VLK 
Rv XhoI 
ACC GCC TCC CTC GAG CTT GGT GCC 
TCC ACC GAA 
integration of restriction 
sites to α-LAM VLК 
α -LAM scFab2 VH 
Fo MfeI 
ACC GCC TCC CAA TTG GAG GAG TCA 
GGA GGT GGC 
integration of restriction 
sites to α-LAM VH 
α -LAM scFab2 VH 
Rv NheI 
ACC GCC TCC GCT AGC TGA GGA GAC 
GGT GAC TGA 
integration of restriction 
sites to α-LAM VH 
Tor-pCMV-mIgG01-
FC-seq-f CAC TTT GCC TTT CTC TCC  
colony PCR pCSE2.5-
hIgG1-Fc-XP 
Tor-pCMV-mIgG01-
Fc-seq-r CAG ATG GCT GGC AAC TAG 
colony PCR pCSE2.5-
hIgG1-Fc-XP 
*(Dübel et al., 1994) 
3.1.11 Peptides 
Peptides were N-acetylated and covalently bound to cellulose-β-alanine membranes in 
form of peptide-spots (~5 nmol per spot). Peptide-spot-membranes were rather 
purchased at JPT1 (Berlin, Germany) or provided by Susanne Daenicke2 (Helmholtz 
Centre for Infection Research, Braunschweig, Germany) as shown in Table 16. For 
further details see appendix. 
 
3 Materials and Methods   
28 
 
Table 16: Peptide-spot-membranes  
antigen total aa peptide 
count 
peptide 
length [aa] 
offset 
[aa] 
overlap 
[aa] 
orientation on 
membrane                 
(lane x spots) 
16 kDa1 144 34 15 4 11 2 lanes (1x20, 1x14) 
85 A2 338 109 15 3 12 5 lanes (4x25, 1x9) 
85 B2 325 105 15 3 12 5 lanes (4x25, 1x5) 
CFP-102 100 30 15 3 12 2 lanes (1x25, 1x5) 
 
3.1.12 Colloidal gold- antibody conjugates 
Coupling of antibodies to colloidal gold was performed by Susanne Kämpfer (Lionex, 
Germany). 
3.1.13 Software and databases 
All software and databases used in this study are listed in Table 17. 
Table 17: Software and databases 
designation purpose reference 
BIAevaluation 4.1 analysis of BIAcore results BIAcore 
EMBOSS Transeq 
translation of nucleic acid 
sequences in 
corresponding aminoacid 
sequences 
(Rice et al., 2000) 
ExPASy Protparam 
computation of physical 
and chemical parameters 
for a protein 
http://web.expasy.org/protparam/ 
(Artimo et al., 2012) 
Finch TV 1.4.0  display of sequencing data  Geospiza Inc., USA  
Vector NTI Advance 
10.3 generation of vector maps InforMax Inc., USA 
MultAlign 
Multiple sequence 
alignment with hierarchical 
clustering 
http://bioinfo.genotoul.fr/ 
multalin/multalin.html 
(Corpet, 1988) 
Protein BLAST Protein Basic Local Alignment Search Tool 
NCBI (National Centre for 
Biotechnology Information) (Altschul 
et al., 1990)  
PubMed US National Library of Medicine 
NCBI 
http://www.ncbi.nlm.nih.gov/pubmed/ 
IMGT 
international 
ImMunoGeneTics 
information system 
http://www.imgt.org/ 
(Lefranc et al., 1999) 
VBASE2 comparison of antibody genes to database 
http://www.vbase2.org/vbase2.php 
(Retter et al., 2004) 
IEDB The Immune Epitope Database 
www.iedb.org 
(Vita et al., 2010) 
AbCheck antibody sequence test  (Martin, 1996) 
TubercuList M. tuberculosis H37Rv genome database 
http://genolist.pasteur.fr/TubercuList/ 
(Institut Pasteur, France) 
EZChrom Elite 
operation software for 
Knauer purification 
systems 
Knauer 
2200 TapeStation 
Software (A.01.02) 
operation software for 
TapeStation Agilent Technologies 
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3.2 Methods of molecular biology 
Basic molecular biological methods were performed as described in (Sambrook and 
Russell, 2001). 
3.2.1 Preparation of plasmid DNA 
Plasmid DNA was prepared from liquid E. coli overnight cultures in 2xYT-G/A using 
QIAprep Spin Miniprep Kit for subcloning, or QIAGEN Plasmid Midi Kit for transfection of 
mammalian cells according to the manufacturer’s instructions. The DNA was eluted with 
EB. 
3.2.2 Isolation of RNA 
Total RNA was isolated from liquid cultures of hybridoma cells (5 x 106 cells mL-1) using 
RNeasy Mini Kit according to the manufacturer’s instructions. The RNA was eluted with 
RNase free water. 
3.2.3 cDNA synthesis 
Using Oligo(dT)12-18 as primer the mRNA contained in total RNA was reverse transcribed 
to cDNA using the Superscript II Kit according to manufacturer’s instructions. 
3.2.4 Amplification of DNA by PCR 
DNA was amplified using polymerase chain reaction (PCR, (Mullis et al., 1986). DNA 
sequences to be amplified were determined using flanking complementary 
oligonucleotides. For corresponding purposes the oligonucleotide combinations, PCR 
mixtures and PCR programs are described below. The sequences of all used 
oligonucleotides are listed in Table 15. 
 
3.2.4.1 Amplification of antibody genes 
Table 18: Oligonucleotide pairs for the amplification of antibody genes 
oligonucleotide pair amplicon 
Bi5 + Bi6 α-LAM VLК from cDNA 
Bi5 + Bi7 α-LAM VLК from cDNA 
Bi5 + Bi8 α-LAM VLК from cDNA 
Bi5 + NS21 α-LAM VLК from cDNA 
mouse VH rv + Bi3 α-LAM VH from cDNA 
mouse VH rv + Bi3b α-LAM VH from cDNA 
mouse VH rv + Bi3d α-LAM VH from cDNA 
MFU_LAM_VH_NcoI_fo + Mouse IgM VH 
rv HindIII introduction of restriction sites to α-LAM VH  
MFU_LAM_VL_MluII_fo + Mouse IgM VL 
rv NotI introduction of restriction sites to α-LAM VLК  
MFU α-LAM scFab VH Fo MfeI + MFU α-
LAM scFab VH Rv NheI 
subcloning of α-LAM scFv to scFab formate 
introduction of restriction sites to α-LAM VH 
MFU α-LAM scFab VLK Fo NcoI + MFU 
α-LAM scFab VLK Rv XhoI 
subcloning of α-LAM scFv to scFab formate 
introduction of restriction sites to α-LAM VLК 
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Table 19: General PCR mixture for amplification of DNA with Phusion polymerase 
component amount [µL] 
5 x Phusion HF Buffer 10 
dNTPs (10 mM each) 1 
template (cDNA, plasmid, gene) 0.5 – 1  
Primer Fo (10 pmol µL-1) 1 
Primer Rv (10 pmol µL-1) 1 
Phusion Polymerase (2 U µL-1) 0,5 
dH2O 35.5 – 36  
∑ 50 
 
Table 20: PCR programs. 
A) amplification of heavy and light chain sequences from α-LAM hybridoma cDNA, b) introduction 
of restriction sites to α-LAM heavy and light chain from TOPO-constructs and c) introduction of 
restriction sites to α-LAM heavy and light chain for subcloning to pHAL20. 
 
a) b) c) 
step temp. time temp. time temp. time 
1. initial denaturation 94.0 °C 180 s 94.0 °C 180 s 98.0 °C 60 s 
2. denaturation 94.0 °C 45 s 94.0 °C 45 s 98.0 °C 20 s 
3. annealing 50.7 °C 45 s 60.0 °C 45 s 61.0 °C 20 s 
4. elongation 72.0 °C 60 s 72.0 °C 60 s 72.0 °C 20 s 
5. final elongation 72.0 °C 300 s 72.0 °C 300 s 72.0 °C 300 s 
6. storage 16.0 °C ∞ 16.0 °C ∞ 16.0 °C ∞ 
cycles: 2 – 4  30 x  30 x  40 x  
 
3.2.4.2 Colony PCR 
Colony PCR is a method were one single bacterial colony is used as template for 
amplification. During the initial denaturation step of PCR the bacterial cells are disrupted. 
Table 21: Oligonucleotide pairs for colony PCR 
oligonucleotide pair amplicon 
MHLacZPro_f + MHgIII_r1 multiple cloning site (MCS) of pHAL14 
MHLacZPro_f + MHCH1_r3 MCS of pHAL20 
MHpOPE_f2 + MHpOPE_r2 MCS of pOPE101-XP 
Tor-pCMV-mIgG01-FC-seq-f + Tor-pCMV-
mIgG01-Fc-seq-r MCS of pCSE2.5-hIgG1-Fc-XP 
 
Table 22: General PCR mixture for colony PCR 
component amount [µL] 
Dream Taq Green mix 10 
Primer Fo (10 pmol µL-1) 0.5 
Primer Rv (10 pmol µL-1) 0.5 
dH2O 9  
∑ 20 
+ one bacterial colony  
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Table 23: PCR programs for colony PCR. 
 
pHAL14, 
pOPE101-XP 
pHAL20, 
pCSE2.5-hIgG1-Fc-XP 
step temp. time temp. time 
1. initial denaturation 95.0 °C 180 s 95.0 °C 180 s 
2. denaturation 95.0 °C 30 s 95.0 °C 30 s 
3. annealing 56.0 °C 30 s 51.0 °C 30 s 
4. elongation 72.0 °C 70 s 72.0 °C 100 s 
5. final elongation 72.0 °C 300 s 72.0 °C 300 s 
6. storage 16.0 °C ∞ 16.0 °C ∞ 
cycles: 2 – 4  30 x  30 x  
 
3.2.5 Agarose gel electrophoresis 
DNA was separated using agarose gel electrophoresis (Lee et al., 2012). Therefore the 
analysed DNA and a size standard were loaded into pre-cast wells in 1 % (w/v) agarose 
gels and a current of 100 V (300 mA) was applied. The DNA in the agarose gel was 
afterwards stained with Gel Star Nucleic Acid Stain in TBE for 45 min at room 
temperature (RT) on a rocker. After three short washing steps with water the DNA could 
be detected under UV light (λ = 312 nm) due to the flourescent properties of Gel Star 
(White et al., 1999). 
3.2.6 Purification of DNA 
DNA purification directly after PCR (only one amplicon) was performed with QIAquick 
PCR Purification Kit according to the manufacturer’s instructions. The DNA was eluted 
with 30 µL 3.3 mM Tris/HCl pH 8.5. 
After PCR (with several amplicons) or enzymatic digestion DNA was purified from 
agarose gels. For this purpose DNA was separated on 1 % (w/v) agarose gel and 
stained as described in chapter 3.2.5. Afterwards the flourescent dye was excited by a 
blue light transilluminator and the DNA fragments were excised with a scalpel. The DNA 
was then purified with QIAquick Gel Extraction Kit according to the manufacturer’s 
instructions and eluted with 30 µL 3.3 mM Tris/HCl pH 8.5. 
3.2.7 T/A-cloning 
VH and VL genes amplified from cDNA were purified over agarose gels and ligated into 
pCR2.1-TOPO using the TOPO T/A-cloning Kit according to the manufacturer’s 
instructions. 
3.2.8 Digestion of DNA with restriction endonucleases 
Enzymatic DNA digestion was carried out using restriction endonucleases type II 
purchased from Fermentas (Germany). Reaction buffers and incubation temperatures 
were chosen according to the manufacturer’s instructions. Digestion was done for up to 6 
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hours at usually 37 °C and was followed by heat inactivation of the restriction enzymes 
(20 min at 65 °C or 80 °C). A typical restriction mixture is shown in Table 24. 
 
Table 24: Typical mixture for enzymatic digestion of DNA with restriction endonucleases. 
component amount [µL] 
restriction endonuclease 1 (10 U µL-1) 2 
restriction endonuclease 2 (10 U µL-1) 2 
10 x buffer 5 
DNA (i.e. PCR amplicon) 30 
dH2O 11 
∑ 50 
 
3.2.9 Ligation of DNA 
Cohesive ends of two strands of DNA were joined by ligation (Engler, M.J. and 
Richardson, C.C., 1982) by Promega T4 DNA Ligase at 22 °C for three hours. The 
composition of the ligation mixture was varying due to the size of vector and insert and 
was determined according to the manufacturer´s instructions and the following equation: 
(1)                                 	
×   

   	

×  
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3.2.10 Sequencing of DNA 
All constructed plasmids were sent for extended hotshot sequencing to Seqlab 
(Germany). Therefore 600 – 700 ng of plasmid were mixed with 20 pmol of 
oligonucleotide primer and adjusted with dH2O to a total volume of 7 µL. 
 
3.3 Microbiological methods 
3.3.1 Glycerol stocks 
For long-term storage of bacteria, glycerol cultures were used. Therefore, 900 μL 
overnight cultures of E. coli in 2xYT-G/A were mixed with 300 μL of 80 % (w/v) glycerol. 
The suspensions were stored at -80°C. 
3.3.2 Chemically competent E. coli  
20 mL of 2xYT-T were inoculated from glycerol stock with E. coli XL-1 blue MRF’ and 
incubated overnight at 37 °C and 120 rpm. From this overnight culture 350 mL of 2xYT-T 
were inoculated to an OD600nm of 0.07 and grown at 37 °C and 120 rpm till OD600nm of 
0.52 was reached. 
The culture was harvested by centrifugation (3,220 x g, 4 min, 4 °C). Supernatants after 
centrifugation were discarded and the bacterial pellets were resuspended in 30 mL of ice 
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cold TFB1 buffer. After incubation on ice for 90 min, the cells were again centrifuged 
(3,220 x g, 4 min, 4 °C). Following centrifugation, supernatants were discarded and the 
cells were resuspended in 4 mL of ice cold TFB2 buffer. Aliquots of 50 µL in 1.5 mL 
microcentrifuge tubes were sharp frozen with liquid nitrogen. The competent cells were 
stored at -80 °C. 
3.3.3 Transformation of E. coli by heat shock 
Chemically competent E. coli cells were transformed by heat shock. Therefore 10 – 20 
µL of DNA was mixed with 50 μL of competent cells and incubated on ice for 20 min. 
After heating the cells for 45 sec to 42 °C, they were chilled on ice for 2 min. For 
regeneration, transformed cells were incubated in 1 mL of SOC medium at 37 °C with 
moderate shaking for 45 min. The transformed E. coli were streaked on 2xYT agar plates 
with appropriate antibiotics and incubated overnight at 37 °C. 
3.3.4 Panning in Microtitre plates (MTP) 
The selection of recombinant antibodies was performed according to (Schirrmann and 
Hust, 2010) with modifications. In short, pannings were performed in 96 well microtitre 
plates (Microlon, Greiner). For the first panning round ten µg of antigen were coated in 
PBS pH 7.4 overnight at 4 °C. The antigen-coated wells and wells for the preincubation 
of the library were blocked with MPBST. 2.5 x 1011 phage particles of the human naive 
antibody gene libraries HAL7 and HAL8 (Hust et al., 2011) were diluted in PBST0.1 with 
1 % (w/v) skim milk and 1% (w/v) bovine serum albumin (BSA) and preincubated for one 
hour. The supernatant, containing the depleted library, was incubated in the antigen-
coated wells at RT for 2 hours followed by ten washing steps with PBST. Afterwards, 
bound scFv phage particles were eluted with 200 µL trypsin solution at 37 °C for 30 min. 
The supernatant containing eluted scFv phage particles was transferred into a new tube. 
Ten µL of eluted scFv phage were used for titration as described by (Schirrmann and 
Hust, 2010). Twenty mL E. coli XL1-Blue MRF' culture in the logarithmic growth phase 
(OD600nm = 0.4 - 0.5) were infected with the remaining scFv-phage at 37 °C for 30 min 
without shaking. The infected cells were harvested by centrifugation for 10 min at 3,220 x 
g and the pellet was resuspended in 250 µL 2xYT-G/A medium, plated on a 15 cm 2xTY-
G/A agar plate and incubated overnight at 37 °C. Colonies were harvested with 5 mL 
2xTY-G/A. Thirty mL of 2xYT-G/A were inoculated with 100 µL of the harvested colony 
suspension and grown to an OD600nm of 0.4 to 0.5 at 37 °C and 250 rpm. Five mL 
bacterial suspension (~2.5 x 109 bacteria) were infected with 5 x 1010 helper phage 
M13K07, incubated at 37 °C for 30 min without shaking, followed by 30 min at 250 rpm. 
Infected cells were harvested by centrifugation for 10 min at 3,220 x g and the pellet was 
resuspended in 30 mL 2xYT-A/K. Antibody phage were produced at 30 °C and 250 rpm 
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for 16 h. Cells were harvested by centrifugation for 10 min at 3,220 x g. The supernatant 
containing the antibody phage (~1 x 1012 cfu mL-1) was directly used for the next panning 
round or stored at 4 °C. Two panning rounds followed with three and one µg of 
immobilized antigen. Only clones from the third panning round were picked for 
screening. 
3.3.5 Production of antibody fragments in E. coli 
3.3.5.1 Production of scFv in MTP 
The identification of monoclonal binders was performed as described in (Hust et al., 
2009) with modifications. 96-well polypropylene (PP) MTPs containing 150 µL 2xYT-G/A 
were inoculated with colonies from the titration plate of the third panning round. MTPs 
were incubated overnight at 37 °C and 850 rpm in a MTP shaker. A volume of 180 µL 
2xYT-G/A in PP-MTP well was inoculated with 10 µL of the overnight culture and grown 
at 37 °C and 850 rpm for two hours. Bacteria were harvested by centrifugation for 10 min 
at 3,220 x g and 180 µL supernatant were removed. The pellets were resuspended in 
180 µL 2xYT-S/A + IPTG and incubated at 30 °C and 850 rpm overnight. Bacteria were 
pelleted by centrifugation for 15 min at 3,220 x g and 4 °C. The scFv-containing 
supernatant was transferred to a new PP-MTP and stored at 4 °C prior to analysis. 
3.3.5.2 Production of scFv in shaking flasks 
Previous to production in shaking flask scale the scFv encoding sequences were 
subcloned to the expression vector pOPE101-XP. After subcloning expression and 
secretion of scFv were tested by small scale production of scFv in MTP followed by 
SDS-PAGE and immunoblot targeting C-myc-tag. For the preculture 80 mL 2xTB-G/A 
were inoculated from glycerol stock and incubated at 37 °C and 120 rpm overnight. For 
the main culture 1 L of TB-G/A in a 2 L shaking flask with baffles was inoculated with the 
overnight culture to an OD600nm of 0,05 and incubated at 37 °C and 120 rpm till OD600nm of 
2.0 was reached. Then the expression of scFv was induced by addition of 50 µm IPTG 
and 50 mM sucrose. Antibodies were produced at 18 °C overnight (16 – 20 hours). The 
next day bacterial cells were harvested by centrifugation at 5,000 x g and 4 °C for 
15 min. The supernatants were discarded and the bacterial pellets were stored at 4 °C 
until further use. 
3.3.6 Cultivation of M. tuberculosis  
M. tuberculosis (Mtb) H37Rv cultures were provided by Dr. Wulf Oehlmann (Lionex 
GmbH)  Mtb was cultivated in the L3 facility of the University of Veterinary Medicine 
Hannover. In general 400 – 700 mL of 7H9 + ADC + Tween or Sauton’s medium in a 1 L 
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Schott bottle were inoculated 1:20 with liquid cultures of Mtb in stationary growth phase 
and incubated without shaking at 37 °C for one week or up to twelve months. 
3.3.7 Concentration of culture filtrates of M. tuberculosis 
Culture filtrates for concentration were obtained only of Mtb cultivated in Sauton’s 
medium. For that purpose 100 – 300 mL of culture were sterile filtrated through 0.22 µm 
syringe filter. To preserve sterility 80 µg mL-1 gentamycin, 34 µg mL-1 chloramphenicol 
and 10 µg mL-1 ethambutol were added. Culture filtrates were concentrated 20 to 30 fold 
with VivaSpin20 or Vivacell100 (Sartorius, Germany) according to the manufacturer’s 
instructions. 
 
3.4 Biochemical methods 
3.4.1 Isolation of the periplasmatic and osmotic shock fraction of E. coli  
The reducing nature of the cytoplasm in E. coli inhibits the formation of intradomain 
disulfide bridges necessary for the correct folding of scFv (Skerra and Plückthun, 1988). 
Through the expression vector pOPE101-XP, scFv were fused with the N-terminal leader 
peptide pelB that directs the recombinant protein towards the SEC protein-translocation 
pathway (Mori and Ito, 2001) into the periplasm of E. coli, where it can be properly folded 
in an oxidizing environment (Popplewell et al., 2005). In addition, through the gentle 
removal of the outer membrane of E. coli, an antibody preparation not contaminated by 
cytoplasmic proteins can be obtained (Rouet et al., 2012).  
The periplasmic enriched fraction (PPP) and osmotic shock fraction (OSP) of E. coli 
were prepared after the method of (Dübel et al., 1995). Cell pellets after production of 
scFv in shaking flasks were resuspended with 100 mL of ice cold PE buffer and 
incubated on ice for 20 min with potent mixing every five minutes. After that the 
suspension was centrifuged at 27,000 x g and 4 °C for 30 min. The resulting 
supernatant, the PPP of E.coli, was collected. The remaining pellet was resuspended 
with 100 mL of ice cold OS buffer and incubated on ice for 20 min with potent mixing 
every five minutes. After this step the suspension was centrifuged at 27,000 x g and 4 °C 
for 30 min. The resulting supernatant, the OSP of E.coli, was collected. Samples of PPP 
and OSP were taken, before both solutions were merged. 
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3.4.2 Purification of His tagged scFv via immobilized-metal affinity 
chromatography (IMAC) 
The antibody expression vector pOPE101-XP delivers scFv with a sixfold His tag at the 
N-terminus of the protein (Hust et al., 2009) allowing enrichment on nickel nitrilo tri acetic 
acid (Ni-NTA) resin (Block et al., 2009). In this study His- tagged scFv were purified from 
periplasmatic and osmotic shock fractions of E. coli under high salt conditions via 5 mL 
Ni-NTA Superflow (QIAgen, Germany) in XK-16 colomns (GE Healthcare). Ni- NTA XK-
16 columns were prepared according to the manufacturer’s instructions. The combined 
PPP + OSP solutions (see chapter 3.4.1) were adjusted to 20 mM Tris/HCl and 500 mM 
NaCl with a 80 mM Tris/HCl 2 M NaCl pH 8.0 stock solution. The resulting solution was 
cleared over a folded filter before it was applied to the Ni-NTA using a Smartline 
preparative pump 1800 (Knauer) and a dynamic mixing chamber (Knauer). The 
necessary steps for this purification are summarised in Table 25.  
Table 25: Overview purification of scFv via Ni-NTA. 
step  volume [mL] solution 
equilibration 30 buffer A* 
sample application 270  sample  
washing 10 buffer A 
linear gradient 25 buffer A mixed with 0 – 50 % (v/v) buffer B   (0 – 250 mM imidazole) 
elution 10 buffer B* 
regeneration 20 20 mM MES, 100 mM NaCl, pH 5.0 
storage 10 20 % (V/V) ethanol 
* running buffer A: 20 mM Tris/HCl, 500 mM NaCl, pH 8.0; elution buffer B: 20 mM Tris/HCl, 500 
mM NaCl, 500 mM imidazol, pH 8.0 
 
The purification was carried out with a constant flow rate of 2 mL min-1 and maximal 72 
psi. Absorption at 280 nm and conductivity [mV] were plotted with Smartline UV detector 
2520 and Smartline 2900 conductivity/pH monitor (both Knauer). 2 mL fractions of the 
washing step, the linear gradient and the elution were collected using Foxy R1 fraction 
collector (Teledyne Isco, USA) in 7 mL collection tubes, and were later analysed by 
SDS-PAGE and Coomassie staining. 
3.4.3 Protein quantification 
Protein concentrations were determined using folin phenol reagent (Lowry et al., 1951) 
(Peterson, 1979) using the DC Protein Assay (Bio-Rad, Germany) according to the 
manufacturer’s instructions.  
3.4.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
In this study SDS-PAGE (Laemmli, 1970) altered after (Schägger and Jagow, 1987) was 
performed. The recipes for separating and stacking gels are listed in Table 26.  
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Table 26: Recipe for four Schaegger and Jagow gels (4 % stacking and 12 % separating). 
step component stacking gel  separating gel  
1 Milli-Q water 11 mL 5.7 mL 
2 gel buffer: tricin 4.65 mL 5.9 mL 
3 glycerol 86 % (w/v) - 2.7 mL 
4 0.1 % (w/v) bromophenol blue 150 µL -  
5 Rotiphorese Gel 40  2.4 mL 9.4 mL 
6 N,N,N',N'-Tetramethylethylendiamin (TEMED) 15 µL 9 µL 
7 40 % (w/v) Ammoniumpersulfat (APS) 38 µL 22 µL 
 ∑ 18 mL 27 mL 
 
The separating gel was poured between glass plates of the Hoeffer Mini dual gel caster 
(10 x 8 cm, Hoeffer, Germany), followed by the stacking gel. A comb was inserted to 
obtain lanes. After polymerization the gel was attached to the Hoeffer Mini 
electrophoresis unit and the chamber was filled with cathode and anode buffer according 
to the orientation of electrodes. Samples were mixed with 2 x sample buffer for SDS-
PAGE and boiled for 10 min at 100 °C. After cooling, 100 mM DTT was added to the 
samples. Samples and a molecular mass standard (Page Ruler Un-/Prestained Protein 
Ladder) were applied to the lanes of a PAA-Gel. A current of 40 V (10 mA) was applied 
for electrophoresis through the stacking gel and after that a current of 100 V (60 mA) 
was applied for electrophoresis through the separating gel till the dye front ran out. 
3.4.5 Coomassie staining 
PAA-gels were stained with Coomassie Brilliant Blue in coomassie staining solution for 
1.5 h to overnight at 50 °C. The PAA-gel was afterwards destained in coomassie 
destaining solution at RT till an adequate protein pattern was visible.  
3.4.6 Silver staining 
PAA-gels were silver-stained according to (Blum et al., 1987) with modifications, in brief 
summarized in Table 27. 
Table 27: Silver staining modified after Blum et al. 1987. 
incubation time solution  recipe 
1 – 20 h fixation 
20 % (v/v) ethanol 
12 % (v/v) acetic acid 
0.5 mL/L formaldehyde (37 %) 
2 x 20 min dehydration 1 50 % (v/v) ethanol 
1 x 20 min dehydration 2 30 % (v/v) ethanol 
1 min pre-treatment 0.2 g/L Na2S2O3 
3 x 20 sec dH2O  
20 min staining 2 g/L AgNO3  
0.75 ml/L formaldehyde (37 %) 
variable development 
60 g/L Na2CO3 
4 mg/L Na2S2O3 
0.5 mL/L formaldehyde (37 %) 
15 min stop 10 % (v/v) ethanol 
12 % (v/v) acetic acid 
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3.4.7 Western blot 
A semi-dry Western blot was performed to transfer proteins from PAA-gels onto 
polyvinylidene fluoride (PVDF) membranes. Therefore a PVDF membrane was activated 
with 10 mL methanol for 1 min followed by addition of 20 mL transfer buffer. The 
membrane and the gel were equilibrated with the transfer-methanol mixture for 30 min. 
After equilibration three pieces of blotting paper were soaked with transfer-methanol 
mixture and applied on the blotting device, followed first by the membrane and second 
by the gel, finished by another three pieces of soaked blotting paper. Transfer of the 
proteins was performed with 3 mA cm-2 (20 V max.) for 30 min. 
3.4.8 Tape Station analysis 
The Tape Station is an automated system for protein quality control from 10 to 200 kDa 
allowing the determination of protein size, product purity and concentration. Proteins 
were labelled with a pyrylium fluorescent dye (McNeill et al., 2010; Craig et al., 2005), 
boiled under reducing conditions, mixed with 10 and 200 kDa in line markers and 
separated on an acrylamide gel matrix by electrophoresis. The obtained results were 
visualized as a gel image comparable to a standard SDS-PAGE or as a chromatogram 
where fluorescence units (FU) are outlined against protein size. The purity of a protein 
preparation is stated as the percentage of the target peak in the overall integrated area.  
Purified antibody solutions were analysed with the Screen Tape P200 Protein Standard 
Kit (Agilent) under reducing conditions on a 2200 Tape Station system (Agilent) 
according to the manufacturer’s instructions. The “P200 molecular weight standard” 
(Agilent) was used as a molecular marker. 
3.4.9 Conjugation of antibodies to horseradish peroxidase (HRP) 
Purified scFv-Fc antibodies were conjugated to HRP over reductive amination (Imagawa, 
M., et al., 1982) with the EZ-Link Plus Activated Peroxidase Kit (Pierce, Germany) 
following the protocol at pH 9.4 according to manufacturer’s instructions. 
 
3.5 Biophysical methods 
3.5.1 Preparative size exclusion chromatographie (SEC) 
Preparative SEC (Porath and Flodin, 1959) was performed for desalting/buffer exchange 
of protein solutions after Ni-NTA purification. Therefore 80 mL Sephadex G-25 fine (GE 
Healthcare) were prepared in a XK-26 (GE Healthcare) column according to the 
manufacturer’s instructions. Eluate fractions containing target protein after Ni-NTA 
(verified via SDS-PAGE) were pooled and applied to the Sephadex-G25-XK-26 column 
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using a Knauer Bioline purification system and a Foxy R1 fraction collector as described 
before. The buffer exchange was carried out with PBS buffer pH 7.4 at a constant flow 
rate of 5 mL min-1 and maximal 72 psi. Absorption at 280 nm and conductivity [mV] were 
plotted. Seven mL fractions were collected. 
3.5.2 Analytical SEC 
Analytical SEC was performed to determine the size and aggregational behaviour of 
proteins. The Knauer PLATINblue HPLC Plus system with a Superdex 200 10/300 GL 
column (GE Healthcare, USA) was used according to the manufacturer’s instructions. 
The flow rate was constant at 0.5 mL min-1. 500 µL of sample were applied, running 
buffer was PBS pH 7.4 (for antibodies) or 10 mM NH4HCO3 (for antigens), the absorption 
at 280 nm and the retention times were plotted. Eight molecular standards (listed in 
Table 28) were used for calibration of the column. 
Table 28 Calibration standards for analytical SEC. 
Mixture of HMW+LMW calibration kit (GE Healthcare, USA). 
protein molecular mass [kDa] 
Thyroglobulin 669 
Apoferritin 443 
ß-Amylase 200 
Alcohol Dehydrogenase 150 
Albumin 66 
Carbonic Anhydrase 29 
Cytochrome c 12.4 
Aprotinin 6.5 
3.5.3 Affinity measurement via surface plasmon resonance (SPR) 
The affinities of scFv and scFv-Fc antibodies were measured by surface plasmon 
resonance using a CM5 sensor chip and a Biacore2000 (GE Healthcare, Germany). For 
affinity measurement of α-16kDa scFv antigen was immobilized on the CM5 chip via 
amine coupling according to the manufacturer’s instructions. 1 µg mL-1 antigen was 
dissolved in 10 mM acetate buffer pH 4.0 and 55.3 response units (RU) were 
immobilized on the surface. During the measurement a flow rate of 30 µL min-1 was 
maintained and four dilutions of scFv in HBS-EP buffer (125 nM, 250 nm, 500 nm, 2x 
1000 nm) were associated for 300 sec and dissociated for 700 sec. Regeneration was 
performed after each scFv dilution with 10 µL 10 mM glycin pH 1.0. Association and 
dissociation constants were calculated using the Biaevaluation software (Karlsson et al., 
1991) and verified with internal consistency tests (Schuck and Minton, 1996). For the 
affinity measurement of α-85 B scFv-Fc the human antibody capture kit (GE Healthcare, 
Germany) was used according to the manufacturer’s instructions. 
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3.6 Immunological methods 
3.6.1 Immunostain 
Proteins blotted onto PVDF membranes were detected using immunostain. Therefore, 
following western blotting, free binding sites on the PVDF membrane were blocked with 
MPBST for minimum 30 min at RT. Subsequently, incubation with protein-specific 
antibody was carried out in MPBST for a minimum of 60 min at RT. After three washing 
steps with PBST0.1 for 5 min the blot was incubated with a secondary antibody coupled 
to HRP in MPBST for at least 45 min at RT. After another three washing steps with 
PBST0.1 the immunostain was developed with TMB peroxidase membrane substrate 
(ready to use) until an adequate signal was obtained. Development was stopped by 
three short washing steps with Milli-Q water.  
3.6.2 Epitope mapping 
Epitope mapping was performed using the technique of oligo-peptide scanning (Morris, 
1996). This technique uses a library of oligo-peptide sequences from overlapping 
segments of a target protein and tests for their ability to bind the antibody of interest. 
Peptides were N-acetylated and covalently bound to cellulose-β-alanine membranes in 
form of peptide-spots (Frank and Overwin, 1996). For further details on the peptide-spot-
membranes see chapter 3.1.11 and appendix. 
The membranes were rinsed with methanol, washed three times for 5 min with TBS and 
blocked with TBS-B for 1.5 h at RT. After that the membranes were incubated with an 
antibody generated against the target antigen in a dilution of 0.67 µg mL-1 antibody in 15 
mL TBS-B for 3 h at RT. After washing three times for 5 min with TBS the membranes 
were incubated with a secondary antibody conjugated to HRP (Goat α-human IgG (Fc)-
HRP 1:20,000 or mouse α-C-Myc-tag-HRP (9E10) 1:1,000) diluted in 15 mL TBS-B for 
1.5 h at RT. After another three washing steps with TBS the immunostain could be 
detected with TMB peroxidase membrane substrate (ready to use). The development 
was stopped after 5 – 11 min with Milli-Q water. After scanning of the array the 
membranes were destained by a short washing step with methanol followed by washing 
with TBS-T till the spots were colourless (usually 3 h to overnight). Regeneration of the 
peptide spots was carried out according to regeneration protocol I in the JPT PepSpot 
Peptides protocol (JPT, Germany). In brief, the membranes were washed 3 x 5 min with 
Milli-Q at RT, 4 x 30 min with regeneration buffer I at 50 °C, 3 x 20 min with 10x PBS for 
epitope mapping at RT, 3 x 20 min with TBS-T at RT, 3 x 10 min with TBS at RT.  
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3.6.3 Enzyme linked immune sorbent assay (ELISA) 
In this work different types of ELISA (Engvall and Perlmann, 1971; Yalow and Berson, 
1960) were used as specified in the following chapters. The standard operation volume 
per cavity was 100 µL or as indicated otherwise. 
3.6.3.1 Indirect ELISA 
Screening ELISA: 
96 wells of Greiner Microlon MTP were coated with 100 ng of antigen or BSA as a 
negative control in PBS buffer overnight at 4 °C. After coating, the wells were blocked 
with PBST-B for 2 h at RT, followed by three washing steps with PBST0.05. For 
identification of binders, supernatants containing monoclonal scFv (see chapter 3.3.5.1) 
were incubated in the antigen coated plates for 1.5 h at RT followed by three PBST0.05 
washing cycles. Bound scFv were detected using mouse α-c-Myc-tag 9E10 (1:1,000 in 
PBST-B; 1.5 h at RT) followed by goat α-mouse IgG (Fc)-HRP (1:30,000 in PBST-B; 45 
min at RT). After three washing steps with PBST0.05 the reactions were visualized with 
TMB as a substrate. The staining reaction was terminated by addition of stop solution. 
Absorbance at 450 nm (620 nm reference) was measured using MRX ELISA reader 
(Dynatec, Germany). 
Antibody titration ELISA: 
Per antibody 24 cavities of Greiner Microlon MTP were coated with 100 ng antigen in 
PBS at 4 °C overnight with BSA coated cavities as a negative control. After coating, the 
wells were blocked with PBST-B for 2 h at RT, followed by three washing steps with 
PBST0.05. Twelve dilutions of antibody in PBST-B were applied in duplicates on the 
antigen and BSA controls and incubated for 1.5 h at RT. Bound scFv-Fc were detected 
using goat α-human IgG (Fc)-HRP (1:130,000 in PBST-B; 45 min at RT). The assay was 
further processed as described above. 
Antigen titration ELISA:  
Twelve dilutions of antigen in PBS buffer were coated in duplicates to 96 wells of Greiner 
Microlon MTP at 4 °C overnight with BSA coated cavities as a negative control. After 
coating, the wells were blocked with PBST-B for 2 h at RT, followed by three washing 
steps with PBST0.05. Antigen detection was carried out with a concentration of antibody 
at half maximal saturation (determined by antibody titration ELISA) in PBST-B for 1.5 h 
at RT followed by three PBST0.05 washing cycles. Bound scFv-Fc were detected using 
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goat α-human IgG (Fc)-HRP (1:130,000 in PBST-B; 45 min at RT). The assay was 
further processed as described above. 
3.6.3.2 Direct ELISA: 
Analyte (antigen or antibody) was coated to the surface of Greiner Microlon 96 Well MTP 
at various concentrations in PBS buffer overnight at 4 °C. Detection of the analyte was 
carried out with an antibody (commercial or in house produced scFv-Fc) conjugated to 
HRP diluted in PBST-B for 1 h at RT. The assay was further processed as described 
above. 
3.6.3.3 Sandwich ELISA 
Sandwich antigen titration:  
100 ng of capture antibodies were coated to the surface of 96 wells of Greiner Microlon 
MTP in PBS buffer overnight at 4 °C. After coating, the wells were blocked with PBST-B 
for 2 h at RT, followed by three washing steps with PBST0.05. Twelve dilutions of 
antigen in PBST-B were applied in duplicates onto the antibody coated cavities and 
incubated for 1.5 h at RT, followed by three washing steps with PBST0.05. Detection of 
bound antigen was performed with HRP conjugated scFv-Fc (exact dilutions described in 
results) in PBST-B for 1.5 h at RT, followed by three washing steps with PBST0.05. The 
assay was further processed as described above. 
Sandwich sample mensuration: 
100 ng of capture antibodies were coated to the surface of 96 wells of Greiner Microlon 
MTP in PBS buffer overnight at 4 °C. After coating, the wells were blocked with PBST-B 
for 2 h at RT, followed by three washing steps with PBST0.05. In duplicates different 
volumes of culture filtrates or cell extracts diluted in PBS (exact amounts described in 
results) were applied to the antibody coated cavities and incubated for 1.5 h at RT, 
followed by three washing steps with PBST0.05. Detection of bound antigen was 
performed with HRP conjugated scFv-Fc (exact dilutions described in results) in PBST-B 
for 1.5 h at RT, followed by three washing steps with PBST0.05. The assay was further 
processed as described above. 
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3.7 Cell culture 
3.7.1 Cultivation and transient transfection of HEK293-6E (scFv-Fc production) 
HEK293-6E cells were cultivated in chemical defined F17 medium supplemented with 
1 g L-1 pluronic F68, 4 mM L-glutamine and 25 mg L-1 G418  at 37 °C and 110 rpm with 5 
% CO2 as described in (Jäger et al., 2013). 
Transient production in suspension HEK293-6E cells was performed as described in 
(Schirrmann and Büssow, 2010). Briefly, two days prior to transfection 5 × 105 cells mL-1 
HEK293-6E were seeded into 25 mL F17 medium (without G418) into 125 mL 
polycarbonate Erlenmeyer flasks with ventilation membrane caps and incubated at 37 °C 
and 110 rpm in an orbital shaker. A total of 1 μg high quality plasmid-DNA and 2.5 μg 
polyethyleneimine (PEI) per mL culture volume were prepared in 1/10 volume of fresh 
F17 medium, incubated for 15 – 30 min at RT and applied to the cells which were further 
cultured for 48 h. Then 0.5 % (w/v) of tryptone N1 were added as described in (Pham et 
al., 2006) together with one additional volume fresh culture medium. Cultivation was 
carried on for another 3 days. Subsequently a final concentration of 1 % (v/v) of FCS 
was added for stabilization of scFv-Fc fusion proteins before harvesting at 3,220 x g and 
4 °C for 30 min.  
3.7.2 Purification of Fc-fusions with Protein A 
All scFv-Fc antibodies were purified by protein A affinity purification using 1 mL Bio-
Scale Mini UNOsphere SUPrA Cartridges and the semiautomated Profinia 2.0 system 
(Bio-Rad, Germany) according to the manufacturer’s instructions.  
3.7.3 Cultivation of Lx143 
A-LAM IgM producing hybridoma cells were cultivated for 14 days in DMEM medium 
supplemented with 10 % (v/v) FCS and 1 % (v/v) Pen/Strep at 37 °C, 5 % CO2 and 95 % 
humidity in a 75 cm2 cell culture flask. 
3.8 Lateral flow immuno assays 
Colloidal gold-antibody conjugates (Lionex GmbH) were used as detection reagents in 
lateral flow immuno assays (LFIA) assembled as described below:  
5 – 80 µL cm-1 of colloidal gold-antibody conjugates were dispensed onto 8 mm glass 
fibre pads using the xyz-dispenser (Biodot) and dried at 37 °C. 1 µL cm-1 dilution of 
capture antibody (sandwich assay) or antigen (direct assay) in PBS were dispensed in a 
line onto Unisart CN 95 nitrocellulose membranes (20 mm) that were already assembled 
onto 300 mm backing cards (DIMA), and dried at 37 °C. The glass fibre conjugate pads 
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were glued onto the backing cards, overlapping the nitrocellulose membrane at the 
connection point for ~ 0.5 – 1 mm. Then cellulose fibre pads (Millipore) were glued onto 
the backing cards as sample and wicking pad, overlapping the nitrocellulose membrane 
at the connection point for ~ 0.5 – 1 mm. The assembled cards were cut into strips of 0.4 
cm width with the CM4000 guillotine-cutter (Biodot). The test strips were placed into 
Lateral Flow Strip Test (LFST) cassettes (Jieyi Biotechnology).Cassettes were packaged 
and sealed into LDPE bags (Viking) including Dessicant bags (Wisepac) for humidity 
control and stored at RT until further use. 
3.8.1 Capillary flow procedure 
120 µL (direct assay) or 150 µL (sandwich assay) of samples were applied onto the 
sample well of the LFIA cassettes and allowed to process with lateral flow for 15 – 20 
min at RT before scanning or photographing. 
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4 Results 
4.1 LAM 
4.1.1 Cloning antibodies from Lx143 hybridoma cells 
The isolation of the variable regions of the LAM specific IgM antibody Lx143 (variable 
light chain (VL) and variable heavy chain (VH)) was performed as described in (Toleikis et 
al., 2004; Dübel et al., 1994) with modifications. An overview of the procedure is outlined 
in Figure 8. 
 
Figure 8: Overview cloning α-LAM antibodies from α-LAM hybridoma cells. 
Antibody symbols adopted from M. Hust with permission. 
 
First total RNA was isolated from Lx143 hybridoma cells. Targeting the poly A tail of 
mRNA cDNA was synthesized. The VH and VL genes were amplified from the cDNA 
using wobble oligonucleotides targeting different mouse gene subfamilies. Interestingly 
six of seven oligonucleotide combinations resulted in a PCR product of about 350 bp 
(estimated size of a variable region) which can be followed in Figure 9. 
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Figure 9: Amplification of variable regions of heavy and light chain from α-LAM IgM Lx143 
cDNA.  
5 µL of PCR product from various oligonucleotide primer combinations and 3 µL of marker (M) 
were separated on 1.5 % agarose gel and visualized with GelStar. 
 
All received antibody genes were subcloned into pCR2.1-TOPO and sequenced. The 
analysis of the obtained results with VBASE2 and MultAlign showed that all isolated 
heavy/light chains were originated from the same subfamily, gene and allel. It was 
reasoned that there was only one functional heavy and light chain combination.  
N-terminal sequencing of the α-LAM IgM was performed at the Helmholtz Centre for 
Infection Research, Germany. The received data showed an antibody sequence not 
identical with any of the sequences extracted from the hybridoma cells. There were 
minimum six N-terminal amino acids (three in VH, three in VL) exchanged. To obtain the 
correct amino acid order, the extracted sequences were altered by PCR. The α-LAM VH 
and VL genes were then provided with appropriate restriction sites and subcloned into 
pHAL14 to complete the linker and form a functional scFv.  
4.1.2 A-LAM scFv 
E.coli XL1Blue MRF’ was transformed with the α-LAM scFv in pHAL14. Positive clones 
were screened by cultivation on selective medium and colony PCR. Confirmation of the 
constructed scFv sequence was carried out by DNA-sequencing. Soluble scFv were 
produced in MTP and analysed by screening ELISA and SDS-PAGE followed by α-c-
Myc-tag immunoblot. The ELISA was performed with controls of both antigen (α-LAM 
IgM detection) and the scFv production/detection system (coproduction of α-lysozyme 
scFv D1.3, BSA negative control). No signal could be obtained by α-LAM scFv in ELISA 
(data not shown), but a protein band of ~ 32 kDa could be detected in the culture 
supernatant after production in MTP via immunostaining (Figure 10). 
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                                           A)                            B) 
 
Figure 10: A) Coomassie staining and B) α-c-Myc-tag immunoblot of culture supernatants 
from production of soluble α-LAM scFv in MTP.  
18 µL culture supernatant and 3 µL marker (M) were separated on reducing 12 % SDS-PAGE 
and rather stained with coomassie or electro blotted to a PVDF membrane. ScFv on the blot were 
detected using mouse α-c-Myc-tag IgG(9E10) followed by goat α-mouse IgG(Fc)-HRP, 
development with TMB. D1.3 represents the positive control. 
 
For further characterization of the scFv a production in 1 L scale (shaking flasks) was 
carried out. There was no scFv detectable in the eluat fractions after Ni-NTA by SDS-
PAGE and silver staining (data not shown). The expression of the scFv was checked by 
means of SDS-PAGE followed by α-c-Myc-tag immunoblot. A slight protein band of scFv 
could be detected in the culture supernatant and in the PPP and OSP, whereas a strong 
band was visible in the pellet after PPP and OSP production (data not shown). This 
surveillance indicates instability and inclusion body formation of the scFv in E. coli. 
Hence a change of antibody format from scFv to scFab seemed necessary, to stabilize 
the antibody. For that purpose the α-LAM VH and VL were provided with appropriate 
restriction sites and subcloned to pHAL20 to complete the linker and to equip the 
variable regions with mouse CH1 and CL for the formation of a functional scFab.  
4.1.3 A-LAM scFab 
Soluble α-LAM scFab were produced in MTP. Culture supernatant and PPP + OSP were 
prepared and tested in the same ELISA setting as described for the α-LAM scFv. No 
reaction of the soluble scFab with the antigen could be detected (data not shown). The 
production of scFab was analysed by SDS-PAGE followed by immunoblot and could be 
verified (Figure 11).   
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                                        A)                              B)             
 
Figure 11: A) Coomassie staining and B) α-c-Myc-tag immunoblot of culture supernatant, 
PPP and OSP from production of soluble α-LAM scFab in MTP.  
18 µL culture supernatant (cs), PPP or OSP and 6 µL marker (M) were separated on reducing 12 
% SDS-PAGE and rather stained with coomassie or electro blotted to a PVDF membrane. 
Immunostain was performed as described in Figure 10. 
 
For further characterization of the scFab a production in 1 L scale was carried out. There 
was no scFab detectable in the eluat fractions after Ni-NTA by SDS-PAGE and silver 
staining (data not shown). Comparable to the scFv only small amounts of protein were 
found in the culture supernatant, PPP and OSP analysed by immunoblot. Whereas a 
great portion of scFab was found in the pellet after PPP and OSP preparation (data not 
shown). It was concluded that the scFab could not be purified. On that account the fusion 
of the single chain α-LAM antibodies with a human IgG1 Fc part was focused on to first 
stabilize the construct and second to fetch an avidity effect and by that means an 
increase of affinity. 
The fusion of α-LAM scFv with a human IgG1 Fc part was performed by subcloning the 
scFv into the eukaryotic expression vector pCSE2.5-hIgG1-Fc-XP.  
4.1.4 Α-LAM scFv-Fc 
HEK293-6E cells were transient transfected with the α-LAM scFv-Fc in pCSE2.5-hIgG1-
Fc-XP. No scFv-Fc could be purified (triplicate approach, with technical assistance of 
Franziska Resch (TU-BS)). To receive further stability the format change from scFv-Fc to 
scFab-Fc was carried out by subcloning the scFab into pCSE2.5-hIgG1-Fc-XP.  
4.1.5 A-LAM scFab-Fc 
HEK293-6E cells were transient transfected with the α-LAM scFab-Fc in pCSE2.5-
hIgG1-Fc-XP. A-LAM scFab-Fc was purified from the culture supernatant via Protein A 
(with technical assistance of Franziska Resch (TU-BS)). A protein yield of 24 mg L-1 was 
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determined by a Lowry protein assay. The obtained antibody solution was analysed by 
SDS-PAGE followed by silver staining, α-human IgG(Fc) immunoblot and reducing gel 
analysis via Tape Station (Figure 12). No degradation could be detected in the antibody 
preparation by either means. Tape station analysis issued a purity of 96.8 % for the 
target 74 kDa band. 
                                A)                        B)                           C) 
                 
Figure 12: A) Silver staining, B) α-human IgG(Fc) immunoblot and C) Tape Station analysis 
of purified α-LAM scFab-Fc. 
A) 75 ng of purified Lx143 α-LAM scFab-Fc and 1 µL of marker (M) were separated on reducing 
12 % SDS-PAGE and silver stained. B) 200 ng of purified Lx143 α-LAM scFab-Fc and 8 µL of 
marker were separated on reducing 12 % SDS-PAGE and electro blotted to a PVDF membrane. 
After blocking, human IgG(Fc) was detected using goat α-human IgG(Fc)-HRP, development with 
TMB, C) scFab-Fc were directly analysed by reducing gel analysis via Tape Station (with 
technical assistance of Wiebke Prilop (Lionex GmbH)). 
 
The antigen recognition of the α-LAM scFab-Fc was analysed by titration ELISA (Figure 
13). The antibody bound BCG derived LAM specifically.  
 
Figure 13: Titration ELISA of α-LAM scFab-Fc. 
A dilution series of scFab-Fc was used for detection of directly coated antigen (LAM BCG) or BSA 
(control), detection of bound scFab-Fc with goat α-human IgG(Fc)-HRP, development with TMB. 
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Further, the reaction with Mtb and BCG cell extracts and culture filtrates was analysed by 
indirect ELISA (Figure 14). In this assay, the α-LAM scFab-Fc bound Mtb and BCG 
derived LAM, whereupon the reaction with Mtb LAM was slightly more intense. In 
addition, LAM was detected in Mtb and BCG cell extracts and Mtb culture filtrate. 
 
Figure 14: Reaction of α-LAM scFab-Fc with Mtb/BCG cell extracts and culture filtrates 
determined by indirect ELISA. 
100 ng/100 µL of the different samples were directly coated to the well, reaction was determined 
with a scFab-Fc concentration of 2.5 µg mL-1, detection of bound scFab-Fc with goat α-human 
IgG(Fc)-HRP, development with TMB. 
 
 
  4 Results 
51 
 
4.2 Selection of antibodies from HAL7/8 
ScFv were isolated in vitro from the human naïve libraries HAL7/8 by panning. Soluble 
monoclonal antibodies were produced in MTP and specific antigen binding was analysed 
by screening ELISA. Individual binders were identified by DNA-sequencing.  
No binders were received concerning LAM or ESAT-6 (Table 29). Six individual AlaDH 
binders were isolated, but the specific antigen recognition could not be reproduced in 
following assays (data not shown). 
Table 29: Overview selection of antibodies from HAL7/8. 
antigen independant pannings* 
screened 
clones 
hits screening 
ELISA 
clones 
sequenced 
individual 
sequences 
LAM 3 276 0 0 0 
ESAT-6 4 418 0 0 0 
AlaDH 2 184* 9 6 6 
16 kDa 4† 644* 135 21 7 
CFP-10 3 322 7 7 3 
85 A 3 322 16 11 4 
85 B 2 184 51 11 5 
85 D 2 184 15 10 3 
total 19 2534 233 66 28 
 *with technical assistance of Saskia Helmsing (TU-BS) and Dr. Wulf Oehlmann (Lionex GmbH), 
†HAL4/7/8 
 
4.2.1 16 kDa 
4.2.1.1 A-16 kDa scFv 
Seven individual 16 kDa binders were identified by panning of HAL4/7/8 and subsequent 
screening ELISA followed by DNA sequencing (data not shown). All these antibodies 
have the same variable gene segment of the heavy chain (HV). In addition to that, 
respectively six out of seven binders have the same joining gene segment of the light 
chain (LJ), the same variable gene segment of the light chain (LV) or the same joining 
gene segment of the heavy chain (HJ) (Table 30). 
Table 30: Comparison of heavy and light chain gene segments of α-16 kDa antibodies. 
  heavy chain light chain 
clone HV D HJ LV LJ 
SH365-E4 IGHV3-15*01 IGHD3-10*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01 
SH365-H4 IGHV3-15*01 IGHD5-24*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01 
SH365-C8 IGHV3-15*01 IGHD6-6*01inv IGHJ4*02 IGLV1-47*01 IGLJ3*01 
L16-3-D12 IGHV3-15*01 IGHD2-8*01 IGHJ4*02  IGLV1-47*02 IGLJ3*01 
L16-3-E12 IGHV3-15*01 IGHD2-2*02inv IGHJ4*02 IGLV1-47*01 IGLJ3*02 
SH451-C11 IGHV3-15*01 IGHD6-6*01inv IGHJ4*02 IGLV1-47*01 IGLJ3*01 
SH451-F11 IGHV3-15*01 IGHD5-24*01 IGHJ5*02 IGLV1-47*01 IGLJ3*01 
Abbreviations: HV: variable (V) gene segment of the heavy chain; D: diversity gene segment; HJ: 
joining (J) gene segment of the heavy chain; LV: variable gene segment of the light chain; LJ: 
joining gene segment of the light chain 
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All scFv were subcloned to the prokaryotic expression vector pOPE101-XP, produced in 
1 L scale (shaking flasks), PPP and OSP were prepared and purified over Ni-NTA IMAC. 
ScFv containing fractions of the eluate (determined by SDS-PAGE followed by 
coomassie staining, data not shown) were pooled and rebuffered into PBS using 
preparative SEC (data not shown). The protein concentration of the received scFv 
preparations was determined by a Lowry assay and the yield per litre was calculated 
(Table 31). The purity of the antibody solutions was analysed by reducing gel analysis 
via Tape Station and SDS-PAGE followed by silver staining. There were no other protein 
bands than the target scFv band (~ 30 kDa) visible in the silver stained SDS-PAGE 
(Figure 15: A). Tape Station analysis revealed a different protein pattern with up to three 
additional bands (Figure 15: B), indicating the presence of contamination (in form of E. 
coli proteins), scFv aggregates or degradation products of these antibodies. 
Table 31: Overview purification of α-16 kDa scFv. 
scFv yield [mg L-1] a purity [%]b monomer [%]c 
SH365-E4 33.50 95.2 93.97 
SH365-H4 5.34 100.0 88.10 
SH365-C8 46.04 100.0 92.94 
L16-3-D12 36.30 80.4 93.72 
L16-3-E12 16.11 100.0 97.40 
SH451-C11 2.32 88.9 74.31 
SH451-F11 1.98 92.3 83.89 
a) determined by Lowry protein quantification assay; b) determined by reducing Tape Station 
analysis, percent of integrated area; c) determined by analytical SEC, percent of integrated area 
 
A)                                                          B) 
         
Figure 15: A) Silver staining and B) Tape Station analysis of purified α-16 kDa scFv. 
A) 100 ng of purified scFv and 1 µL of marker were separated on reducing 12 % SDS-PAGE and 
silver stained. B) scFv were directly analysed by reducing gel analysis via Tape Station (with 
technical assistance of Wiebke Prilop (Lionex GmbH)). 
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A disadvantage of the scFv format is the possible formation of associates promoted by 
high antibody concentrations (Wörn and Plückthun, 2001). Dimers and multimers may 
contain more than one paratope and, due to the avidity affect, exhibit stronger apparent 
binding characteristics than the corresponding monomers. Aggregates might handicap 
the antigen binding due to sterical inhibition or on account of a wrong conformation of the 
antigen binding site. Therefore the quaternary structures of the scFv in PBS pH 7.4 were 
analysed via analytical SEC. All antibodies showed a dominant peak at an estimated 
size of ~30 kDa which reflects the theoretical size of a monomeric scFv. In addition to 
that, all scFv preparations displayed another peak (to an extent of 26 % of the integrated 
area, compare Table 31) with an estimated size ranging from 65 – 90 kDa that could 
indicate the presence of di- and trimers. Exemplary the analytical SEC of L16-3-E12 is 
displayed in Figure 16. 
 
Figure 16: Analytical SEC of L16-3-E12 scFv. 
100 µL of L16-3-E12 scFv (1.24 mg mL-1) were applied to Superdex 200 10/300 GL column, 
running buffer was PBS pH 7.4. Standards: 1. 669 kDa 19 min, 2. 440 kDa 22 min, 3. 158 kDa 27 
min, 4. 75 kDa 29 min, 5. 65 kDa 30 min, 6. 33 kDa 33 min; pink line: molecular standards, blue 
line: sample, green line: conductivity. Analysis was performed with technical assistance of Dr. Ralf 
Spallek (Lionex GmbH). 
 
The antigen binding of the scFv was analysed by titration ELISA (Figure 17). All 
antibodies bound 16 kDa specifically in this assay. 
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Figure 17: Titration ELISA of α-16 kDa scFv. 
Different dilutions of scFv were used for detection of 100 ng directly coated antigen (16 kDa) or 
BSA (negative control), detection of bound scFv with mouse α-c-Myc-tag 9E10 IgG followed by 
goat α-mouse IgG(Fc)-HRP, development with TMB. 
 
Cross reactivity with other Mtb antigens was determined by indirect ELISA (Figure 18). 
L16-3-E12 and L16-3-D12 showed a slight cross reactivity with 85 complex antigens, but 
delivered the highest signals with the 16 kDa antigen at the same time. 
 
Figure 18: Cross reactions of α-16 kDa scFv with other Mtb antigens determined by ELISA. 
100 ng of the diffferent antigens in PBS were directly coated to the well, cross reaction was 
determined with a scFv concentration of 1.25 µg mL-1, detection of bound scFv with mouse α-c-
Myc-tag 9E10 IgG followed by goat α-mouse IgG(Fc)-HRP, development with TMB. 
 
To determine whether the α-16 kDa antibodies recognized continuous or conformational 
epitopes, α-16 kDa immunoblots were performed (data not shown). In these assays all 
antibodies bound non-reduced (10 min 56 °C, no DTT) antigen strongly and reduced (10 
min 96 °C, + 1 M DTT) antigen weakly, indicating the recognition of at least partial 
continuous epitopes. 
  4 Results 
55 
 
Epitope mapping of the α-16 kDa scFv was carried out on PepSpot membranes (Figure 
19). The reaction of the antibodies with the PepSpots was weak. In addition a strong 
cross reaction of the secondary antibody with the spots 1, 2, 6, 7, 8, 23, 24 and 29 was 
monitored (Figure 19: red encircled area), which could not be avoided by changing the 
antibody or the visualization system. Nevertheless it could be observed that all scFv 
reacted with the same three spots on the membrane (Figure 19: spots 20, 21 and 22) 
and hence it was reasoned that they recognize the same continuous sequence. Through 
the overlap of the peptide sequences (Table 32) the epitope was determined to 
“KDFDGRS”, which is located from amino acid 85 – 91 in the 16 kDa antigen sequence. 
 
Figure 19: Epitope mapping of α-16 kDa scFv with PepSpot membrane.  
Membrane was incubated with respectively 0.67 µg mL-1 antibody, detection of bound scFv with 
mouse α-c-Myc-tag 9E10 IgG followed by goat α-mouse IgG(Fc)-HRP, development with TMB. 
Immunostained spots are encircled. 
 
Table 32: Epitope mapping of α-16kDa scFv, amino acid sequences of peptides on 16 kDa 
PepSpot membrane.  
The immunostained spots and the identified epitope are highlighted. 
spot 
no. 
peptide 
19 GQLTIKAERTEQKDF 
20 
    IKAERTEQKDFDGRS 
21 
        RTEQKDFDGRSEFAY 
22 
            KDFDGRSEFAYGSFV 
23 
                GRSEFAYGSFVRTVS 
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To create a ranking of the α-16 kDa scFv, their binding characteristics for the antigen 
were determined by surface plasmon resonance (SPR). The antibody with the lowest KD 
and therefore the highest affinity was determined to be L16-3-E12 (Table 33). 
Table 33: Affinity measurement of α-16 kDa scFv via SPR. 
List of binding parameters for the reviewed antibodies. The dissociation constant KD is the 
common dimension for the description of affinity. 
scFv ka [M-1 s-1] 
kd 
[s-1 ] 
Rmax 
[RU] 
KA  
[M-1 ] 
KD  
[M] Χ² 
% X² 
(Rmax)* 
L16-3-D12 1.38E+03 3.82E-04 20.6 3.62E+06 2.76E-07 0.050 0.24 
SH365-E4 2.35E+04 4.90E-03 10.2 4.80E+06 2.08E-07 0.453 4.44 
SH451-C11 1.32E+04 1.68E-03 16.0 7.87E+06 1.27E-07 0.184 1.15 
SH365-H4 2.99E+04 3.37E-03 16.9 8.88E+06 1.13E-07 0.201 1.19 
SH451-F11 1.58E+04 1.78E-03 15.8 8.88E+06 1.13E-07 0.193 1.22 
SH365-C8 2.66E+04 1.98E-03 14.7 1.34E+07 7.44E-08 0.062 0.42 
L16-3-E12 1.48E+04 1.57E-04 13.2 9.44E+07 1.06E-08 0.140 1.06 
*X2 should be less than 5 % of Rmax 
Because all α-16 kDa scFv presumably recognized the same epitope only the antibody 
with the highest affinity for the antigen was chosen for further biochemical 
characterization. L16-3-E12 was subcloned to pCSE2.5-hIgG1-Fc-XP to equip it with a 
human IgG01 Fc part for better stability, detection possibilities and conjugation 
procedures. 
4.2.1.2 A-16 kDa scFv-Fc 
HEK293-6E cells were transient transfected with the L16-3-E12 scFv-Fc in pCSE2.5-
hIgG1-Fc-XP. The scFv-Fc was purified from the culture supernatant via Protein A (with 
technical assistance of Franziska Resch (TU-BS)). A yield of 112 mg L-1 was determined 
by a Lowry protein assay. The obtained antibody solution was analysed by SDS-PAGE 
followed by silver staining, α-human IgG(Fc) immunoblot and reducing gel analysis via 
Tape Station (Figure 20). No degradation could be detected in the antibody preparation 
by either means. Tape station analysis revealed two faint additional protein bands at 199 
and 238 kDa, issuing a purity of 96.6 % for the 59 kDa scFv-Fc band. 
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                                A)                         B)                          C) 
                 
Figure 20: A) Silver staining, B) α-human IgG(Fc) immunoblot and C) Tape Station analysis 
of purified L16-3-E12 scFv-Fc. 
Analysis carried out as described in Figure 12. 
The antigen recognition of L16-3-E12 scFv-Fc was analysed by titration ELISA (Figure 
21). In this assay, L16-3-E12 bound the antigen specifically. 
 
Figure 21: Titration ELISA of α-16 kDa L16-3-E12 scFv-Fc. 
A dilution series of scFv-Fc was used for detection of directly coated antigen (16 kDa) or BSA 
(negative control), detection of bound scFv-Fc with goat α-human IgG(Fc)-HRP, development with 
TMB. 
 
The antigen detection limit of L16-3-E12 scFv-Fc, meaning the lowest antigen 
concentration triggering a signal in ELISA distinguishable from the negative control, was 
determined to ~ 10 ng mL-1 by antigen titration ELISA (Figure 22). 
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Figure 22: Antigen titration ELISA with α-16 kDa L16-3-E12 scFv-Fc. 
Different dilutions of antigen (16 kDa) were directly coated to the wells. Antigen detection with 
L16-3-E12 scFv-Fc at a concentration of 150 ng mL-1, detection of bound scFv-Fc with goat α-
human IgG(Fc)-HRP, development with TMB. Negative control BSA A450 = 0.01. 
 
Recognition of Mtb and BCG cell extracts and culture filtrates was analysed by indirect 
ELISA (Figure 23). A slight reaction of L16-3-E12 scFv-Fc with Mtb culture filtrate and 
cell extract was discovered. 
 
Figure 23: Reaction of α-16 kDa L16-3-E12 scFv-Fc with Mtb/BCG cell extracts and culture 
filtrates determined by indirect ELISA. 
100 ng/100 µL of the different samples were directly coated to the well, reaction was determined 
with a scFv-Fc concentration of 2.5 µg mL-1, detection of bound scFv-Fc with goat α-human 
IgG(Fc)-HRP, development with TMB. 
 
4.2.1.3 A-16 kDa scFv-Fc-HRP 
L16-3-E12 scFv-Fc was conjugated to HRP. The necessary dilution of the HRP-
conjugate was determined by direct ELISA to ~ 100 ng mL-1 (data not shown). The cross 
reactivity of the achieved antibody-HRP conjugate was analysed by immunoblot (Figure 
24). The reaction with the 16 kDa antigen was slight, comparable to the reaction during 
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epitope mapping (compare Figure 19). Again a weak cross reaction with the Mtb 
antigens 85 A and 85 B, as observed before with the scFv in indirect ELISA (compare 
Figure 18), was detected. In exchange there was no cross reaction with human samples 
(sputum and serum) or E. coli and HEK cells. 
 
Figure 24: Cross reactions of α-16 kDa L16-3-E12 scFv-Fc-HRP in immunoblot. 
500 ng of purified 16 kDa (04-3/1), 85 A (07-1/1), 85 D (07-1/3), 1 µg of purified 85 B (10-1/1), 9 
µL E. coli BL21 (DE3) culture (OD600 ~7), 0.45 µL of human serum (DRK 895), 3.4 µL of human 
sputum (B-Sp-0029), 4.5x104 cells HEK293-6E, 5 µg M. tuberculosis H37Rv extract and 8 µL of 
marker were separated on reducing 12 % SDS-PAGE and electro blotted to a PVDF membrane. 
After blocking, membrane was incubated with L16-3-E12 scFv-Fc-HRP at a concentration of ~ 0.6 
µg mL-1, development with TMB. 
 
Nanoelectrospray mass spectrometry revealed the dodecameric structure of the 16 kDa 
antigen of M. tuberculosis recombinantly expressed in and purified from E. coli 
(Kennaway, 2005). Analytical SEC of the available recombinant 16 kDa from Lionex 
GmbH offered a partial multimeric conformation (Figure 25). Therefore, even if there was 
only one antibody recognizing one epitope on the 16 kDa antigen, a sandwich ELISA 
was performed. Sampling different 16 kDa batches (with a multimere peak in SEC) no 
signal could be obtained in α-16 kDa sandwich ELISA (data not shown). Furthermore M. 
tuberculosis culture filtrate (cultured three months in 7H9 + ADC + Tween at 37 °C) was 
tested in α-16 kDa sandwich ELISA to no avail (data not shown). 
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Figure 25: Analytical SEC of 16 kDa batch 12-2/1. 
500 µL of 16 kDa (1 mg mL-1) were applied to Superdex 200 10/300 GL column, running buffer 
was PBS pH 7.4. Standards: 1. 669 kDa 17 min, 2. 443 kDa 20 min, 3. 200 kDa 23 min, 4. 150 
kDa 24 min, 5. 66 kDa 26 min, 6. 29 kDa 31 min, 7. 12,4 kDa 34 min, 8. 6,5 kDa 37 min. (Analysis 
performed with technical assistance of Wiebke Prilop (Lionex GmbH).) 
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4.2.2 CFP-10 
4.2.2.1 A-CFP-10 scFv  
Three individual CFP-10 binders were identified by panning HAL7/8 and subsequent 
screening ELISA followed by DNA sequencing (data not shown). The gene segments 
appearing in this α-CFP-10 antibodies are outlined in Table 34.  
Table 34: Comparison of heavy and light chain gene segments of α-CFP-10 antibodies. 
  heavy chain light chain 
clone HV D HJ LV LJ 
MFU48-C8 IGHV6 IGHD3-22*01 IGHJ3*02 IGLV3-21*03 IGLJ3*02 
MFU48-E1 IGHV3-23*01 IGHD3-10*01 IGHJ1*01 IGLV1-44*01 IGLJ3*01 
MFU48-G4 IGHV6 IGHD3-22*01 IGHJ3*02  IGLV3-21*02 IGLJ7*01 
For abbrevations see Table 30. 
All scFv were subcloned to the eukaryotic transient expression vector 
pCSE2.5-hIgG1-Fc-XP. 
4.2.2.2 A-CFP-10 scFv-Fc 
HEK293-6E cells were transient transfected with the α-CFP-10 scFv-Fc in 
pCSE2.5-hIgG1-Fc-XP. The scFv-Fc could be successfully expressed and purified from 
the culture supernatant via Protein A (with technical assistance of Franziska Resch (TU-
BS)). The protein yields were determined by a Lowry protein assay (Table 35). The 
protein band patterns of the antibody preparations could be visualized by silver stained 
SDS-PAGE (Figure 26: A) and reducing gel analysis via Tape Station (Figure 26: C). 
Additional bands at ~36 kDa and ~230 kDa were detected in all three antibody 
preparations. No degradation of the Fc-part could be detected in the antibody solutions 
by α-human IgG(Fc) immunoblot (Figure 26: B). Tape Station analysis issued a purity 
(scFv-Fc band) between 80 and 93 % for the explored samples (Table 35). 
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A)                                            B)                                              C)                                         
     
Figure 26: A) Silver staining, B) α-human IgG(Fc) immunoblot and C) Tape Station analysis 
of purified α-CFP-10 scFv-Fc. 
Analysis carried out as described in Figure 12. Results of two experiments joined. 
 
Table 35: Protein yield and purity of α-CFP-10 scFv-Fc preparations. 
scFv-Fc yield [mg L-1]a purity [%]b 
MFU48-C8 111.2 89.5 
MFU48-E1 157.6 93.0 
MFU48-G4 173.6 79.0 
a) determined by Lowry protein quantification assay; b) determined by reducing Tape Station 
analysis, percent of integrated area 
 
The antigen binding was analysed by titration ELISA (Figure 27). All α-CFP-10 
antibodies bound specifically.  
 
Figure 27: Titration ELISA of α-CFP-10 scFv-Fc. 
Dilution series of scFv-Fc were used for detection of directly coated antigen (CFP-10) or BSA 
(control), detection of bound scFv-Fc with goat α-human IgG (Fc)-HRP, development with TMB. 
 
Western blotting of CFP-10 was not feasible. Therefore it was not possible to determine 
whether sequential of conformational epitopes were recognized. Nevertheless, epitope 
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mapping of the α-CFP-10 scFv-Fc was carried out on PepSpot membranes (Figure 28). 
MFU48-C8 and MFU48-G4 reacted with the peptides. It was concluded, that these 
antibodies recognized continuous epitopes. Further, it was observed that MFU48-C8 and 
MFU48-G4 reacted with the same three spots on the membrane (Figure 28: spots 5, 6 
and 7) and thereby recognized the same epitope. Through the overlap of the peptide 
sequences (Table 36) the epitope was determined to “ERISGDLKT”, which is located 
from amino acid 19 – 27 in the CFP-10 antigen sequence. The epitope of MFU48-E1 
was not distinguishable due to the wide variety of reactions with the PepSpots, which 
indicated unspecific reactions or a conformational epitope. 
 
Figure 28: Epitope mapping of α-CFP-10 scFv-Fc with PepSpot membrane. 
Membrane was incubated with respectively 5 µg scFv-Fc, detection of bound scFv-Fc with goat α-
human IgG(Fc)-HRP, development with TMB. Immunostained spots are encircled. 
 
Table 36: Epitope mapping of α-CFP-10 scFv-Fc, amino acid sequences of peptides on 
CFP-10 PepSpot membrane. 
The immunostained spots and the identified epitope are highlighted. 
spot no. peptide 
4 TLAQEAGNFERISGD 
5 
   QEAGNFERISGDLKT 
6 
      GNFERISGDLKTQID 
7 
         ERISGDLKTQIDQVE 
8 
            SGDLKTQIDQVESTA 
 
The α-CFP-10 scFv-Fc were analysed by antigen titration ELISA (Figure 29). The 
antigen detection limit was determined to ~ 300 ng mL-1. 
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Figure 29: Antigen titration ELISA with α-CFP-10 scFv-Fc. 
Different dilutions of antigen (CFP-10) were directly coated to the wells. Antigen detection with a 
scFv-Fc concentration of half maximal saturation, detection of bound scFv-Fc with goat α-human 
IgG (Fc)-HRP, development with TMB. Negative control BSA A450 = 0.05. 
 
Recognition of Mtb and BCG cell extracts and culture filtrates was analysed by indirect 
ELISA (Figure 30). No reaction with the samples was detected. 
 
Figure 30: Reaction of α-CFP-10 scFv-Fc with Mtb/BCG cell extracts and culture filtrates 
determined by indirect ELISA. 
Assay carried out as described in Figure 23. 
 
A sandwich Lateral Flow Immuno Assay (LFIA) was attempted by Susanne Kämpfer 
(Lionex GmbH) with MFU48-E1 (epitope not distinguishable) as capture antibody and 
MFU48-C8 (epitope: ERISGDLKT) conjugated to colloidal gold as detection antibody. 
This LFIA only yielded un-reproducible results (data not shown). No signal was detected 
in another approach using α-CFP-10 scFv-Fc conjugated to HRP for detection in a 
sandwich ELISA (data not shown). 
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4.2.3 85 D 
4.2.3.1 A-85 D scFv 
Three individual 85 D binders were identified by panning HAL7/8 and subsequent 
screening ELISA followed by DNA sequencing (data not shown). The gene segments 
appearing in these α-85 D antibodies are outlined in Table 37. 
Table 37: Comparison of heavy and light chain gene segments of α-85 D antibodies. 
  heavy chain light chain 
clone HV D HJ LV LJ 
MFU51-A6 IGHV1-46*01 IGHD3-10*01 IGHJ4*02 IGLV3-21*01 IGLJ3*01 
MFU51-B10 IGHV3-9*01 IGHD3-16*01 IGHJ5*02 IGLV1-40*01 IGLJ3*02 
MFU51-C2 IGHV3 IGHD6-19*01 IGHJ4*02 IGLV2-14*04 IGLJ3*02 
 
All scFv were subcloned to the eukaryotic transient expression vector 
pCSE2.5-hIgG1-Fc-XP. 
4.2.3.2 A-85 D scFv-Fc 
HEK293-6E cells were transient transfected with the α-85 D scFv-Fc in 
pCSE2.5-hIgG1-Fc-XP. The scFv-Fc were purified from the culture supernatant via 
Protein A (with technical assistance of Franziska resch (TU-BS)). The protein yields were 
determined by a Lowry protein assay (Table 38). The obtained antibody solutions were 
analysed by SDS-PAGE followed by silver staining, α-human IgG(Fc) immunoblot and 
reducing gel analysis via Tape Station (Figure 31). A slight degradation of the Fc-part 
could be detected for MFU51-A6 by α-human IgG(Fc) immunoblot (Figure 31: B). This 
disassembly was visible in Tape Station analysis as well, issuing a five band pattern with 
87.8 % purity for the target scFv-Fc (55 kDa) band (Figure 31: C). The other two α-85 D 
antibody purifications showed no sign of degradation, but additional protein bands of 204 
and 231 kDa size.
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A)                                             B)                                             C) 
         
Figure 31: A) Silver staining, B) α-human IgG(Fc) immunoblot and C) Tape Station analysis 
of purified α-85 D scFv-Fc. 
Analysis carried out as described in Figure 12. Results of two experiments joined for A) and B). 
 
Table 38: Protein yields and purity of α-85 D scFv-Fc preparations. 
scFv-Fc yield [mg L-1]a purity [%]b 
MFU51-A6 72.8 87.8 
MFU51-B10 194.4 93.2 
MFU51-C2 52.8 95.6 
Analysis carried out as described in Table 35. 
The antigen binding was analysed by titration ELISA (Figure 32). The antibodies bound 
85 D specifically. 
 
Figure 32: Titration ELISA of α-85 D scFv-Fc. 
Dilution series of scFv-Fc were used for detection of directly coated antigen (85 D) or BSA 
(negative control), detection of bound scFv-Fc with goat α-human IgG(Fc)-HRP, development with 
TMB. 
 
The cross reactivity with the other 85 complex antigens was analysed by ELISA (Figure 
33) and immunoblot (Figure 34). It turned out, that MFU51-A6 and MFU51-C2 showed 
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cross reactivity with 85 A and 85 B. Whereas MFU51-B10 displayed no reactivity with the 
other 85 complex antigens neither in ELISA nor in immunoblot. A summary of the cross 
reactions is given in Table 39. 
 
Figure 33: A-85 D indirect ELISA with α-85 D scFv-Fc, cross reactions with other 85 
complex antigens. 
100 ng of the antigens were directly coated to the wells. 85 D detection with α-85D scFv-Fc (using 
concentrations at half maximal saturation), detection of bound scFv-Fc with goat α-human IgG 
(Fc)-HRP, development with TMB. 
 
 
Figure 34: A-85 D immunoblot with α-85 D scFv-Fc, cross reactions with other 85 complex 
antigens. 
500 ng of antigens 85 A, 85 B, 85 D and 7 µL of marker were separated on reducing 12 % SDS-
PAGE and electro blotted to a PVDF membrane. After blocking, blots were incubated with 
respectively 5 µg scFv-Fc, bound scFv-Fc were detected using goat α-human IgG(Fc)-HRP, 
development with TMB. 
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Table 39: Cross reactions of α-85 D antibodies with other 85 complex antigens. 
reaction with 85 complex antigens in ELISA 
clone 85 A 85 B 85 D total 
MFU51-A6 none none medium none 
MFU51-B10 none none strong none 
MFU51-C2 medium none strong 85 A 
reaction with 85 complex antigens in immunoblot 
clone 85 A 85 B 85 D total 
MFU51-A6 weak medium strong 85 A, 85 B 
MFU51-B10 none none strong none 
MFU51-C2 weak medium strong 85 A, 85 B 
reaction with 85 complex antigens summary 
clone 85 A 85 B 85 D total 
MFU51-A6 immunoblot immunoblot immunoblot ELISA 85 A, 85 B 
MFU51-B10 none none immunoblot, ELISA none 
MFU51-C2 immunoblot, ELISA immunoblot 
immunoblot, 
ELISA 85 A, 85 B 
 
The reaction of the α-85 D antibodies with Mtb and BCG cell extracts and culture filtrates 
was analysed by indirect ELISA (Figure 35). A slight reaction with Mtb culture filtrate and 
Mtb/BCG cell extracts was discovered for MFU51-A6 and MFU51-B10. 
 
Figure 35: Reaction of α-85 D scFv-Fc with Mtb/BCG cell extracts and culture filtrates 
determined by indirect ELISA. 
Assay carried out as described in Figure 23. 
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4.2.4 85 A 
4.2.4.1 A-85 A scFv 
Four individual 85 A binders were identified by panning HAL7/8 and subsequent 
screening ELISA followed by DNA sequencing (data not shown). All these antibodies 
have the same joining gene segment of the heavy chain (HJ, Table 40). 
Table 40: Comparison of heavy and light chain gene segments of α-85 A antibodies. 
  heavy chain light chain 
clone HV D HJ LV LJ 
MFU12-D8 IGHV3-33*01 IGHD5-5*01 IGHJ4*02 IGLV6-57*01 IGLJ3*01 
MFU53-A3 IGHV3-23*04 IGHD6-25*01 IGHJ4*02 IGLV2-8*01 IGLJ3*01 
MFU53-F3 IGHV1-2*02 IGHD6-19*01 IGHJ4*02 IGLV3-19*01 IGLJ3*01 
MFU53-G2 IGHV3-30*03 IGHD3-22*01 IGHJ4*02 IGLV1-44*01 IGLJ3*02 
 
All scFv were subcloned to the eukaryotic transient expression vector 
pCSE2.5-hIgG1-Fc-XP. 
4.2.4.2 A-85 A scFv-Fc 
HEK293-6E cells were transient transfected with the α-85 A scFv-Fc in 
pCSE2.5-hIgG1-Fc-XP. The scFv-Fc were purified from the culture supernatant via 
Protein A (with technical assistance of Franziska Resch (TU-BS)). The protein yield was 
determined by a Lowry protein assay (Table 41). The obtained antibody solutions were 
analysed by SDS-PAGE followed by silver staining, α-human IgG(Fc) immunoblot and 
reducing gel analysis via Tape Station. No degradation of the scFv-Fc was detected by 
either means (Figure 36). Tape Station analysis revealed one additional protein band per 
antibody preparation (except for MFU12-D8) issuing a purity of 97.8 – 100 % for the 
target scFv-Fc band (Table 41).  
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A)                                                B) 
              
C) 
 
Figure 36: A) Silver staining, B) α-human IgG(Fc) immunoblot and C) Tape Station analysis 
of purified α-85 A scFv-Fc. 
Analysis carried out as described in Figure 12. Results of three experiments joined for B) and C). 
 
Table 41: Protein yield and purity of α-85 A scFv-Fc preparations. 
scFv-Fc yield[mg L-1]a purity [%]b 
MFU12-D8 36.8 100 
MFU53-A3 176.0 97.8 
MFU53-F3 51.2 98.2 
MFU53-G2 215.2 98.3 
Analysis carried out as described in Table 35. 
The antigen binding of the α-85 A scFv-Fc was analysed by titration ELISA (Figure 37). 
An unspecific reaction of MFU53-F3 with BSA, at a concentration higher than 200 ng mL-
1
, was discovered. The other antibodies bound specifically to 85 A.  
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Figure 37: Titration ELISA of α-85 A scFv-Fc. 
Dilution series of scFv-Fc were used for detection of directly coated antigen (85 A) or 
negative control (BSA), detection of bound scFv-Fc with goat α-human IgG(Fc)-HRP, 
development with TMB. 
 
Epitope mapping of the α-85 A scFv-Fc was carried out on PepSpot membranes (Figure 
38). MFU12-D8 reacted strong with the peptides 23 – 25, and weak with the peptides 22 
and 26. In addition to that weak reactions with six other peptides were observed. Due to 
the tryptophan content of these peptides, which can lead to stickiness (S. Dübel, 
personal communication), the reactions were ignored for epitope determination. Through 
the overlap of the peptide sequences (22 – 26) the epitope was determined to “SPA” (aa 
76 – 78 of antigen 85 A) (Table 42). MFU53-A3 reacted strong with the peptides 24 – 27 
and hence it was concluded it recognized “LYLLDG” (aa 79 – 84), which is directly 
preceded by “SPA” in the antigen sequence. The antigenic determinant of MFU53-G2 
was identified to “AFSRPGLPV” (aa 43 – 51), due to weak reactions with the peptides 13 
– 15. The epitope of MFU53-F3 was not distinguishable because of the variety of 
reactions with the PepSpots, which indicated unspecificity or a conformational epitope. 
  
Figure 38: Epitope mapping of α-85 A scFv-Fc with PepSpot membrane. 
Membrane was incubated with respectively 5 µg scFv-Fc (except for MFU53-F3, only 1 µg), 
detection of bound scFv-Fc with goat α-human IgG (Fc)-HRP, development with TMB. 
Immunostained spots are encircled. No cross reaction of the secondary antibody with the 
PepSpots was determined (data not shown). 
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Table 42: Epitope mapping of α-85 A scFv-Fc, amino acid sequences of peptides on 85 A 
PepSpot membrane. 
The immunostained spots and the identified epitopes are highlighted. 
clone spot no. peptide 
MFU12-D8 21 MGRDIKVQFQSGGAN 
 
22    DIKVQFQSGGANSPA 
 
23       VQFQSGGANSPALYL 
 
24          QSGGANSPALYLLDG 
 
25             GANSPALYLLDGLRA 
 
26                SPALYLLDGLRAQDD 
 
27                   LYLLDGLRAQDDFSG 
MFU53-A3 23 VQFQSGGANSPALYL 
 
24    QSGGANSPALYLLDG 
 
25       GANSPALYLLDGLRA 
 
26          SPALYLLDGLRAQDD 
 
27             LYLLDGLRAQDDFSG 
 
28                LDGLRAQDDFSGWDI 
MFU53-G2 12 AVGGTATAGAFSRPG 
 
13    GTATAGAFSRPGLPV 
 
14       TAGAFSRPGLPVEYL 
 
15          AFSRPGLPVEYLQVP 
 
16             RPGLPVEYLQVPSPS 
 
The crystal structure of antigen 85 A was determined by (Ronning et al., 2004). 
Therefore it was possible to visualize the determined epitopes on the three-dimensional 
(3D) structure of the antigen (Figure 39). The distance between epitope region “LYLLDG” 
and “AFSRGPLV” was computed to ~ 2.5 nm. Considering the width of an antibody (~ 4 
nm, (Boehm et al., 1999) sandwich detection of an 85 A monomer with the investigated 
scFv-Fc was expected to be difficult. 
 
Figure 39: 3D structure of antigen 85 A, epitopes of α-85 A antibodies. 
Pdb1sfr (Resolution 2.7 Å,(Ronning et al., 2004) was modified with 3D molecule viewer 
(Invitrogen). Only protein chain A is shown, atoms are displayed as space filling balls, epitopes 
are marked in blue, distance measurement in red. 
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Sequence comparison of the epitopes of the α-85 A antibodies with corresponding 
sequences of the other 85 complex antigens provided information about possible cross 
reactions (Table 43: A). The complete epitope “AFSRPGPLV” is present in antigen 85 B 
and 85 C, not in 85 D. Homologous regions of the epitope region “SPALYL(LDG)” can be 
found in 85 B, C, and D. Experimental study of this cross reactions was carried out by 
indirect ELISA (Figure 40) and immunoblot (Figure 41). It was discovered that not all 
expected cross reactions actually came to pass. Only a very weak cross reaction of 
MFU53-A3 with 85 D was detected by immunoblot, whereupon additional cross reaction 
with 85 B was expected. Strong cross reactivity with 85 B in ELISA and immunoblot was 
observed for MFU53-F3. MFU53-G2 displayed a weak reaction with 85 B in ELISA and 
no reaction with 85 D, as predicted by sequence comparison. Despite the existence of 
the entire MFU12-D8 epitope on the 85 B sequence, no cross reaction was observed. A 
summary of the expected cross reactions in comparison to determined cross reactions is 
given in Table 43. 
 
Figure 40: A-85 A indirect ELISA with α-85 A scFv-Fc, cross reactions with other 85 
complex antigens. 
Assay carried out as described in Figure 33. 
 
4 Results   
74 
 
 
Figure 41: A-85 A immunoblot with α-85 A scFv-Fc, cross reactions with other 85 complex 
antigens. 
Assay carried out as described in Figure 34. 
 
Table 43: Cross reactions of α-85 A antibodies with other 85 complex antigens. 
A) sequence comparison (corresponding sequences to α-85 A epitopes) 
clone 85 A 85 B 85 C* 85 D expected 
cross reaction 
MFU12-D8 SPA SPA PHA PHA 85 B 
MFU53-A3 LYLLDG VYLLDG VYLLDG VYLLDA 85 B, 85 C, 85 D 
MFU53-F3 ? ? ? ? 85 B, 85 C, 85 D 
MFU53-G2 AFSRPGLPV AFSRPGLPV AFSRPGLPV - 85 B, 85 C 
B) reaction with 85 complex antigens in ELISA  
clone 85 A 85 B 85 C* 85 D determined 
cross reaction 
MFU12-D8 strong none - none none 
MFU53-A3 strong none - none none 
MFU53-F3 strong strong - none 85 B 
MFU53-G2 strong weak - none weak 85 B 
C) reaction with 85 complex antigens in immunoblot  
clone 85 A 85 B 85 C* 85 D determined 
cross reaction 
MFU12-D8 strong none - none none 
MFU53-A3 strong none - weak weak 85 D 
MFU53-F3 strong strong - none 85 B 
MFU53-G2 strong none - none none 
D) reaction with 85 complex antigens summary 
clone 85 A 85 B 85 C* 85 D determined 
cross reaction 
MFU12-D8 western, ELISA none - none none 
MFU53-A3 western, ELISA none - western 85 D 
MFU53-F3 western, ELISA 
western, 
ELISA - none 85 B 
MFU53-G2 western, ELISA ELISA - none 85 B 
*Purified antigen 85 C was not available for immunological assays, nevertheless it is listed for 
completeness of the illustration 
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The antigen detection limits of the α-85 A scFv-Fc were determined to ~ 10 ng mL-1 for 
MFU12-D8 and MFU53-A3, and ~ 60 ng mL-1 for MFU53-F3 and MFU53-G2 by antigen 
titration ELISA (Figure 42). 
 
Figure 42: Antigen titration ELISA with α-85 A scFv-Fc. 
Different dilutions of antigen (85 A) were directly coated to the wells. Antigen detection with a 
scFv-Fc concentration of half maximal saturation, detection of bound scFv-Fc with goat α-human 
IgG(Fc)-HRP, development with TMB. Negative control BSA A450 = 0.05.  
 
The reaction of the α-85 A antibodies with Mtb and BCG cell extracts and culture filtrates 
was analysed by indirect ELISA (Figure 43). No specific reaction with Mtb/BCG cell 
extracts or culture filtrates was detected. 
 
Figure 43: Reaction of α-85 A scFv-Fc with Mtb/BCG cell extracts and culture filtrates 
determined by indirect ELISA. 
Assay carried out as described in Figure 23. 
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4.2.4.3 A-85 A scFv-Fc-HRP 
Visualization of the α-85 A antibody epitopes on the 3D structure of the antigen revealed 
an unfavourable position for sandwich detection. Considering that (Ronning et al., 2004) 
discovered a trimeric structure for antigen 85 A, a sandwich assay was attempted 
nevertheless. Therefore MFU53-A3 scFv-Fc (recognizing “LYLLDG”) and MFU53-G2 
scFv-Fc (recognizing “AFSRGPLV”) were conjugated to HRP. The necessary dilution of 
the antibody-HRP conjugates was determined by direct ELISA (data not shown) to 0.6 
µg mL-1 for MFU53-G2 and 0.07 µg mL-1 for MFU53-A3. The cross reactivity of the 
achieved antibody-HRP conjugates was analysed by α-85 A immunoblot and α-85 A 
direct ELISA. No cross reactions were detected through immunoblot (exemplary 
displayed for MFU53-A3-HRP in Figure 44). Slight cross reactions with 85 B were 
detected by ELISA (exemplary displayed for MFU53-A3-HRP in Figure 47).  
 
Figure 44: Cross reactions of α-85 A MFU53-A3 scFv-Fc-HRP in immunoblot. 
Blot preparation as described in Figure 24. After blocking, membrane was incubated with MFU53-
A3 scFv-Fc-HRP at a concentration of ~ 0.2 µg mL-1, development with TMB. 
 
Sandwich detection of the antigen was attempted with all four α-85 A scFv-Fc as capture 
antibodies and MFU53-A3/G2-HRP as detection antibodies. Sandwich detection of the 
recombinant antigen was successful with all combinations, offering a detection limit of 
~ 125 ng mL-1 (exemplary displayed for MFU53-A3-HRP detection in Figure 45). 
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Figure 45: Sandwich 85 A (07-1/1) titration ELISA with α-85 A scFv-Fc. 
100 ng of capture scFv-Fc were directly coated to the wells, after blocking different dilutions of 
antigen 85 A (batch 07-1/1) were applied and incubated, detection of bound antigen with MFU53-
A3-scFv-Fc-HRP at ~ 0.07 µg mL-1, development with TMB. Negative control BSA A450 = 0.08. 
 
Capturing with MFU53-A3 and simultaneous detection with MFU53-A3-HRP was 
possible (the same was observed for MFU53-G2), which indicated the detection of 
antigenic associates. There was not enough sample of the antigen batch (07-1/1) left to 
investigate the aggregation behavior. But another 85 A batch (12-2/1) was available and 
was analysed using analytical SEC. 
 
Figure 46: Analytical SEC of antigen 85 A (batch 12-2/1). 
500 µL of sample were applied to Superdex 200 10/300 GL column, running buffer was PBS pH 
7.4. Standards: 1. 669 kDa 17 min, 2. 443 kDa 20 min, 3. 200 kDa 23 min, 4. 150 kDa 24 min, 5. 
66 kDa 26 min, 6. 29 kDa 31 min, 7. 12.4 kDa 34 min, 8. 6.5 kDa 37 min. Analysis was performed 
with technical assistance of Wiebke Prilop (Lionex GmbH). 
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The theoretical molecular mass of an 85 A monomer (recombinant with N-terminal His-
tag and without the signal sequence) was computed with the ExPASy prot param tool to 
32.6 kDa. A dominant peak at 31.2 kDa was visible in the chromatogram of the analytical 
SEC (Figure 46). Based on this result 85 A (batch 12-1/1 in PBS pH 7.4) was considered 
to be mainly monomeric. A sandwich ELISA assay with both antigen batches in 
comparison offered a ~ 50 % greater reaction with batch 07-1/1 than with batch 12-1/1 
(Figure 47). Using only one antibody for capturing and detection was possible with batch 
12-1/1 as well, indicating the presence of associates in this antigen preparation. 
 
Figure 47: A-85 A sandwich ELISA with α-85 A scFv-Fc, recognition of multimers, cross 
reactions. 
100 ng of capture scFv-Fc were directly coated to the wells, after blocking 100 ng of the samples 
were applied and incubated, detection of bound antigen with MFU53-A3-scFv-Fc-HRP at ~ 0.07 
µg mL-1, development with TMB. 
 
 
Figure 48: Sandwich 85 A (12-1/1) titration ELISA with α-85 A scFv-Fc. 
Assay performed as described in Figure 48, but with 85 A batch 12-1/1. 
 
By antigen titration of batch 12-1/1 a detection limit of ~ 500 ng mL-1 was determined, 
which was four times less sensitive than with batch 07-1/1. Assuming that batch 07-1/1 
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contained a greater amount of multimers, sandwich detection of 85 A was benefitted by 
antigenic associates. Regarding the obtained data, a final statement if the α-85 A 
sandwich ELISA recognized only associates was not possible. 
4.2.4.4 A-85 A scFv-Fc-gold 
A-85 A scFv-Fc were conjugated to colloidal gold by Lionex GmbH. The obtained 
scFv-Fc-gold preparations reacted with the antigen in a direct assay. Sandwich assays 
with different antibody combinations were performed, delivering only unspecific results 
(data not shown).  
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4.2.5 85 B 
4.2.5.1 A-85 B scFv 
After panning HAL7/8 for α- 85 B scFv, 92 clones from the third panning round were 
produced in MTP. Their ability to bind 85 B was analysed by screening ELISA, resulting 
in 51 signals higher than A450 = 0.1 (Figure 49). From 11 of these clones plasmid DNA 
was isolated and sent for DNA-sequencing.  
 
Figure 49: Screening ELISA for 85 B binding scFv in HAL7/8. 
Culture supernatants containing soluble scFv of 92 single clones (3. panning round) were 
screened for their ability to bind antigen (85 B) and BSA (negative control). Detection of bound 
scFv with mouse α-c-Myc-tag 9E10 IgG followed by goat α-mouse IgG(Fc)-HRP, development 
with TMB. 
 
In the end five individual 85 B binders were identified (Table 44). All α-85 B antibodies 
contain a variable gene segment of the heavy chain (HV) of subfamily VH3. Four binders 
have a lambda light chain (VLλ), one has a kappa light chain (VLκ). All VLλ clones have a 
joining segment of the heavy chain (HJ) of subfamily J4, a joining segment of the light 
chain (LJ) of subfamily J3, and a variable gene segment of the heavy chain (HV) of 
subfamily VH3 gene 30. 
 
Table 44: Comparison of heavy and light chain gene segments of α-85 B antibodies. 
  heavy chain light chain 
clone HV D HJ LV LJ 
MFU50-A10 IGHV3-30*04 IGHD6-19*01 IGHJ4*02 IGLV8-61*01 IGLJ3*02 
MFU50-C10 IGHV3 IGHD2-15*01 IGHJ6*02 IGKV1-12*01 IGKJ2*01 
MFU50-D4 IGHV3-30*18 IGHD3-3*02 IGHJ4*02 IGLV2-14*01 IGLJ3*01 
MFU50-D7 IGHV3-30*04 IGHD4-17*01 IGHJ4*02 IGLV3-21*02 IGLJ3*02 
MFU50-E2 IGHV3-30*03 IGHD6-13*01 IGHJ4*02 IGLV7-43*01 IGLJ3*02 
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All scFv were subcloned to the eukaryotic transient expression vector 
pCSE2.5-hIgG1-Fc-XP. 
4.2.5.2 A-85 B scFv-Fc 
HEK293-6E cells were transient transfected with the α-85 B scFv-Fc in 
pCSE2.5-hIgG1-Fc-XP. The scFv-Fc were purified from the culture supernatant via 
Protein A (with technical assistance of Franziska Resch (TU-BS)). The protein yield was 
determined by a Lowry protein assay (Table 45). No degradation could be detected by 
silver-stained SDS-PAGE (Figure 50: A), α-human IgG(Fc) immunoblot (Figure 50: B) or 
reducing gel analysis via Tape Station (Figure 50: C). Up to three very faint additional 
protein bands with a higher molecular mass than the target scFv-Fc were detected by 
Tape Station, issuing a purity of 93.4 – 96.9 % for the antibody preparations (Table 45). 
A)                                             B) 
           
C) 
 
Figure 50: A) Silver staining, B) α-human IgG(Fc) immunoblot and C) Tape Station analysis 
of purified α-85 B scFv-Fc. 
Analysis carried out as described in Figure 12. A) silver staining of MFU50-A10 scFv-Fc is 
missing, B) results of two experiments joined. 
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Table 45: Protein yields and purity of α-85 B scFv-Fc preparations. 
scFv-Fc yield [mg L-1]a purity [%]b 
MFU50-A10 198.4 94.4 
MFU50-C10 196.8 94.8 
MFU50-D4 194.4 96.9 
MFU50-D7 183.2 96.4 
MFU50-E2 50.4 93.4* 
Analysis carried out as described in Table 35. *53 + 54 kDa values combined* 
Antigen binding of the α-85 B scFv-Fc was analysed by titration ELISA (Figure 51). All 
antibodies bound 85 B specifically. Further, all α-85 B antibodies were binding to 
continuous sequences determined by immunoblot (data not shown). 
 
Figure 51: Titration ELISA of α-85 B scFv-Fc. 
Dilution series of scFv-Fc were used for detection of directly coated antigen (85 B) or BSA 
(negative control), detection of bound scFv-Fc with goat α-human IgG(Fc)-HRP, development with 
TMB. 
 
Epitope mapping of the α-85 B scFv-Fc was carried out on PepSpot membranes (Figure 
52). Through the overlap of the peptide sequences the epitopes were determined (Table 
46). It was observed that MFU50-D7 and MFU50-D4 recognized the same region of the 
antigen “AFSRPGLPV(EYL)” (aa 39 – 51 respectively aa 39 – 47). Similarly the epitope 
of MFU50-A10 and MFU50-E2 was identified to “SSDPAWERN(DPT) “(aa 223 – 234 
respectively aa 223 – 231). MFU50-C10 reacted with a third antigenic determinant 
“SPAVYL” (aa 73 – 78). Interestingly corresponding sequences of the epitope regions 
“AFSRGPLVEYL” and “SPAVYL” were recognized by the α-85 A antibodies as well.  
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Figure 52: Epitope mapping of α-85 B scFv-Fc with PepSpot membrane. 
Membrane was incubated with respectively 5 µg scFv-Fc, detection of bound scFv-Fc with goat α-
human IgG(Fc)-HRP, development with TMB. Immunostained spots are encircled. No cross 
reaction of the secondary antibody with the PepSpots was determined (data not shown). 
 
Table 46: Epitope mapping of α-85 B scFv-Fc, amino acid sequences of peptides on 85 B 
PepSpot membrane. 
The immunostained spots and the identified epitopes are highlighted. 
clone spot no. peptide 
MFU50-D7 12 GAATAGAFSRPGLPV 
 13    TAGAFSRPGLPVEYL 
 14       AFSRPGLPVEYLQVP 
  15          RPGLPVEYLQVPSPS 
MFU50-D4 11 LAGGAATAGAFSRPG 
 12    GAATAGAFSRPGLPV 
 13       TAGAFSRPGLPVEYL 
 14          AFSRPGLPVEYLQVP 
  15             RPGLPVEYLQVPSPS 
MFU50-A10 73 ADMWGPSSDPAWERN 
 74    WGPSSDPAWERNDPT 
 75       SSDPAWERNDPTQQI 
  76          PAWERNDPTQQIPKL 
MFU50-E2 72 YKAADMWGPSSDPAW 
 73    ADMWGPSSDPAWERN 
 74       WGPSSDPAWERNDPT 
 75          SSDPAWERNDPTQQI 
 76             PAWERNDPTQQIPKL 
MFU50-C10 21 DIKVQFQSGGNNSPA 
 22    VQFQSGGNNSPAVYL 
 23       QSGGNNSPAVYLLDG 
 24          GNNSPAVYLLDGLRA 
 25             SPAVYLLDGLRAQDD 
  26                VYLLDGLRAQDDYNG 
 
The crystal structure of antigen 85 B was determined by Anderson and colleagues 
(Anderson et al., 2001). Therefore it was possible to visualize the determined epitopes 
on the 3D structure of the antigen (Figure 53). The distance between epitope regions 
“AFSRGPLV(EYL)” and “SPAVYL” was computed to ~ 2.5 nm, between “SPAVYL” and 
“SSDPAWERN(DPT)” to ~ 4 nm and between “SSDPAWERN(DPT)” and 
“AFSRGPLV(EYL)” to ~ 5 nm. Considering the width of an antibody (~ 4 nm, (Boehm et 
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al., 1999)), sandwich detection was likely targeting epitopes on different sites of the 
antigen. 
 
Figure 53: 3D structure of antigen 85 B, epitopes of α-85 B antibodies. 
Pdb1f0n (Resolution 1.9 Å, (Anderson et al., 2001) was modified with 3D molecule viewer 
(Invitrogen). Only protein chain A is shown, atoms are displayed as space filling balls, epitopes 
are marked in yellow, distance measurement in red.  
 
Sequence comparison of the epitopes of the α-85 B antibodies with corresponding 
sequences of the other 85 complex antigens provided information about possible cross 
reactions (Table 47: A). The complete epitope “AFSRPGPLV(EYL)” is present in antigen 
85 A and 85 C, not in 85 D. Homologous regions of the epitopes “SPAVYL” and 
“SSDPAWERN(DPT)” can be found in 85 A, C, and D. Experimental study of 85 complex 
cross reactivity was carried out by indirect ELISA (Figure 54) and immunoblot (Figure 
55). MFU50-A10 reacted with 85 A and 85 D in ELISA and immunoblot, and MFU50-D4 
displayed a weak cross reactivity with 85 A in ELISA as predicted. MFU50-E2 bound 
antigen 85 B weakly and showed no cross reactions. MFU50-D7 reacted weakly with 85 
B in ELISA and strong in immunoblot, no reaction with the other 85 complex antigens 
was detected by either method. MFU50-C10 was not cross reactive as well. A summary 
of the expected cross reactions in comparison to determined cross reactions is outlined 
in Table 47. 
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Figure 54: A-85 B indirect ELISA with α-85 B scFv-Fc, cross reactions with other 85 
complex antigens. 
Assay carried out as described in Figure 33. 
 
 
Figure 55: A-85 B immunoblot with α-85 B scFv-Fc, cross reactions with other 85 complex 
antigens. 
Assay carried out as described in Figure 34. 
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Table 47: Cross reactions of α-85 B antibodies with other 85 complex antigens. 
A) sequence comparison (corresponding sequences to α-85 B epitopes) 
clone 85 A 85 B 85 C* 85 D expected cross 
reaction 
MFU50-A10 KEDPAW QRNDPL 
SSDPAW 
ERNDPT 
SSDPAW 
KRNDPM 
ASDPAA 
 
85 A, 85 C, 85 D 
MFU50-C10 SPALYL SPAVYL PHAVYL PHAVYL 85 A, 85 C, 85 D 
MFU50-D4 AFSRPG LPV 
AFSRPG 
LPV 
AFSRPG 
LPV - 85 A, 85 C 
MFU50-D7 AFSRPG LPVEYL 
AFSRPG 
LPVEYL 
AFSRPG 
LPVEYL - 85 A, 85 C 
MFU50-E2 KEDPAW QRN 
SSDPAW 
ERN 
SSDPAW 
KRN 
ASDPAA 
 
85 A, 85 C, 85 D 
B) reaction with 85 complex antigens in ELISA 
clone 85 A 85 B 85 C* 85 D determined 
cross reaction 
MFU50-A10 strong strong - strong 85 A, 85 D 
MFU50-C10 none strong - none none 
MFU50-D4 weak strong - none weak 85 A 
MFU50-D7 none weak - none none 
MFU50-E2 none weak - none none 
C) reaction with 85 complex antigens in immunoblot 
clone 85 A 85 B 85 C* 85 D determined 
cross reaction 
MFU50-A10 weak strong - weak 85 A, 85 D 
MFU50-C10 none strong - none none 
MFU50-D4 none strong - none none 
MFU50-D7 none strong - none none 
MFU50-E2 none weak - none none 
D) reaction with 85 complex antigens summary 
clone 85 A 85 B 85 C* 85 D determined 
cross reaction 
MFU50-A10 western, ELISA 
western, 
ELISA - 
western, 
ELISA 85 A, 85 D 
MFU50-C10 none western, ELISA - none none 
MFU50-D4 ELISA western, ELISA - none 85 A 
MFU50-D7 none western, ELISA - none none 
MFU50-E2 none western, ELISA - none none 
*Purified antigen 85 C was not available for immunological assays, nevertheless it is listed for 
completeness of the illustration 
 
The antigen detection limits of the α-85 B scFv-Fc were determined by antigen titration 
ELISA (Figure 56). About 5 ng mL-1 were detected by MFU50-C10, ~ 10 ng mL-1 by 
MFU50-A10 and MFU50-E2, and ~ 30 ng mL-1 by MFU50-D4 and MFU50-D7. 
  4 Results 
87 
 
 
Figure 56: Antigen titration ELISA with α-85 B scFv-Fc. 
Different dilutions of antigen (85 B) were directly coated to the wells. Antigen detection with a 
scFv-Fc concentration of half maximal saturation, detection of bound scFv-Fc with goat α-human 
IgG(Fc)-HRP, development with TMB. Negative control BSA A450 = 0.05.  
 
The α-85 B antibody binding to Mtb/BCG cell extracts and culture filtrates was analysed 
by indirect ELISA (Figure 57). In this assay only MFU50-A10 reacted with Mtb culture 
filtrate and Mtb/BCG cell extracts. The other antibodies bound merely 85 B. A weak 
cross reaction of MFU50-A10 with 7H9 medium was detected.  
 
Figure 57: Reaction of α-85 B scFv-Fc with Mtb/BCG cell extracts and culture filtrates 
determined by indirect ELISA. 
Assay carried out as described in Figure 23. 
 
4.2.5.3 A-85 B sandwich ELISA 
Due to the availability of five different antibodies with three different epitopes on the 
target antigen a sandwich α-85 B assay was attempted. MFU50-A10 (epitope 
“SSDPAWERNDPT”), MFU50-C10 (epitope “SPAVYL”) and MFU50-D4 (epitope 
“AFSRPGLPV”) scFv-Fc were conjugated to HRP. The necessary dilutions of the 
antibody-HRP conjugates were determined by direct ELISA (data not shown) to 
~ 0.05 µg mL-1 for all preparations. Sandwich detection of the antigen was attempted 
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with MFU50-A10-HRP, MFU50-C10-HRP or MFU50-D4-HRP as detection antibodies 
and capturing was carried out with corresponding antibodies recognizing different 
epitopes (than the detection antibody) on the target. Sandwich detection of the 
recombinant antigen was successful with all combinations (Figure 58). 
 
Figure 58: α-85 B sandwich antigen titration ELISA 
100 ng of capture scFv-Fc were directly coated to the wells, after blocking different dilutions of 
antigen were applied and incubated. Detection of bound antigen with: A) MFU50-A10-scFv-Fc-
HRP at ~ 0.05 µg/mL, development with TMB. Negative control (BSA) A450=0.02, B) MFU50-C10-
scFv-Fc-HRP at ~ 0.05 µg/mL, development with TMB. Negative control (BSA) A450=0.05, C) 
MFU50-D4-scFv-Fc-HRP at ~ 0.05 µg/mL, development with TMB. Negative control (BSA) 
A450=0.02. 
 
The antigen detection limit for capturing with MFU50-A10, MFU50-C10, MFU50-D4 or 
MFU50-D7 was determined to ~ 10 ng mL-1, independent from the detection antibody. 
Capturing with MFU50-E2 resulted in a detection limit of ~ 25 ng mL-1. The highest 
signals were obtained by combination of MFU50-A10 as capture antibody and MFU50-
C10-HRP as detection antibody-conjugate, hence this combination was considered most 
suitable. Mtb culture filtrate (Mtb cultivated in 7H9+ADC+Tween for 3 months at 37 °C) 
was analysed by α-85 B sandwich titration ELISA (Figure 59: A, red curve), resulting in 
weak binding barely distinguishable from the medium control (Figure 59: A, pink curve). 
Mtb culture filtrate was further analysed by direct α-85 B ELISA (Figure 59: A, black 
curve). In this assay no increase of the signal by increase of the sample volume was 
obtained. Additionally, Mtb cell extract was analysed by α-85 B sandwich titration ELISA 
(Figure 59: B, red curve), showing no binding distinguishable from the negative control 
(except for the highest concentration (Figure 59: B, grey curve). Whereupon, in a direct 
α-85 B ELISA specific binding to Mtb cell extract was observed (Figure 59: B, black 
curve). 
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Figure 59: A) Mtb culture filtrate and B) Mtb cell extract titration in α-85 B direct and 
sandwich ELISA. 
Direct ELISA: A) various volumina of Mtb culture filtrate or B) different dilutions of Mtb cell extract 
were directly coated to the wells, after blocking antigen was detected using MFU50-C10-scFv-Fc-
HRP at ~ 0.05 µg/mL, development with TMB.  
Sandwich ELISA: 100 ng of capture scFv-Fc MFU50-A10 were directly coated to the wells, after 
blocking A) various volumina of Mtb culture filtrate or B) different dilutions of Mtb cell extract were 
applied and incubated, detection of bound antigen with MFU50-C10-scFv-Fc-HRP at ~ 0.05 
µg/mL, development with TMB. Negative controls: BSA, M. smegmatis cell extract, M. vaccae cell 
extract all A450=0.05. 
 
The failed detection of 85 B in Mtb cells extract in sandwich ELISA compared to the 
successful detection in direct ELISA was further analysed. It was hypothesized, that 
sample treatment, especially autoclaving, was the cause for differing antigen detection. 
Cell extracts were fabricated by autoclaving at 121 °C for 20 min. The influence of 
sample pre-treatment by heat on 85 B detection was investigated by direct ELISA 
(Figure 60). Antigen binding was reduced, when 85 B was boiled. Further examination of 
the susceptibility of 85 B to heat was carried out by analytical SEC (Figure 61). 
 
Figure 60: Detection of boiled 85 B by α-85 B direct ELISA. 
100 ng of antigens in PBS (boiled for 20 min at 100 °C or directly taken from storage at 2 – 8 °C) 
were coated to the wells, after blocking bound antigen was detected using MFU50-A10/-C10/-D4-
scFv-Fc-HRP at ~ 0.05 µg/mL, development with TMB. Negative control BSA A450=0.02. 
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Figure 61: Analytical SEC of antigen 85 B (batch 09-2/1). 
A) sample stored at 2 – 8 °C, B) sample boiled for 20 min at 100 °C. 500 µL of sample were 
applied to Superdex 200 10/300 GL column, running buffer was PBS pH 7.4. Standards: 1. 669 
kDa 17 min, 2. 443 kDa 20 min, 3. 200 kDa 23 min, 4. 150 kDa 24 min, 5. 66 kDa 26 min, 6. 29 
kDa 31 min, 7. 12.4 kDa 34 min, 8. 6.5 kDa 37 min. Analysis was performed with technical 
assistance of Wiebke Prilop (Lionex GmbH). 
 
The theoretical molecular mass of an 85 B monomer (recombinant with C-terminal His-
tag) was computed with the ExPASy prot param tool to 35.4 kDa. The untreated sample 
of 85 B displayed a small monomer peak at 33.8 kDa and a dominant multimere peak 
with a molecular mass out of the measurement range but definitely greater than 669 kDa 
(Figure 61: A). In comparison to that the boiled 85 B sample offered a dominant peak at 
the size of a monomer (35.3 kDa), multiple peaks with lower molecular mass and a few 
non-dominant multimere peaks (Figure 61: B). Interestingly, aggregation was greater in 
the untreated sample than in the boiled sample. It was concluded that the aggregation 
was benefitting sandwich detection. If multimers were detected by sandwich ELISA, than 
use of the same antibody for capturing and detection should be possible. Experimental 
study by α-85 B sandwich ELISA (Figure 62) verified this assumption. In the untreated as 
well as in the boiled sample sandwich detection with only one antibody was possible 
(Figure 62, arrows).  
  4 Results 
91 
 
 
Figure 62: Detection of 85 B multimers in α-85 B sandwich ELISA. 
100 ng of capture scFv-Fc were coated to the wells, after blocking 100 ng of 85 B in PBS 
(untreated or boiled for 20 min at 100 °C) were applied to the wells and incubated, bound antigen 
was detected using MFU50-A10/-C10/-D4-scFv-Fc-HRP at ~ 0.05 µg/mL, development with TMB. 
Negative control BSA A450=0.05. Multimer-detection is indicated by arrows. 
 
Further study of the binding properties of the α-85 B scFv-Fc was carried out by SPR. 
Therefore the human antibody capture kit and a CM5 chip were used. ScFv-Fc 
antibodies were successfully bound to the α-human IgG antibody on the surface, but 
when antigen was applied there was either no signal obtained or the signal lay out of the 
measurement range. It was reasoned that the multimeric structure of the recombinant 
antigen was responsible for that. Boiling of recombinant 85 B reduced the amount of 
aggregates to a minimum (compare SEC Figure 61: B), hence the antigen was 
pretreated this way before SPR. Now an association of antigen and antibody was 
detectable but no dissociation followed. It was assumed that the debris of boiled antigen 
85 B caused disturbing flow characteristics. With this antigen preparation no 
determination of binding characteristics via SPR was possible 
4.2.5.4 A-85 B sandwich LFIA 
All α-85 B scFv-Fc were conjugated to colloidal gold (40 nm) by Lionex GmbH. General 
conjugation-parameters and an overview of the performed experiments is given in Table 
48. Every scFv-Fc-gold conjugate reacted with 400 ng 85 B dispensed on a 
nitrocellulose membrane (direct assay), the weakest signal was obtained by MFU50-E2-
gold (Table 48: B) and therefore this conjugate was processed no further. Cross 
reactivity with different antigens was determined in direct assays, revealing slight cross 
reactions of MFU50-C10-gold with Rv0211 and MPB70 (Table 48: C), hence this 
conjugate was processed no further. Sandwich detection of 85 B was carried out with 
MFU50-A10, MFU50-C10 or MFU50-D4 as capture antibodies and the remaining scFv-
Fc-gold conjugates as detection antibodies. Sandwich detection was successful, but 
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background appeared using MFU50-C10 for capturing (exemplary displayed for MFU50-
D4 scFv-Fc-gold in Figure 63: B). Thus capturing was further accomplished with MFU50-
A10 and MFU50-D4. Sandwich detection was most sensitive using MFU50-A10 as 
capture antibody and MFU50-D4-gold as detection antibody (detection limit ≤ 50 ng mL-1, 
Table 48: E). These results were reproducible in small scale but after upscale of the 
MFU50-D4-gold conjugation background reactions occurred. 
Table 48: Overview α-85 B LFIA development. 
 
scFv-Fc-gold 
 
MFU50-E2 MFU50-C10 MFU50-A10 MFU50-D7 MFU50-D4 
A) conjugation-parameters 
pH 6.4 9.8 6.8 8.4 8.8 
c (scFv-Fc) 
[µg/mL] 75 100 75 75 75 
blocking agent BSA BSA BSA BSA BSA 
B) direct assay (antigen detection) 
85 B weak strong strong strong strong 
C) direct assay (cross reactions) 
Rv0467 - none none none none 
Rv3019 - none none none none 
Rv0211 - weak none none none 
Rv1636 - none none none none 
MPB70 - weak none none none 
D) sandwich assay (antigen detection) 
capture scFv-Fc      
MFU50-A10 - - - specific specific 
MFU50-C10 - - unspecific unspecific unspecific 
MFU50-D4 - - specific - - 
MFU50-D7 - - - - - 
MFU50-E2 - - - - - 
E) detection limit [ng mL-1] 
MFU50-A10 - - - ≤ 100 ≤ 50 
MFU50-D4 - - ≤ 100 - - 
F) reproduction 
MFU50-A10 - - - - successful 
G) upscale 
MFU50-A10 - - - - unspecific 
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A)                                                                         B) 
 
Figure 63: A-85 B sandwich LFIA, configuration and capture antibody selection. 
A) general configuration of LFIA, modified after (Wong and Tse, 2009) B) 1 µL cm-1 of MFU50-
A10 or MFU50-C10 scFv-Fc (each 1 mg mL-1) were dispensed onto nitrocellulose membrane, 
membrane was cut in 0.4 cm strips, glass fibre pad soaked with MFU50-D4 scFv-Fc-gold was 
applied, LFIA were assembled. Assay with 120 µL of PBS pH 7.4 as negative control and 120 µL 
PBS spiked with 1 µg of antigen 85 B as positive control. Scan after 15 min. 
 
Removal of these background reactions was attempted by substituting constituents of 
the LFIA, dilution of the antibodies, blocking trials and variation of pH. The influence of 
individual conditions is displayed in Table 49. 
Table 49: Influence of conditions in α-85 B sandwich LFIA. 
 influence on 
diversified condition background antigen recognition 
constituents buffer batch none none 
 gold sol batch none none 
dilutions scFv-Fc-gold 
conjugate weaker with dilution 
 capture scFv-Fc weaker with dilution 
blocking membrane none none 
 glass fibre pad none none 
 running buffer none none 
 capture scFv-Fc none none 
electrochemical pH strong strong 
 
The background reaction was predominantly influenced by pH. LFIA at the pH of 
scFv-Fc-gold conjugation (pH 8.8 for MFU50-D4) removed the background. 
Unfortunately antigen detection at pH 8.8 was impossible in a sandwich assay and in a 
direct assay as well. In summary antigen detection at physiological pH 7.4 was possible 
(with background) and not possible at conjugation pH 8.8 (no background).  
Several experiments were carried out to determine a procedure that would allow 
sensitive antigen detection and a low background combined with good feasibility (data 
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not shown). The best option for a manageable LFIA was to add a diluent to the sample 
before applying it to the sample well. Therefore 1/3 sample volume (50 µL) of 
conjugation buffer (2.2 mM borax pH 8.8) enriched with 8 % (w/v) BSA were mixed with 
100 µL sample and applied to the LFIA. After 15 – 20 min results were evaluated. A 
detection limit of ≤ 5 ng mL-1 was determined (Figure 64). 
No reaction with Mtb cell extract or culture filtrate (concentrated and unconcentrated) 
was observed. Spiking experiments with human sputum and urine samples were 
performed by Lionex GmbH. The spike was fully retrieved from the urine samples, but 
only to 50 % from sputum samples. All available sputum samples of confirmed TB 
patients were autoclaved prior to storage at 2 – 8 °C at Lionex GmbH. Previous 
experiments with boiled 85 B (chapter 4.2.5.3) showed an extensive drop down of the 
signals in sandwich ELISA compared to untreated 85 B, hence no further examination of 
the allocatable samples was carried out.  
 
Figure 64: A-85 B sandwich LFIA, determination of detection limit. 
MFU50-D4 scFv-Fc-gold on glass fibre pad for detection, MFU50-A10 scFv-Fc on membrane for 
capturing (lower line), Protein A as control (upper line). Measurement of a dilution series of 7H9 
medium spiked with 85 B. 100 µL sample + 50 µL 2.2 mM borax pH 8.8 containing 8 % BSA were 
applied on sample pad, read out after 20 min. 
 
4.2.5.5 A-85 B immunoblot 
Sandwich detection of antigen 85 B in Mtb culture filtrates and cell extracts was complex 
in previously described sandwich ELISA and LFIA. As an alternative a direct α-85 B 
immunoblot assay was developed to avoid the challenge of sample pre-treatment in 
sandwich detection. Mtb culture filtrates may contain a too small amount of antigen to be 
detectable in the described assays. Therefore concentration of culture filtrates was 
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carried out. To avoid enrichment of protein ingredients from nutrient broth, Mtb was 
cultured in Sauton’s minimal medium. An older culture (54 days old at the start of the 
experiments) and a fresh inoculated culture were examined. Weekly samples were 
taken, concentrated 20 to 30 fold and analysed by reducing gel analysis via Tape Station 
and α-85 B immunoblot. No 85 B was detected in 7 and 16 days old cultures by either 
means (data not shown). After 22 days a protein band at ~30 kDa (according to Tape 
Station analysis, Figure 65: B) was recognized by MFU50-A10 in immunoblot (Figure 65: 
A). Additionally, 85 B expression was verified for 61 and 70 days old cultures (data not 
shown). The Tape Station and α-85 B immunoblot results for 22 and 76 days old cultures 
are given in Figure 65. 
A) 
 
B) 
 
Figure 65: A) α-85 B immunoblot and B) Tape Station analysis of concentrated Mtb culture 
filtrates (22 d or 76 d at 37 °C) 
A) 100 ng of recombinant 85 B, 25 µL of concentrated Mtb culture filtrates (after 22 or 76 days at 
37 °C in Sauton‘s medium) and 8 µL of marker (M) were separated on reducing 12 % SDS-PAGE 
and electro blotted to a PVDF membrane. After blocking, blots were incubated with scFv-Fc-HRP, 
development with TMB. B) Samples were directly analysed by reducing gel analysis via Tape 
Station. 
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In summary antigen 85 B was detectable in concentrated culture filtrates of Mtb after 
17 – 22 days of cultivation in Sauton’s medium at 37 °C via α-85 B immunblot. A more 
accurate determination of the necessary cultivation time was not possible due to the lack 
of access to the L3 facility in Hannover. The positively tested culture filtrates were further 
analysed by α-85 B direct and sandwich ELISA in addition to α-85 B sandwich LFIA. 
There was no reaction detectable via LFIA. In ELISA a massive background reaction of 
the culture filtrates with TMB was observed. 
4.3 Summary 
For clarity the properties of the generated antibodies are summarized in Table 50, Table 
51 and Table 52. 
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Table 50: Properties of generated antibodies part 1. 
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Table 51: Properties of generated antibodies part 2. 
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Table 52: Properties of generated antibodies part 3. 
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5 Discussion 
For the detection of Mtb, antibodies against the antigens 16 kDa, CFP-10, 85 A, 85 B 
and 85 D were isolated by panning of the naïve human phage display libraries HAL7/8. 
In addition, a recombinant α-LAM antibody was generated from an IgM expressing 
hybridoma clone. Furthermore, these antibodies were purified in different formats, 
biochemically characterised and examined regarding their suitability in different Mtb 
antigen detection assays. 
5.1 LAM 
The human naïve phage display libraries HAL7/8 (Hust et al., 2011) were screened by 
panning on immobilized LAM. Unfortunately, no LAM specific antibodies could be 
isolated. LAM is a lipopolysaccharide and appears to be a poor immunogen. 
Carbohydrates in general show only inadequate immunogenicity (Hirvonen et al., 2013). 
If polyclonal or monoclonal α-carbohydrate antibodies can be raised by immunization, 
they are typically of the IgM class (Kannagi and Hakomori, 2001). It seems efficient 
binding of carbohydrate-specific antibodies depends on multivalency (Karush 1970; 
Winter et al. 1994). In this work a monovalent phage display technique with naïve, IgM 
originated scFv libraries was used. Therefore a multivalent display technique, by i.e. 
shortening of the peptide linker and following multimerization of scFv due to steric 
hindrance (Ravn et al., 2004), may have been more successful. In addition, the 
presentation of the antigen on the surface of microtiter plates can be suboptimal. This 
could be solved by panning on LAM-carrier protein conjugates or panning on magnetic 
beads.  
Because no scFv were selected, further work was pursued with the IgM expressing 
hybridome Lx143. From this clone several slightly different variable gene segments were 
isolated, but none was coding for the functional antibody. Isolation of a great variety of 
antibody genes from one cell line, ranging from slight differences in one allel to different 
light or heavy chain types, was reported by several authors before (Chen et al., 1986; 
Shimizu et al., 1991; Pauza et al., 1993). Aberrant variable gene transcripts may derive 
either from the non-secreting myeloma fusion partner or from unproductively rearranged 
alleles present in the B cell (Irani et al., 2008). Furthermore, hybridomas grow uncoupled 
from any regulatory apparatus allowing for allelic dysregulation, and several passages of 
the cells increase the risk of mutation leading to heterologous culture (Toleikis and 
Frenzel, 2012). In addition, the amplification process itself can introduce variations, 
because unknown sequences have to be amplified by use of wobbled oligonucleotides 
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and hybridization conditions allowing for mismatches (Dübel et al., 1994). Functional 
scFv can be chosen from a variety of possible VH/VL combinations by phage display and 
subsequent panning on antigen (Krebber et al., 1997). In this study the functional protein 
sequence has been already known and corresponding oligonucleotides were constructed 
to alter the isolated DNA sequences. 
5.1.1 A-LAM scFv/scFab 
A scFv construct of the original IgM was generated. The expression level of soluble scFv 
was low and no antigen recognition in ELISA was detectable, further antibody purification 
was not possible. Production levels in E. coli for scFv derived from hybridoma cell lines 
can vary heavily. On the one hand intrinsic features of the encoding genes (i.e. codon 
usage) can influence the expression (Tiwari et al., 2010). On the other hand the folding 
efficacy is crucial, because not correctly folded antibodies cannot bind antigen or 
accumulate into insoluble inclusion bodies (Li et al., 1999; Zhu et al., 2013). Codon 
optimization and co-expression with molecular chaperones can result in higher amounts 
of soluble scFv (Min et al., 2010). The reducing chemical environment of the cytoplasm 
in E. coli inhibits the formation of intradomain disulfide bridges necessary for the correct 
folding of scFv (Skerra, Plückthun 1988). In this study scFv were fused with the 
N-terminal leader peptide pelB that directs the recombinant protein into the periplasm of 
E. coli, where it can be properly folded in an oxidizing environment (Popplewell et al. 
2005). The absence of constant regions in scFv, in comparison to the parental IgM, may 
lead to conformational changes of the paratope or reduced stability. Further, 
glycosylation may contribute to antigen binding and increase solubility and stability, 
which cannot be achieved by expression in E. coli (Lizak et al., 2011). In this particular 
case, the antigen is a lipopolysaccharide, indicating a potential role of glycosylation in 
antigen recognition. Finally, the scFv may have a too low apparent affinity to create a 
detectable signal in the performed ELISA. IgM antibodies are produced early during 
immune responses, before somatic hypermutation and affinity maturation have taken 
place (Murphy et al., 2008), and usually recognize repetitive epitopes like 
polysaccharides on bacterial cell walls (like LAM). The avidity effect of the ten-arm IgM 
can neutralize low affinities, but is missing in the monovalent scFv (Roggenbuck et al., 
1994). 
In order to stabilize the antibody, a format change from scFv to scFab (with mouse CL 
and CH1) was performed. The results were very similar to those determined for the scFv. 
The expression of soluble antibody was low, no reaction in ELISA, and no purification 
possible. A positive effect of the constant regions in the scFab construct could not be 
detected. 
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5.1.2 A-LAM scFv-Fc/scFab-Fc 
To fetch an avidity effect and facilitate glycosylation, the scFv was fused to a human 
IgG1 Fc-part in an eukaryotic expression system (HEK293-6E cells, (Jäger et al., 2013)). 
There was no detectable expression of scFv-Fc and hence no purification possible. 
Finally, the scFab was fused to a human IgG1 Fc-part resulting in a scFab-Fc (scIgG) 
construct. Interestingly, expression and purification of this antibody was possible. This 
finding indicates a stabilizing effect of the CL and CH1 domains that are present in the 
scFab-Fc but absent in the scFv-Fc. Furthermore, the avidity effect caused by the 
Fc-mediated homodimerisation of scFab-Fc (Jäger et al., 2013; Powers et al., 2001) may 
be responsible for an increased apparent affinity. Moreover, a possible contribution of 
glycosylation to antigen binding cannot be excluded. The antibody yield was low 
(24 mg/L) in comparison to scFv-Fc antibodies (36 – 215 mg/L) produced in this study, 
probably due to the increased size of a scFab-Fc or due to the hybridoma origin.  
LAM is a component of the mycobacterial cell wall, and it’s presence is not limited to 
virulent strains of mycobacteria (Besra and Brennan, 1997; Chatterjee and Khoo, 1998). 
A reaction of the α-LAM scFab-Fc with Mtb and BCG cell extracts and purified Mtb/BCG 
LAM was detected by indirect ELISA. But the reaction with BCG derived LAM was 
weaker in both cases, indicating potential differences between Mtb LAM and BCG LAM. 
Similar results were encountered for the parental IgM (personal communication with 
F. Jonas) and for other monoclonal antibodies raised against Mtb LAM (Prinzis et al., 
1993). 
In future, purification of the scFab, eventually by refolding inclusion bodies from E. coli 
(Min et al., 2010) or by papain digestion of the scFab-Fc, could enlighten the role of 
avidity and glycosylation in antigen binding. If any scFab bound LAM, then the avidity 
effect would not be necessary for antigen recognition. If an E. coli derived scFab bound 
LAM, then glycosylation would not be essential for antigen binding. 
 
5.2 16 kDa 
5.2.1 Selection of antibodies against 16 kDa 
Seven individual α-16 kDa antibodies were isolated from the human naïve libraries 
HAL4/7. Interestingly, all these antibodies share the same variable gene segment of the 
heavy chain. In addition, respectively six out of seven antibodies have the same joining 
gene segment of the light chain, the same variable gene segment of the light chain or the 
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same joining gene segment of the heavy chain. The highest variability is found in the 
diversity gene segment of the heavy chain. Antigen binding is mainly influenced by 
CDR3 length and sequence variation (Davis et al., 1997). Especially the diversity of 
CDR3 of the heavy chain is often enough to mediate antigen specificity, and somatic 
mutations only in VH CDR3 can increase the affinity (Xu, Davis 2000). According to IMGT 
(Lefranc et al., 1999) there are 7 subfamilies of human VH (mathematical probability of 
IGHV3 = 14.3 %), 53 genes of VH3 (mathematical probability of IGHV3-15 = 1.9 %) and 8 
allels of gene IGHV3-15 (mathematical probability of IGHV3-15*01 = 12.5 %). In 
summary, the mathematical probability for the IGHV3-15*01 gene is about 0.03 %. 
Further, the mathematical probability for a combination of IGHV3-15*01 with IGLV1-47 
and IGLJ3, which are present in every α-16 kDa clone, is about 0.00006 %. Interestingly, 
this combination was selected from two different libraries. The minor chances for a 
combination of these genes, in addition to the appearance in two libraries, suggest a 
preferential combination of these gene segments in phage display libraries and/or in 
vivo. Indeed, the variable gene segments VH3 and Vλ1 are overrepresented in vivo 
(Knappik et al., 2000) and in naïve phage display libraries (Schofield et al., 2007). 
Furthermore, scFv antibodies with a combination of VH3 and Vλ1 are the most abundant 
in the HAL7 library with a probability for selection of about 23.3 % (Hust et al., 2011). In 
phage display, antibodies with higher stability and production yields in E. coli are 
favoured (Loset et al., 2005). Ewert and colleagues found VH3 to possess the highest 
thermodynamic stability of all isolated VH domains, and scFv including VH3 were the most 
stable with the highest production yields in E. coli (Ewert et al., 2003). Thereby, the 
combination of VH3 with Vλ1 seems common. Nevertheless, the homogeneity of the α-16 
kDa antibodies in combination of not only gene subfamilies but in addition particular 
genes and allells is remarkable. In this study, none of the selected antibodies against 
different antigens shared the exact gene combination. It seems there is a preferential 
combination of genes against the 16 kDa antigen.  
5.2.2 Characterization of α-16 kDa antibodies 
All scFv were expressed in and purified from E. coli, volumetric yields ranging from 2 
mg/L (SH451-F11) to 46 mg/L (SH365-C8). ScFv expression in E. coli is various, 
depending on the production system and the individual antibody sequence (Frenzel et 
al., 2013). An AbCheck analysis (Martin, 1996) revealed an extraordinary methionine in 
the light chain of SH451-F11, on the contrary the AbCheck analysis of SH365-C8 
showed no unusual sequence features. In addition, the quaternary structures of the scFv 
in PBS pH 7.4 were analysed. The analytical SEC of SH451-F11 offered about 16 % 
possible multimers, whereupon SH365-C8 showed no aggregates. The predicted grand 
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average of hydropathicity of SH451-F11 is double as positive as that of SH365-C8, 
determined by ExPASy Protparam (Artimo et al., 2012). Transient opening of the 
interface between VH and VL domains, allowed by the peptide linker, exposes 
hydrophobic patches that favour aggregation (Wörn and Plückthun, 2001). Therefore the 
formation of associates promoted by hydrophobic interactions is more likely for SH451-
F11, which is supported by the experimental findings. Although the combination of VH3 
with Vλ1 was found to produce the most stable scFv, antibody stability and production 
yields highly depend on the light chain CDR3 sequences (Ewert et al., 2003), that vary 
by substitution of 1 – 2 amino acids in the α-16 kDa antibodies.  
Epitope mapping of the α-16 kDa scFv suggested the recognition of the same epitope 
“KDFDGRS” by all antibodies. But the reactions with the peptides (and with reduced 
antigen in immunoblot) were weak, indicating that the epitopes may at least partially be 
conformational. Cross reactions of L16-3-D12 and L13-3-E12 with 85 A and 85 B were 
determined by indirect ELISA and direct immunblot, although the sequence “KDFDGRS” 
is not present in any of the 85 complex antigens (BLASTP, NCBI). Further none of the 
other α-16 kDa antibodies showed cross reactivity. Suggesting, there are different 
epitopes of the antibodies not distinguishable by screening overlapping peptide libraries. 
The complete amino acid sequence “KDFDGRS” is present in three other mycobacteria 
(M. canettii, M. fortuitum and M. avium) and a few non-pathogenic bacteria (Neisseria 
cinerea, Saccharomonospora ssp., Jostella marina), but absent in M. bovis identified by 
BLASTP (NCBI). Thereby, cross reactions with a few non-tuberculous organisms are 
likely but insignificant, because clinical pictures vary from that of TB. Further, the epitope 
region “KDFDGRS” shows great immunogenicity. Synthetic peptides including this 
sequence were found to induce T cell responses in mice (Vordermeier et al., 1993) and 
humans (Friscia et al., 1995). Furthermore, the epitopes of mouse monoclonal 
antibodies, human sera and llama VHH antibodies against 16 kDa were found to include 
“KDFDGRS” (Verbon et al., 1992; Srivastava et al., 2013). 
The affinities of the α-16 kDa scFv were determined by SPR, ranging from 2.76x10-07 M 
(L16-3-D12) to 1.06x10-08 M (L16-3-E12). Trilling and colleagues (Trilling et al., 2011) 
reported α-16 kDa llama VHH antibodies, selected from an immune phage display 
library, with affinities of maximum 4x10-10 M. A human α-16 kDa IgA, isolated from a 
naïve phage display library, had an affinity of 6.99 x 10-8 M (Balu et al., 2011). 
Since all antibodies were reactive with one sequence of the antigen, work was pursued 
with the antibody possessing the highest affinity (L16-3-E12). A slight reaction of this 
antibody with Mtb cell extracts and culture filtrate was measured by indirect ELISA. The 
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16 kDa antigen is the most abundant protein in M. tuberculosis during its dormant, non-
replicative phase but is not present under conditions of logarithmic growth (Yuan et al. 
1996; Hu, Coates 1999). Since the cultures examined in this study are usually 
proliferating, only marginal antigen expression can be expected. In addition, 16 kDa is 
associated with the mycobacterial cell wall and not secreted (Lee et al., 1992), therefore 
presence in Mtb culture filtrates can only be expected by cell lysis.  
The dodecameric structure of native 16 kDa, probably build up by association of six 
homodimers (Kennaway, 2005; Srivastava et al., 2013) could facilitate sandwich 
detection of the antigen with only one antibody. In this work, an α-16 kDa sandwich 
ELISA with L16-3-E12 scFv-Fc as capture antibody and detection HRP-conjugate was 
not successful neither with partly multimeric recombinant antigen nor Mtb filtrate. This 
might be due to sterical inhibition by an epitope blocking arrangement in the protein 
aggregate, or by a multimer amount below the detection limit. 
In future, scFv suitable for 16 kDa sandwich detection may be isolated by modified 
panning on pre-bound antigen. Therefore native antigen (isolated from Mtb) should be 
captured by L16-3-E12, and panning on this antigen-antibody complex, with human IgG 
pre-blocked phages, should be performed. In addition, the performance (affinity, stability, 
etc.) of these recombinant antibodies can be altered by construction of randomly 
mutagenized secondary phage display libraries and panning with increased selective 
pressure (Thie et al., 2009; Steidl et al., 2008). Furthermore, a passive immunization trial 
with the presented α-16 kDa antibodies is promising. A human α-16 kDa IgA antibody 
selected by phage display, with an undistinguished conformational epitope, mediated 
protection against TB in mice transgenic for human CD89 (Balu et al., 2011). 
Considering the fully human nature of the isolated antibodies and the availability of 
humanized FcRN mouse models (Proetzel and Roopenian, 2013), a similar approach is 
possible.  
 
5.3 CFP-10 
Three individual scFv antibodies binding CFP-10 were isolated from HAL7/8. The 
antibodies were purified as scFv-Fc fusions and further characterised. The epitope of 
MFU48-E1 was not determinable by screening overlapping peptide libraries. Considering 
that MFU48-E1 was not cross reactive with other Mtb antigens, BSA or with BCG, it was 
concluded that this antibody recognized a discontinuous epitope. MFU48-C8 and 
MFU48-G4 were recognizing the same continuous epitope “ERISGDLKT”. Interestingly, 
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these two antibodies have (except for one amino acid exchange in VH CDR2) exactly the 
same heavy chain but much more different light chains. This finding further underlines 
the key role of the heavy chain in antigen specificity, as mentioned before for the α-16 
kDa antibodies and found by other authors (Barbas, 3rd et al., 1993; Xu and Davis, 
2000). The combination of MFU48-E1 as capture antibody and MFU48-C8 as detection 
antibody in sandwich immune assays only yielded unreproducible results. It is possible 
that MFU48-E1 recognizes an epitope close to or overlapping “ERISGDLKT”. Thereby 
sandwich detection would be sterically inhibited. Furthermore, presuming different 
epitopes, the small size of the antigen (~ 10 kDa) and the width of a scFv arm (~ 4 nm 
(Boehm et al., 1999)) indicate sterical inhibition by the capture antibody. Moreover, 
considering that MFU48-E1 is presumed to recognize a discontinuous epitope, it is 
possible that binding of one antibody to “ERISGDLKT” causes a change in antigen 
conformation and therewith disables the binding of MFU48-E1. To investigate the 
reaction with “native” antigen, the α-CFP-10 antibodies were probed with Mtb cell extract 
and culture filtrate. There was no measurable binding in ELISA. Since CFP-10 is 
produced early during cultivation and the examined cultures are mostly a few weeks old, 
there was enough time for degradation. Further, secreted CFP-10 forms a tight 1:1 
complex with ESAT-6 (Figure 66: A) (Renshaw et al., 2002). Once bound by an α-CFP-
10 antibody, the rest of the CFP-10 site of the complex is probably blocked by ESAT-6 
(Figure 66: B). 
A)                                                                                               B) 
      
Figure 66: A) 3D structure of the CFP-10/ESAT-6 complex, epitope of α-CFP-10 antibodies, 
B) possible sterical inhibition of CFP-10 sandwich binding by ESAT-6. 
Pdb3fav (Resolution 2.15 Å, (Poulsen et al., 2009)) was modified with 3D molecule viewer 
(Invitrogen). Only protein chains C (CFP-10, green) and D (ESAT-6, yellow) are shown, atoms are 
displayed as space filling balls, the epitope “ERISGDLKT” is marked in blue. Antibody symbol 
adopted from M. Hust with permission.  
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Thus it seems more promising to target the CFP-10/ESAT-6 complex and not individual 
antigens. Since α-CFP-10 antibodies were already isolated, further work should focuss 
on the isolation of α-ESAT-6 antibodies. In this work, no antibodies against ESAT-6 
could be selected from HAL7/8. But this finding does not mean that there are no ESAT-6 
binders in those libraries. ESAT-6 is a small protein (6 kDa). Thereby antigen 
presentation on the surface of a MTP can be suboptimal. A different approach by fusion 
of ESAT-6 to a carrier protein, biotinylation or by panning on magnetic beads could 
improve antigen presentation. Furthermore, to avoid the selection of sterically inhibited 
antibodies (in sandwich detection), panning on pre-bound CFP-10/ESAT-6 heterodimer 
could be useful. Therefore, the complex must be isolated from Mtb culture filtrate or by in 
vitro fusion of the antigens. The α-CFP-10 antibodies could be used for capturing, and α-
ESAT-6 antibodies may be isolated by panning with human IgG pre-blocked HAL7/8 
phages. 
 
5.4 85 B 
5.4.1 Selection of antibodies against 85 B 
Five individual antibodies were selected from the human naïve libraries HAL7/8 (Hust et 
al., 2011). The examined antibodies showed homogeneity in the subfamily of the 
variable gene segment of the heavy chain (all VH3). In this study 18 out of 22 antibodies 
against different epitopes have a VH3 domain, indicating this variable gene segment of 
the heavy chain is advantageous. This finding correlates with the overrepresentation of 
VH1 and VH3 in the HAL7/8 libraries (Frenzel et al., 2012) and in vivo (Knappik et al., 
2000). Further, VH3 was found to possess the highest thermodynamic stability of all 
isolated VH domains, and scFv including VH3 were the most stable with the highest 
production yields in E. coli (Ewert et al., 2003). Four α-85 B antibodies have a lambda 
light chain, one a kappa light chain. In this study only one out of 22 clones has a kappa 
light chain, suggesting an advantage of lambda scFv in the selection process. 
Interestingly, in humans kappa antibodies outnumber lambda antibodies 1:20 (Murphy et 
al., 2008). Therefore the advantage of lambda antibodies seems to be limited to E. coli 
associated applications. It was found that lambda scFv are expressed in higher yields in 
E. coli compared to kappa scFv, which can be beneficial in phage display (Frenzel et al., 
2012; Hust et al., 2011; Loset et al., 2005). The antibody MFU50-C10 has a germline 
combination of VH3 and Vκ1, which is common in vivo and in naïve libraries (Hust et al., 
2011; Schofield et al., 2007; Knappik et al., 2000). The lambda germline sequences 
present in the other antibodies are from the subfamilies 1, 2, 3, 7 and 8. Subfamilies 
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Vλ1,2 and 3 are dominant in vivo, whereupon Vλ7 and 8 are rare in vivo (Knappik et al., 
2000; Schofield et al., 2007). In the HAL7 library Vλ7 and 8 are more frequent (Hust et 
al., 2011). Thereby, phage display allows selection of scFv (i.e. with Vλ7) that can hardly 
be raised by immunization techniques, probably exhibiting characteristics rarely found in 
vivo. 
5.4.2 Characterization of α-85 B antibodies 
All α-85 B antibodies recognized continuous sequences of the antigen, and the 
corresponding epitopes were determined by screening overlapping peptides immobilized 
on a cellulose membrane. MFU50-D4 recognized “AFSRPGLPVEYL” and MFU50-D7 
recognized “AFSRPGLPV”. This epitope region seems to be a potent T cell antigen. 
Synthetic peptides including this sequence were found to induce cytokine release or 
immune cell proliferation in peripheral blood of individuals with varying TB status 
(Huygen et al. 1994; Launois et al. 1994; Roche et al. 1994; Commandeur et al. 2011). 
Yet only weak human B cell responses against these peptides were reported (Roche et 
al. 1994; Shen et al. 2009). Therefore generation of antibodies against this region by 
immunization could be difficult. In this work, human antibodies were successfully 
generated by screening phage display libraries, fortifying the advantage of phage display 
technology over conventional immunization methods. Protein sequence comparison of 
the 85 complex proteins revealed the presence of the epitope in antigen 85 A and 85 C, 
suggesting cross reactivity. In ELISA and immunoblot analysis MFU50-D7 showed no 85 
A binding, whereupon MFU50-D4 showed a slight cross reactivity with 85 A (85 C was 
not available for examination). Furthermore, a protein blast search (BLASTP, NCBI) 
disclosed the existence of the entire epitope in several different mycobacterial strains 
(i.e. M. bovis, M. ulcerans, M. marinum, M. smegmatis, M. vaccae, etc.), suggesting 
cross reactivity.  
The α-85 B antibodies MFU50-A10 and MFU50-E2 recognized the epitopes 
“SSDPAWERNDPT” and “SSDPAWERN” respectively. This epitope region appears to 
possess great immunogenicity. Shen and coworkers (Shen et al. 2009) reported the 
synthetic peptide “GPSSDPAWERNDPTQ QIPKL” (epitope ID 21797, IEDB) was 
recognized by sera (IgG) of TB+ individuals. Similar peptides containing the epitope 
“SSDPAWERNDPT” were found to induce cytokine release or T cell proliferation in 
various assays with samples of TB+ individuals (Roche et al. 1994; Lightbody et al. 
1998; Valle et al. 2001; D'Souza et al. 2003; Commandeur et al. 2011). The entire amino 
acid sequence “SSDPAWERNDPT” is present only in 85 B of M. tuberculosis and 
M. bovis BCG. Similar sequences are present in Mtb 85 A, 85 C, 85 D and in 85 complex 
proteins from other mycobacterial species (identified by BLASTP). Cross reactivity of 
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MFU50-A10 with Mtb 85 A, 85 D and M. bovis BCG cell extract and culture filtrate was 
detected by indirect ELISA and immunoblot. Landowski and colleagues (Landowski et al. 
2001) found a “SSDPAWERNDPT” specific chicken IgY antibody to be cross reactive 
with Mtb 85 A and 85 C as well as 85 complex proteins of M. avium. Suggesting, the 
antibodies MFU50-A10 and MFU50-E2 could be cross reacting with Mtb 85 C and 
M. avium as well. The reaction of MFU50-A10 with 85 A, B and D indicates a possible 
smaller epitope than determined by epitope mapping. The amino acid sequence “DPA” is 
conserved throughout these 85 complex antigens, but the adjacent amino acids are 
differing from “SDPAWE” in 85 B to “EDPAWQ” in 85 A and “SDPAAM” in 85 D. It is 
possible that the epitope of MFU50-A10 is “SDPAW” or “DPAWE”, respectively two 
amino acids changed in 85 A or 85 D, which would explain the weaker recognition. 
Furthermore, the comparison of the 3D structures of antigen 85 A and 85 B (Figure 67), 
revealed that the glutamic acid in 85 B forms a pin structure in front of the “DPAW” 
region. This formation is missing in 85 A, instead of glutamic acid there is glutamine. 
Glutamic acid can mediate strong electrostatic attractions and hydrogen bridges through 
the loaded carboxylgroup, whereupon glutamine is uncharged and can only mediate 
hydrogen bridges through the amino- and the ketogroup (Murphy et al., 2008). Thus, it is 
reasoned that the glutamic acid pin structure is needed structurally for correct docking, 
and physico-chemically for full strength binding to the antigen. In future, co-crystallization 
of the respective antigen with the MFU50-A10 antibody and structural analysis by X-ray 
diffraction could illustrate the exact epitope. 
 
Figure 67: 3 D structures of antigens A) 85 A and B) 85 B around the amino acid sequence 
“DPAW”. 
A) Pdb1sfr (Resolution 2.7 Å, Ronning et al. 2004) and B) Pdb1f0n (Resolution 1.9 Å, Anderson 
et al. 2001) were modified with 3D molecule viewer (Invitrogen). Respectively only protein chain A 
is shown, atoms are displayed as space filling balls, “DPAW” is marked in blue, glutamic acid in 
85 B is encircled in comparison to glutamine in 85 A. 
 
  5 Discussion 
111 
 
MFU50-C10 recognized the epitope “SPAVYL”, which is close to the suggested active 
site of antigen 85 B (Ronning et al., 2000; Anderson et al., 2001), offering a possible 
inhibitory effect by steric hindrance (Arnon 1975). Thereby, MFU50-C10 may be suitable 
as a TB drug. The region around the active site of 85 B seems to be of strong 
immunogenicity. Synthetic peptides including “SPAVYL” were found to induce cytokine 
release and T cell proliferation in peripheral blood mononuclear cells of TB+ humans 
(Valle et al. 2001; Mustafa et al. 2005; Roche et al. 1994; Commandeur et al. 2011) and 
antibodies against these peptides were detected in sera of TB+ individuals (Gaseitsiwe 
et al. 2008; Shen et al. 2009). According to BLASTP similar sequences, with substitution 
of one amino acid, are present in the other 85 complex proteins. Furthermore, equivalent 
sequences are present in several other mycobacterial species (i.e. M. bovis, 
M. marinum, M. leprae, M. vaccae, M. ulcerans, M. avium, etc.). No cross reactivity with 
85 A and 85 D (sequence in 85 C is identical) was detected by indirect ELISA and 
immunoblot, suggesting specificity for antigen 85 B.  
To the author’s knowledge, in this study the first human recombinant antibodies 
(MFU50-C10, MFU50-D7 and MFU50-E2) specific for antigen 85 B were isolated. These 
antibodies, in combination with the α-85 A and α-85 D antibodies generated in this work, 
allow discrimination between individual components of the 85 complex. Ferrara and 
co-workers (Ferrara et al. 2012) selected 48 antibodies directed against the Mtb 85 
complex in a combination of yeast and phage display. None of these antibodies was 
specific for one antigen but cross reactive with all other 85 complex proteins. Landowski 
and colleagues (Landowski et al. 2001) isolated an α-85 B chicken IgY cross reactive 
with 85 complex proteins. Drowart et al. (Drowart et al. 1992) generated seven 
monoclonal α-85 complex antibodies, which were all cross reactive with other 
mycobacterial species and none was specific for antigen 85 B.  
5.4.3 A-85 B sandwich ELISA 
Sandwich ELISA detection of recombinant 85 B with the α-85 B scFv-Fc was successful 
in all performed assays. The most suitable combination, capturing with MFU50-A10 and 
detection with MFU50-C10-HRP, reached a detection limit of ~ 10 ng mL-1 (0.3 nM). 
Sandwich LFIA detection of recombinant 85 B was successful capturing with 
MFU50-A10 and detecting with MFU50-D4-gold. A detection limit of 5 ng/strip (0.03 
ng/mL, 0.8 pM) was evaluated. To the author’s knowledge there are no comparable 
studies on antigen 85 B sandwich detection. Only whole 85 complex sandwich assays 
were reported. Ferrara and colleagues reported a detection limit of 6.1 nM 85 complex in 
PBS in a sandwich fluorescence assisted cell sorting assay with antibodies displayed on 
phages and yeast cells (Ferrara et al., 2012). Mukundan and co-workers reported a 
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detection limit of 183 nM 85 complex in spiked human serum in a sandwich ELISA with 
monclonal antibodies (Mukundan et al., 2012). Further, the presence of 85 complex in 
human serum was demonstrated by indirect dot immunobinding assays (Bentley-Hibbert 
et al., 1999) and indirect ELISA (Kashyap et al., 2007), but in these studies no 
quantification was performed.  
Sandwich detection of recombinant 85 B was enhanced by multimeric antigen 
conformation, and reduced by monomeric antigen conformation. The small size of the 
antigen (~ 5 nm diameter, (Anderson et al., 2001)) may be responsible for this finding. 
Considering the length of a human scFv of ~ 4.5 nm (Boehm et al., 1999) and the Fc-
mediated homodimerisation of scFv-Fc fusions (Jäger et al., 2013; Powers et al., 2001), 
sterical inhibition by the capture antibody is possible. The commercially available 
immunochromatographic assays for MPT64 antigen detection in Mtb cultures are 
sandwich assays with monoclonal antibodies (Yin et al., 2013). The Capilia TB Test Kit 
(Ngamlert et al., 2009) uses only one monoclonal antibody for a sandwich assay, 
indicating multimer detection. Recombinant antigen MPT64 showed multimerization by 
disulphide bonds in two unrelated studies (Geisbrecht et al., 2006; Chu and Yuann, 
2011) and no difference in immunogenicity compared to native antigen (Geisbrecht et al., 
2006; Oettinger et al., 1997). These findings imply multimerization of native MPT64 and 
that these aggregates are detected in sandwich assays.  
In future, antibodies suitable for native 85 B sandwich detection can be selected by 
modified panning on pre-bound antigen. Therefore native antigen should be captured by 
the antibodies presented in this work, and panning on this antigen-antibody complex, 
with human IgG pre-blocked phages, ought to be carried out. 
5.4.4 A-85 B sandwich LFIA 
All α-85 B scFv-Fc were conjugated to colloidal gold and direct detection of recombinant 
85 B was possible with all conjugates. The most suitable combination for sandwich 
detection was evaluated to MFU50-A10 for capturing and MFU50-D4-gold for detection. 
Unfortunately, large production of MFU50-D4-gold conjugate led to background 
reactions, which were predominantly influenced by pH. Antigen detection at physiological 
pH 7.4 was possible (with background) and not possible at conjugation pH 8.8 (no 
background). These results indicate that the scFv-Fc-gold conjugate was instable at pH 
7.4 and therefore loose colloidal gold particles caused background reactions. 
Furthermore it was reasoned that the antibodies were not able to detect antigen at pH 
8.8, when the scFv-Fc-gold conjugate was stable. MFU50-A10 and MFU50-C10 scFv-Fc 
antibodies display theoretical isoelectric points (pI) of 8.19 and 8.64, leading to a positive 
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netto charge at pH 7.4. In comparison to that antigen 85 B (recombinant with C-terminal 
His-tag) has a pI of 6.29, resulting in a negative netto charge at physiological pH (Table 
53). Probably certain charges of amino acids in the epitope areas and CDRs (Table 53) 
are necessary for association of the antigen-antibody complex. Further, the conformation 
of the antibodies at pH 8.8 probably was altered so that the reaction with the antigen was 
inhibited and not detectable in the explored system.  
Table 53: Electrochemical properties of α-85 B scFv-Fc and antigen 85 B. 
 theoretical pI* netto charge 
at pH 7.4 
charged aa in 
epitopes 
charged aa in 
CDRs 
MFU50-A10 8.19 positive  4 5 
MFU50-C10 8.64 positive  0 13 
MFU50-D4 8.18 positive  1 5 
MFU50-D7 7.11 negative  2 11 
MFU50-E2 8.50 positive  3 4 
85 B (C-His) 6.29 negative    
*determined with the ExPASY Prot Param tool (Artimo et al., 2012) 
Background reactions were minimized with preserved antigen recognition by addition of 
a diluent. With this optimized assay a detection limit of 5 ng recombinant 85 B per strip in 
7H9 medium was reached. No reaction with Mtb cell extract or culture filtrates 
(concentrated and un-concentrated) was observed. Similarly to the sandwich ELISA, lack 
of multimers in the explored samples may be responsible for these findings. In addition, 
even if multimers are present, the 85 B proteins can be arranged in an epitope blocking 
conformation.  
Furthermore, human urine and sputum samples were spiked with recombinant 85 B and 
analysed by sandwich LFIA. The spike was fully retrieved from the urine samples, but 
only to 50 % from sputum samples. Proteases present in sputum may be responsible for 
protein degradation and therefore lack of spike recovery. The presence of the 85 
complex was demonstrated in human serum (Kashyap et al. 2007), urine (Bentley-
Hibbert et al. 1999), cerebrospinal fluid (Kashyap et al. 2005) and sputum (Wallis et al. 
1998). All available sputum/urine samples of confirmed TB patients were autoclaved 
prior to storage at Lionex GmbH. Previous experiments with boiled 85 B showed 
decreased antigen recognition in ELISA compared to untreated 85 B. If there has been a 
detectable amount of 85 B in the sputum samples, it was probably destroyed by 
autoclaving. In addition to that, considering the presence of proteases in sputum and the 
storage of the samples at 2 – 8 °C over years, it was assumed that 85 B not affected by 
autoclaving would have been already digested.  
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5.4.5 A-85 B immunoblot 
Detection of 85 B in Mtb culture filtrates was difficult probably due to antigen 
conformation and/or amount of antigen in previously described assays. The antibodies 
used in this assays were selected by panning on recombinant 85 B produced in E. coli. 
Although 85 complex proteins do not require posttranslational modifications, differences 
in protein folding may occur. Further, 85 B contains an N-terminal signal sequence 
(Borremans et al., 1989), which is not processed in E. coli but at least partially cleaved 
for secretion in M. tuberculosis. All α-85 B scFv-Fc recognized continuous epitopes. 
Therefore antigen detection in samples, mostly independent from conformation, by an 
immunoblot assay was considered possible. Indeed, after 22 days of cultivation 85 B 
was detected in 20 fold Mtb culture filtrate by MFU50-A10-HRP. No reaction with 
MFU50-C10-HRP and MFU50-D4-HRP was detected. As mentioned before, MFU50-A10 
is cross reactive with antigens 85 A and 85 D (probably 85 C), which can lead to an 
advantage over MFU50-C10 and MFU50-D4 that are specific for 85 B. Commercial 
MPT64 antigen detection is mostly performed from un-concentrated liquid cultures of 
M. tuberculosis grown in minimal medium for approximately 2 – 3 weeks (Abe et al., 
1999). Thereby, MPT64 detection is as fast as the presented 85 B detection, but more 
sensitive. The α-MPT64 monoclonal IgG antibodies in commercial kits are affinity 
matured, in comparison to the naïve recombinant antibodies used here. The affinities of 
the α-85 B antibodies could not be evaluated by surface plasmon resonance due to the 
multimeric conformation of the recombinant antigen (data not shown). Affinities of scFv 
derived from the HAL7/8 libraries are usually in the range of 10-7 to 10-10 M-1 (personal 
communication with M. Hust). In vitro affinity maturation by construction of secondary 
libraries, introducing additional mutations, and following selection by increased selective 
pressure in phage display could improve the affinities of the explored antibodies to 
picomolar range (Thie et al., 2009; Steidl et al., 2008). Furthermore, the presented 
immunoblot assay may be suitable for detection of 85 B in human serum. Landowski and 
colleagues (Landowski et al. 2001) generated an oligoclonal chicken IgY antibody 
against 85 complex and demonstrated 55 % sensitivity and 85 % specificity for detection 
of circulating 85 complex in human blood by an immunoblot approach.  
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5.5 85 A 
Four individual α-85 A scFv were solated from HAL7/8 and purified as scFv-Fc 
antibodies. All antibodies were strongly reactive with reduced 85 A in immunoblot, 
therefore recognition of a continuous epitope was supposed. Epitope mapping was 
carried out by screening overlapping 85 A peptides immobilized on a cellulose 
membrane. The antibody MFU53-F3 was reacting with a great variety of peptides. Such 
observations usually indicate a discontinuous epitope. Furthermore, this antibody 
showed strong cross reactivity in immunoblot and ELISA with 85 B, but no reaction with 
85 D. Suggesting, a conformational epitope is recognized, which is present in 85 A and 
85 B but absent in 85 D. In addition, unspecific reactions with BSA at concentrations 
above 200 ng/mL were encountered in ELISA. However, unspecificity can be provoked 
by high antibody concentrations. Therefore, it remains unclear which kind of epitope 
MFU53-F3 recognizes and how specific the binding is. For the other α-85 A antibodies 
the epitopes were determined. MFU12-D8 recognized the sequence “SPA” and MFU53-
A3 recognized the adjacent sequence “LYLLDG”. Interestingly, the α-85 B antibody 
MFU50-C10 recognized a similar sequence “SPAVYL”. Like MFU50-C10 for 85 B, the α-
85 A antibody MFU12-D8 showed no cross reactions with the other 85 complex proteins, 
neither in ELISA nor in immunoblot, and seems to be specific for 85 A. The amino acids 
“SPA” in both antigens form identical structures and are located in a cavity, yet they are 
surrounded by a ring of different amino acids (Figure 68). No reactions with those 
surrounding amino acids were detected in epitope mapping. The linear epitope “SPA” 
seems to be complemented by the structurally surrounding amino acid residues.  
 
Figure 68: 3 D structures of antigens A) 85 A and B) 85 B around the amino acid sequence 
“SPA”. 
A) Pdb1sfr protein chain A (Resolution 2.7 Å, Ronning et al. 2004) and B) Pdb1f0n protein chain 
B (Resolution 1.9 Å, Anderson et al. 2001) were modified with 3D molecule viewer (Invitrogen). 
Atoms are displayed as space filling balls, different amino acids are displayed with different 
colours, “SPAnYLLDG” is marked in black. 
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Further, the sequence “SPALYLLDG” (aa 76 – 84) is interpenetrating a part of antigen 85 
A, whereat “SPA” is located at one site and “LYLLDG” at the other site. The “SPA” 
(aa 76 - 78) cavity is close to the catalytic serin 126 (Ronning et al., 2004), which may be 
sterically blocked by binding of MFU12-D8. Furthermore, the “LYLLDG” cavity is located 
in the carbohydrate binding pocket of antigen 85 A and could also mediate sterical 
inhibition. Thereby, considering the importance of 85 A in Mtb growth (Armitige et al., 
2000; Belisle et al., 1997), MFU12-D8 and MFU53-A3 may be suitable as TB drugs.  
Sandwich ELISA detection of recombinant 85 A was possible with all antibody 
combinations. Similar to antigen 85 B, multimeric antigen conformation seemed to 
enhance sandwich detection. For antigen 85 A; only two epitope areas were determined 
with close proximity (2 - 3 nm). Once monomeric antigen was bound by the capture 
antibody, the other epitope could be directed towards the surface of the MTP, and hence 
sterically prohibit sandwich detection (Figure 69).  
 
Figure 69: Possible sterical inhibition of 85 A sandwich binding. 
Pdb1sfr (Resolution 2.7 Å, Ronning et al. 2004) was modified with 3D molecule viewer 
(Invitrogen). Only protein chain A is shown (yellow), atoms are displayed as space filling balls, 
epitopes are marked in blue. Antibody symbol adopted from M. Hust with permission.  
 
In future, antibodies suitable for sandwich detection of native 85 A can be isolated by 
panning on pre-bound antigen, and the biochemical charcteristics of these antibodies 
can be altered, as described for the α-85 B antibodies.  
In this work, antibodies specifically binding to Mtb antigens 85 A, 85 B or 85 D were 
isolated. To the author’s knowledge, there are only studies presenting antibodies cross 
reacting with minimum one other antigen of the 85 complex (Ferrara et al., 2012; 
Landowski et al., 2001; Drowart et al., 1992). Thereby, with the presented antibodies, 
discrimination between individual components of the 85 complex is possible for the first 
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time. Easy applicability of the presented antibodies to in vitro experiments was showed in 
this study by conjugation to colloidal gold or HRP. Due to the recombinant nature of the 
explored antibodies, they can easily be altered to different formats, fused to different Fc-
parts or fused to markers such as green fluorescent protein (GFP, (Kremer et al., 1995)) 
for in vivo experiments. Thus the role of particular 85 proteins in Mtb cell wall 
biosynthesis and evasion of the host’s immune response may be explored. 
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8.1 Plasmid maps 
 
Figure 70: Plasmid map for pHAL14. 
Vector for phage display of scFv (Hust et al., 2011). 
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Figure 71: Plasmid map for pHAL20. 
Vector for phage display of scFab (M. Hust unpublished) 
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Figure 72: Plasmid map for pOPE101-XP. 
Vector for scFv and scFab expression in prokaryotic cells (E. coli) (Hust et al., 2009). 
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Figure 73: Plasmid map for pCSE2.5-hIgG1-Fc-XP. 
Vector for scFv-Fc and scFab-Fc expression in eukaryotic cells (HEK293-6E) (Jäger et al., 2013). 
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8.2 Peptides for epitope mapping 
 
Table 54: Peptide sequences on 16 kDa peptide-spot membrane. 
spot start 
aa 
peptide sequence spot start 
aa 
peptide sequence 
1 1 MATTLPVQRHPRSLF 19 73 GQLTIKAERTEQKDF 
2 5 LPVQRHPRSLFPEFS 20 77 IKAERTEQKDFDGRS 
3 9 RHPRSLFPEFSELFA 21 81 RTEQKDFDGRSEFAY 
4 13 SLFPEFSELFAAFPS 22 85 KDFDGRSEFAYGSFV 
5 17 EFSELFAAFPSFAGL 23 89 GRSEFAYGSFVRTVS 
6 21 LFAAFPSFAGLRPTF 24 93 FAYGSFVRTVSLPVG 
7 25 FPSFAGLRPTFDTRL 25 97 SFVRTVSLPVGADED 
8 29 AGLRPTFDTRLMRLE 26 101 TVSLPVGADEDDIKA 
9 33 PTFDTRLMRLEDEMK 27 105 PVGADEDDIKATYDK 
10 37 TRLMRLEDEMKEGRY 28 109 DEDDIKATYDKGILT 
11 41 RLEDEMKEGRYEVRA 29 113 IKATYDKGILTVSVA 
12 45 EMKEGRYEVRAELPG 30 117 YDKGILTVSVAVSEG 
13 49 GRYEVRAELPGVDPD 31 121 ILTVSVAVSEGKPTE 
14 53 VRAELPGVDPDKDVD 32 125 SVAVSEGKPTEKHIQ 
15 57 LPGVDPDKDVDIMVR 33 129 SEGKPTEKHIQIRST 
16 61 DPDKDVDIMVRDGQL 34 133 PTEKHIQIRSTN 
17 65 DVDIMVRDGQLTIKA 35 137 HIQIRSTN 
18 69 MVRDGQLTIKAERTE 36 141 RSTN 
 
Table 55: Peptide sequences on CFP-10 peptide-spot membrane. 
spot start 
aa 
peptide sequence spot start 
aa 
peptide sequence 
1 1 MAEMKTDAATLAQEA 16 46 AAGTAAQAAVVRFQE 
2 4 MKTDAATLAQEAGNF 17 49 TAAQAAVVRFQEAAN 
3 7 DAATLAQEAGNFERI 18 52 QAAVVRFQEAANKQK 
4 10 TLAQEAGNFERISGD 19 55 VVRFQEAANKQKQEL 
5 13 QEAGNFERISGDLKT 20 58 FQEAANKQKQELDEI 
6 16 GNFERISGDLKTQID 21 61 AANKQKQELDEISTN 
7 19 ERISGDLKTQIDQVE 22 64 KQKQELDEISTNIRQ 
8 22 SGDLKTQIDQVESTA 23 67 QELDEISTNIRQAGV 
9 25 LKTQIDQVESTAGSL 24 70 DEISTNIRQAGVQYS 
10 28 QIDQVESTAGSLQGQ 25 73 STNIRQAGVQYSRAD 
11 31 QVESTAGSLQGQWRG 26 76 IRQAGVQYSRADEEQ 
12 34 STAGSLQGQWRGAAG 27 79 AGVQYSRADEEQQQA 
13 37 GSLQGQWRGAAGTAA 28 82 QYSRADEEQQQALSS 
14 40 QGQWRGAAGTAAQAA 29 85 RADEEQQQALSSQMG 
15 43 WRGAAGTAAQAAVVR 30 88 ADEEQQQALSSQMGF 
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Table 56: Peptide sequences on 85 A peptide-spot membrane. 
spot start 
aa 
peptide sequence spot start 
aa 
peptide sequence 
1 1 MQLVDRVRGAVTGMS 56 166 VGLSMAASSALTLAI 
2 4 VDRVRGAVTGMSRRL 57 169 SMAASSALTLAIYHP 
3 7 VRGAVTGMSRRLVVG 58 172 ASSALTLAIYHPQQF 
4 10 AVTGMSRRLVVGAVG 59 175 ALTLAIYHPQQFVYA 
5 13 GMSRRLVVGAVGAAL 60 178 LAIYHPQQFVYAGAM 
6 16 RRLVVGAVGAALVSG 61 181 YHPQQFVYAGAMSGL 
7 19 VVGAVGAALVSGLVG 62 184 QQFVYAGAMSGLLDP 
8 22 AVGAALVSGLVGAVG 63 187 VYAGAMSGLLDPSQA 
9 25 AALVSGLVGAVGGTA 64 190 GAMSGLLDPSQAMGP 
10 28 VSGLVGAVGGTATAG 65 193 SGLLDPSQAMGPTLI 
11 31 LVGAVGGTATAGAFS 66 196 LDPSQAMGPTLIGLA 
12 34 AVGGTATAGAFSRPG 67 199 SQAMGPTLIGLAMGD 
13 37 GTATAGAFSRPGLPV 68 202 MGPTLIGLAMGDAGG 
14 40 TAGAFSRPGLPVEYL 69 205 TLIGLAMGDAGGYKA 
15 43 AFSRPGLPVEYLQVP 70 208 GLAMGDAGGYKASDM 
16 46 RPGLPVEYLQVPSPS 71 211 MGDAGGYKASDMWGP 
17 49 LPVEYLQVPSPSMGR 72 214 AGGYKASDMWGPKED 
18 52 EYLQVPSPSMGRDIK 73 217 YKASDMWGPKEDPAW 
19 55 QVPSPSMGRDIKVQF 74 220 SDMWGPKEDPAWQRN 
20 58 SPSMGRDIKVQFQSG 75 223 WGPKEDPAWQRNDPL 
21 61 MGRDIKVQFQSGGAN 76 226 KEDPAWQRNDPLLNV 
22 64 DIKVQFQSGGANSPA 77 229 PAWQRNDPLLNVGKL 
23 67 VQFQSGGANSPALYL 78 232 QRNDPLLNVGKLIAN 
24 70 QSGGANSPALYLLDG 79 235 DPLLNVGKLIANNTR 
25 73 GANSPALYLLDGLRA 80 238 LNVGKLIANNTRVWV 
26 76 SPALYLLDGLRAQDD 81 241 GKLIANNTRVWVYCG 
27 79 LYLLDGLRAQDDFSG 82 244 IANNTRVWVYCGNGK 
28 82 LDGLRAQDDFSGWDI 83 247 NTRVWVYCGNGKPSD 
29 85 LRAQDDFSGWDINTP 84 250 VWVYCGNGKPSDLGG 
30 88 QDDFSGWDINTPAFE 85 253 YCGNGKPSDLGGNNL 
31 91 FSGWDINTPAFEWYD 86 256 NGKPSDLGGNNLPAK 
32 94 WDINTPAFEWYDQSG 87 259 PSDLGGNNLPAKFLE 
33 97 NTPAFEWYDQSGLSV 88 262 LGGNNLPAKFLEGFV 
34 100 AFEWYDQSGLSVVMP 89 265 NNLPAKFLEGFVRTS 
35 103 WYDQSGLSVVMPVGG 90 268 PAKFLEGFVRTSNIK 
36 106 QSGLSVVMPVGGQSS 91 271 FLEGFVRTSNIKFQD 
37 109 LSVVMPVGGQSSFYS 92 274 GFVRTSNIKFQDAYN 
38 112 VMPVGGQSSFYSDWY 93 277 RTSNIKFQDAYNAGG 
39 115 VGGQSSFYSDWYQPA 94 280 NIKFQDAYNAGGGHN 
40 118 QSSFYSDWYQPACGK 95 283 FQDAYNAGGGHNGVF 
41 121 FYSDWYQPACGKAGC 96 286 AYNAGGGHNGVFDFP 
42 124 DWYQPACGKAGCQTY 97 289 AGGGHNGVFDFPDSG 
43 127 QPACGKAGCQTYKWE 98 292 GHNGVFDFPDSGTHS 
44 130 CGKAGCQTYKWETFL 99 295 GVFDFPDSGTHSWEY 
45 133 AGCQTYKWETFLTSE 100 298 DFPDSGTHSWEYWGA 
46 136 QTYKWETFLTSELPG 101 301 DSGTHSWEYWGAQLN 
47 139 KWETFLTSELPGWLQ 102 304 THSWEYWGAQLNAMK 
48 142 TFLTSELPGWLQANR 103 307 WEYWGAQLNAMKPDL 
49 145 TSELPGWLQANRHVK 104 310 WGAQLNAMKPDLQRA 
50 148 LPGWLQANRHVKPTG 105 313 QLNAMKPDLQRALGA 
51 151 WLQANRHVKPTGSAV 106 316 AMKPDLQRALGATPN 
52 154 ANRHVKPTGSAVVGL 107 319 PDLQRALGATPNTGP 
53 157 HVKPTGSAVVGLSMA 108 322 QRALGATPNTGPAPQ 
54 160 PTGSAVVGLSMAASS 109 324 ALGATPNTGPAPQGA 
55 163 SAVVGLSMAASSALT    
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Table 57: Peptide sequences on 85 B peptide-spot membrane. 
spot start 
aa 
peptide sequence spot start 
aa 
peptide sequence 
1 1 MTDVSRKIRAWGRRL 54 160 SAAIGLSMAGSSAMI 
2 4 VSRKIRAWGRRLMIG 55 163 IGLSMAGSSAMILAA 
3 7 KIRAWGRRLMIGTAA 56 166 SMAGSSAMILAAYHP 
4 10 AWGRRLMIGTAAAVV 57 169 GSSAMILAAYHPQQF 
5 13 RRLMIGTAAAVVLPG 58 172 AMILAAYHPQQFIYA 
6 16 MIGTAAAVVLPGLVG 59 175 LAAYHPQQFIYAGSL 
7 19 TAAAVVLPGLVGLAG 60 178 YHPQQFIYAGSLSAL 
8 22 AVVLPGLVGLAGGAA 61 181 QQFIYAGSLSALLDP 
9 25 LPGLVGLAGGAATAG 62 184 IYAGSLSALLDPSQG 
10 28 LVGLAGGAATAGAFS 63 187 GSLSALLDPSQGMGP 
11 31 LAGGAATAGAFSRPG 64 190 SALLDPSQGMGPSLI 
12 34 GAATAGAFSRPGLPV 65 193 LDPSQGMGPSLIGLA 
13 37 TAGAFSRPGLPVEYL 66 196 SQGMGPSLIGLAMGD 
14 40 AFSRPGLPVEYLQVP 67 199 MGPSLIGLAMGDAGG 
15 43 RPGLPVEYLQVPSPS 68 202 SLIGLAMGDAGGYKA 
16 46 LPVEYLQVPSPSMGR 69 205 GLAMGDAGGYKAADM 
17 49 EYLQVPSPSMGRDIK 70 208 MGDAGGYKAADMWGP 
18 52 QVPSPSMGRDIKVQF 71 211 AGGYKAADMWGPSSD 
19 55 SPSMGRDIKVQFQSG 72 214 YKAADMWGPSSDPAW 
20 58 MGRDIKVQFQSGGNN 73 217 ADMWGPSSDPAWERN 
21 61 DIKVQFQSGGNNSPA 74 220 WGPSSDPAWERNDPT 
22 64 VQFQSGGNNSPAVYL 75 223 SSDPAWERNDPTQQI 
23 67 QSGGNNSPAVYLLDG 76 226 PAWERNDPTQQIPKL 
24 70 GNNSPAVYLLDGLRA 77 229 ERNDPTQQIPKLVAN 
25 73 SPAVYLLDGLRAQDD 78 232 DPTQQIPKLVANNTR 
26 76 VYLLDGLRAQDDYNG 79 235 QQIPKLVANNTRLWV 
27 79 LDGLRAQDDYNGWDI 80 238 PKLVANNTRLWVYCG 
28 82 LRAQDDYNGWDINTP 81 241 VANNTRLWVYCGNGT 
29 85 QDDYNGWDINTPAFE 82 244 NTRLWVYCGNGTPNE 
30 88 YNGWDINTPAFEWYY 83 247 LWVYCGNGTPNELGG 
31 91 WDINTPAFEWYYQSG 84 250 YCGNGTPNELGGANI 
32 94 NTPAFEWYYQSGLSI 85 253 NGTPNELGGANIPAE 
33 97 AFEWYYQSGLSIVMP 86 256 PNELGGANIPAEFLE 
34 100 WYYQSGLSIVMPVGG 87 259 LGGANIPAEFLENFV 
35 103 QSGLSIVMPVGGQSS 88 262 ANIPAEFLENFVRSS 
36 106 LSIVMPVGGQSSFYS 89 265 PAEFLENFVRSSNLK 
37 109 VMPVGGQSSFYSDWY 90 268 FLENFVRSSNLKFQD 
38 112 VGGQSSFYSDWYSPA 91 271 NFVRSSNLKFQDAYN 
39 115 QSSFYSDWYSPACGK 92 274 RSSNLKFQDAYNAAG 
40 118 FYSDWYSPACGKAGC 93 277 NLKFQDAYNAAGGHN 
41 121 DWYSPACGKAGCQTY 94 280 FQDAYNAAGGHNAVF 
42 124 SPACGKAGCQTYKWE 95 283 AYNAAGGHNAVFNFP 
43 127 CGKAGCQTYKWETFL 96 286 AAGGHNAVFNFPPNG 
44 130 AGCQTYKWETFLTSE 97 289 GHNAVFNFPPNGTHS 
45 133 QTYKWETFLTSELPQ 98 292 AVFNFPPNGTHSWEY 
46 136 KWETFLTSELPQWLS 99 295 NFPPNGTHSWEYWGA 
47 139 TFLTSELPQWLSANR 100 298 PNGTHSWEYWGAQLN 
48 142 TSELPQWLSANRAVK 101 301 THSWEYWGAQLNAMK 
49 145 LPQWLSANRAVKPTG 102 304 WEYWGAQLNAMKGDL 
50 148 WLSANRAVKPTGSAA 103 307 WGAQLNAMKGDLQSS 
51 151 ANRAVKPTGSAAIGL 104 310 QLNAMKGDLQSSLGA 
52 154 AVKPTGSAAIGLSMA 105 311 LNAMKGDLQSSLGAG 
53 157 PTGSAAIGLSMAGSS    
 
